
<html lang="en"     class="pb-page"  data-request-id="1a457e05-b0f3-4a66-9096-3f39bc9c23a3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-5;article:article:10.1021/jm401396p;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase" /></meta><meta name="dc.Creator" content="Maxwell D.  Cummings" /></meta><meta name="dc.Creator" content="Tse-I  Lin" /></meta><meta name="dc.Creator" content="Lili  Hu" /></meta><meta name="dc.Creator" content="Abdellah  Tahri" /></meta><meta name="dc.Creator" content="David  McGowan" /></meta><meta name="dc.Creator" content="Katie  Amssoms" /></meta><meta name="dc.Creator" content="Stefaan  Last" /></meta><meta name="dc.Creator" content="Benoit  Devogelaere" /></meta><meta name="dc.Creator" content="Marie-Claude  Rouan" /></meta><meta name="dc.Creator" content="Leen  Vijgen" /></meta><meta name="dc.Creator" content="Jan Martin  Berke" /></meta><meta name="dc.Creator" content="Pascale  Dehertogh" /></meta><meta name="dc.Creator" content="Els  Fransen" /></meta><meta name="dc.Creator" content="Erna  Cleiren" /></meta><meta name="dc.Creator" content="Liesbet  van der Helm" /></meta><meta name="dc.Creator" content="Gregory  Fanning" /></meta><meta name="dc.Creator" content="Origène  Nyanguile" /></meta><meta name="dc.Creator" content="Kenny  Simmen" /></meta><meta name="dc.Creator" content="Pieter  Van Remoortere" /></meta><meta name="dc.Creator" content="Pierre  Raboisson" /></meta><meta name="dc.Creator" content="Sandrine  Vendeville" /></meta><meta name="dc.Description" content="Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in..." /></meta><meta name="Description" content="Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 8, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401396p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401396p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401396p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401396p" /></link>
        
    
    

<title>Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401396p" /></meta><meta property="og:title" content="Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0015.jpeg" /></meta><meta property="og:description" content="Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in conjunction with in vivo evaluation in rats identified several compounds showing (i) nanomolar potency in HCV replicon cells, (ii) limited toxicity and off-target activities, and (iii) encouraging preclinical pharmacokinetic profiles characterized by high liver distribution. This effort culminated in the identification of TMC647055 (10a), a nonzwitterionic 17-membered-ring macrocycle characterized by high affinity, long polymerase residence time, and broad genotypic coverage. In vitro results of the combination of 10a with the HCV protease inhibitor TMC435 (simeprevir) supported an evaluation of this combination in patients with regard to virus suppression and resistance emergence. In a phase 1b trial with HCV genotype 1-infected patients, 10a was considered to be safe and well-tolerated and demonstrated potent antiviral activity, which was further enhanced in a combination study with TMC435." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401396p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401396p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401396p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401396p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401396p&amp;href=/doi/10.1021/jm401396p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1880-1892</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4016894" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401420j" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maxwell+D.++Cummings">Maxwell D. Cummings</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tse-I++Lin">Tse-I Lin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lili++Hu">Lili Hu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Abdellah++Tahri">Abdellah Tahri</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++McGowan">David McGowan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katie++Amssoms">Katie Amssoms</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefaan++Last">Stefaan Last</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benoit++Devogelaere">Benoit Devogelaere</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marie-Claude++Rouan">Marie-Claude Rouan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leen++Vijgen">Leen Vijgen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan+Martin++Berke">Jan Martin Berke</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pascale++Dehertogh">Pascale Dehertogh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Els++Fransen">Els Fransen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erna++Cleiren">Erna Cleiren</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liesbet++van+der+Helm">Liesbet van der Helm</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Fanning">Gregory Fanning</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Orig%C3%A8ne++Nyanguile">Origène Nyanguile</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenny++Simmen">Kenny Simmen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pieter++Van+Remoortere">Pieter Van Remoortere</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Raboisson">Pierre Raboisson</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandrine++Vendeville">Sandrine Vendeville</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Janssen Infectious Diseases BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div><div class="corresp-info"><strong>*</strong>Phone: + 32 14 64 17 84. E-mail: <a href="/cdn-cgi/l/email-protection#a8dbdecdc6cccdde99e8c1dcdb86c2c6c286cbc7c5"><span class="__cf_email__" data-cfemail="8bf8fdeee5efeefdbacbe2fff8a5e1e5e1a5e8e4e6">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401396p&amp;href=/doi/10.1021%2Fjm401396p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1880–1892</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 21, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 September 2013</li><li><span class="item_label"><b>Published</b> online</span>8 November 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 March 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401396p" title="DOI URL">https://doi.org/10.1021/jm401396p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1880%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMaxwell%2BD.%2BCummings%252C%2BTse-I%2BLin%252C%2BLili%2BHu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D5%26contentID%3Djm401396p%26title%3DDiscovery%2Band%2BEarly%2BDevelopment%2Bof%2BTMC647055%252C%2Ba%2BNon-Nucleoside%2BInhibitor%2Bof%2Bthe%2BHepatitis%2BC%2BVirus%2BNS5B%2BPolymerase%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1892%26publicationDate%3DMarch%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401396p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1843</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401396p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Maxwell&quot;,&quot;last_name&quot;:&quot;D. Cummings&quot;},{&quot;first_name&quot;:&quot;Tse-I&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Lili&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Abdellah&quot;,&quot;last_name&quot;:&quot;Tahri&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;McGowan&quot;},{&quot;first_name&quot;:&quot;Katie&quot;,&quot;last_name&quot;:&quot;Amssoms&quot;},{&quot;first_name&quot;:&quot;Stefaan&quot;,&quot;last_name&quot;:&quot;Last&quot;},{&quot;first_name&quot;:&quot;Benoit&quot;,&quot;last_name&quot;:&quot;Devogelaere&quot;},{&quot;first_name&quot;:&quot;Marie-Claude&quot;,&quot;last_name&quot;:&quot;Rouan&quot;},{&quot;first_name&quot;:&quot;Leen&quot;,&quot;last_name&quot;:&quot;Vijgen&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Martin Berke&quot;},{&quot;first_name&quot;:&quot;Pascale&quot;,&quot;last_name&quot;:&quot;Dehertogh&quot;},{&quot;first_name&quot;:&quot;Els&quot;,&quot;last_name&quot;:&quot;Fransen&quot;},{&quot;first_name&quot;:&quot;Erna&quot;,&quot;last_name&quot;:&quot;Cleiren&quot;},{&quot;first_name&quot;:&quot;Liesbet&quot;,&quot;last_name&quot;:&quot;van der Helm&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Fanning&quot;},{&quot;first_name&quot;:&quot;Origène&quot;,&quot;last_name&quot;:&quot;Nyanguile&quot;},{&quot;first_name&quot;:&quot;Kenny&quot;,&quot;last_name&quot;:&quot;Simmen&quot;},{&quot;first_name&quot;:&quot;Pieter&quot;,&quot;last_name&quot;:&quot;Van Remoortere&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Raboisson&quot;},{&quot;first_name&quot;:&quot;Sandrine&quot;,&quot;last_name&quot;:&quot;Vendeville&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;1880-1892&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401396p&quot;},&quot;abstract&quot;:&quot;Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in conjunction with in vivo evaluation in rats identified several compounds showing (i) nanomolar potency in HCV replicon cells, (ii) limited toxicity and off-target activities, and (iii) encouraging preclinical pharmacokinetic profiles characterized by high liver distribution. This effort culminated in the identification of TMC647055 (10a), a nonzwitterionic 17-membered-ring macrocycle characterized by high affinity, long polymerase residence time, and broad genotypic coverage. In vitro results of the combination of 10a with the HCV protease inhibitor TMC435 (simeprevir) supported an evaluation of this combination in patients with regard to virus suppression and resistance emergence. In a phase 1b trial with HCV genotype 1-infected patients, 10a was considered to be safe and well-tolerated and demonstrated potent ant&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401396p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401396p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401396p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401396p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401396p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401396p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401396p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401396p&amp;href=/doi/10.1021/jm401396p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401396p" /></input><a href="/doi/pdf/10.1021/jm401396p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401396p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401396p%26sid%3Dliteratum%253Aachs%26pmid%3D24144360%26genre%3Darticle%26aulast%3DCummings%26date%3D2014%26atitle%3DDiscovery%2Band%2BEarly%2BDevelopment%2Bof%2BTMC647055%252C%2Ba%2BNon-Nucleoside%2BInhibitor%2Bof%2Bthe%2BHepatitis%2BC%2BVirus%2BNS5B%2BPolymerase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D5%26spage%3D1880%26epage%3D1892%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jmcmar.2014.57.issue-5/production/jmcmar.2014.57.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in conjunction with in vivo evaluation in rats identified several compounds showing (i) nanomolar potency in HCV replicon cells, (ii) limited toxicity and off-target activities, and (iii) encouraging preclinical pharmacokinetic profiles characterized by high liver distribution. This effort culminated in the identification of TMC647055 (<b>10a</b>), a nonzwitterionic 17-membered-ring macrocycle characterized by high affinity, long polymerase residence time, and broad genotypic coverage. In vitro results of the combination of <b>10a</b> with the HCV protease inhibitor TMC435 (simeprevir) supported an evaluation of this combination in patients with regard to virus suppression and resistance emergence. In a phase 1b trial with HCV genotype 1-infected patients, <b>10a</b> was considered to be safe and well-tolerated and demonstrated potent antiviral activity, which was further enhanced in a combination study with TMC435.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/57/5"><issue-title>HCV Therapies</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C virus (HCV) represents a major global health burden and is associated with increased risk of liver cirrhosis and hepatocellular carcinoma, which is the leading cause of liver transplants in the USA.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Despite the availability of new therapies combining either of the recently approved direct-acting antiviral agents (DAAs) boceprevir<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> and telaprevir,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> both of which are NS3 protease inhibitors, with PEGylated interferon α (as weekly injections) and ribavirin (b.i.d.), there remains a high medical need for new DAAs with complementary modes of action. Such regimens involving clinically validated protease inhibitors and inhibitors of the NS5B polymerase and the NS5A replication complex are needed in order to (i) increase cure rates, especially in difficult-to-treat patients; (ii) limit the development of resistant mutants; (iii) optimize the tolerability/side-effect profile; and (iv) decrease treatment duration. Ultimately, it is anticipated that combinations of several DAAs in an all-oral interferon-sparing regimen will lead to highly effective and better-tolerated treatments.</div><div class="NLM_p">The NS5B polymerase plays an essential role in the life cycle of HCV since it is responsible for viral replication.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Two classes of polymerase inhibitors have shown proof-of-concept in clinical development: nucleoside analogues recognized by the active site and incorporated into nascent RNA as chain (or delayed chain) terminators<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> and non-nucleoside inhibitors (NNIs) binding to at least four distinct allosteric sites.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> NNI-1 inhibitors, also called thumb domain 1 or finger-loop inhibitors, bind in a pocket distal to the catalytic site at the interface of the finger and thumb domains of the polymerase.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> A 6-carboxylic acid indole chemotype represented by the early lead compound <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was optimized by several groups based on two distinct strategies, both of which yielded clinical candidates. In the first strategy, extension from the carboxylic acid moiety and incorporation of rather large and charged diamide moieties, combined with the more metabolically stable cyclopentyl group rather than the cyclohexyl group, led to the clinical candidate BILB1941 (<b>2</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In the second strategy, conformational rigidification by introduction of a tether between the indole nitrogen and the C2-aryl group was explored, leading to tetracyclic and pentacyclic structures, most of which were zwitterions, as exemplified by MK-3281 (<b>3</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), a compound that reached human phase 1 clinical study.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the early lead compound <b>1</b>, the clinical candidates <b>2</b> (BILB1941) and <b>3</b> (MK-3281), and initial 1,6- and 2,6-indole-based macrocycles <b>4</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To avoid the possible formation of acyl glucuronide metabolites from the carboxylic acid group<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (a potential cause of immunogenic reactions and toxicity<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a>) and the presence of a zwitterionic structure (a possible cause of exposure variability in patients<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>), we applied a structure-based macrocyclization strategy centered on the introduction of a linker in the solvent-exposed region, incorporating a carboxylic acid bioisostere. It was anticipated that this strategy would improve the permeability and avoid the formation of potentially toxic glucuronide acid derivatives as phase 2 metabolites while providing inhibitors with superior potency and pharmacokinetic (PK) profiles due to the effect of conformational restriction. Early crystal structures provided details on the binding mode of this chemotype to the NNI-1 site,<a onclick="showRef(event, 'ref15 ref26'); return false;" href="javascript:void(0);" class="ref ref15 ref26">(15, 26)</a> and we used this information to guide the initial exploration of three macrocycle classes. The first type of macrocycle, in which the linker is attached to the indole nitrogen and the C6 position of the indole via an amide, served as a proof-of-concept for this strategy, since micromolar potency was obtained in the replicon assay with macrocycle <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) while its open precursor (prior to the ring-closure metathesis step) was completely inactive (not shown).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As expected, an acyl sulfamide replacement for the amide group proved to be a much better bioisostere of the carboxylic acid and provided macrocycles <b>5a</b> and <b>5b</b> with submicromolar EC<sub>50</sub>’s of 0.79 and 0.43 μM, respectively. Similar findings were obtained for the second type of macrocycle, where the linker is attached to the C2 aryl group instead of the indole nitrogen in an effort to restrict the free rotation of the aryl moiety and favor the bioactive conformation. Thus, macrocycle <b>6</b> displayed an improved potency of 0.18 μM in the replicon assay. However, while most of our initial criteria, including cellular potency, no potential for acyl glucuronide formation, no zwitterion, and good bioavailability and distribution to the liver in rats after oral administration, had been satisfied with this second series of macrocycles, this series was still hampered by rather high in vivo clearance in rats despite moderate in vitro metabolic turnover in microsomes [clearances typically higher than 7 L h<sup>–1</sup> kg<sup>–1</sup> after IV administration of 2 mg/kg compound in 70:30 PEG400/saline]. We then concentrated our efforts on a third series of macrocycles in which the linker originates from a bridge and forms a seven-membered ring between the indole nitrogen and the C2 aryl group. Our subsequent optimization efforts involved the exploration of three types of bridge: saturated, unsaturated, and incorporating a cyclopropyl group.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p last">In this article, we describe the discovery of the macrocyclic indole TMC647055 (<b>10a</b>), which is currently being evaluated in phase 2 clinical trials in combination with TMC435 (simeprevir), a once-daily protease inhibitor discovered at Janssen during a research collaboration with Medivir. We review the synthesis, structure–activity relationships, and binding interactions of this new series of tetracyclic indole-based macrocycles, and we also discuss genotypic coverage, resistance, and mutant selection. The potential for combination with other DAAs and preliminary results in healthy volunteers and HCV genotype 1-infected patients, including those obtained in combination with TMC435,<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> are also presented.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0016.gif" alt="" id="GRAPHIC-d2701e448-autogenerated" /></img></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Macrocyclic indole derivatives <b>10a</b>–<b>i</b> were synthesized following a six-step procedure starting from the orthogonally protected bisester tetracycle <b>7</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The synthetic route is exemplified with the structure of TMC647055 (<b>10a</b>) in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. After hydrolysis of the methyl ester, a HATU-mediated amide coupling was performed using an excess of the symmetrical bisamine 2,2′-oxybis(<i>N</i>-methylethanamine) under diluted conditions in THF to give amide <b>8a</b> in 93% yield. A monoprotected unsymmetrical bisamine could also be used stoichiometrically and then further deprotected under acidic conditions (i.e., TFA in DCM for the removal of the Boc protecting group) or under basic conditions using thiophenol in the case of the nosyl protecting group. The free amino group was then converted to the sulfamide moiety using an excess of sulfamide in dioxane at 100 °C to give derivative <b>9a</b> in good yield (95%). The <i>tert</i>-butyl ester was subsequently cleaved under acidic conditions (TFA in DCM) in quantitative yield, and the ring closure was performed using a tandem of reactions involving activation of the carboxylic acid by CDI followed by intramolecular attack of the anion of the sulfamide group, formed by addition of DBU. This synthetic route yielded macrocycle <b>10a</b> in 49% overall yield from bisester <b>7</b> and was also used to synthesize macrocycles <b>10b</b>–<b>i</b>. Alternatively, ring closure could be performed by a HATU-mediated macrolactamization under high dilution after successive introduction of a sulfamide derivative containing a protected amine using the two-step CDI/DBU procedure described above and cleavage of the methyl ester and then the amino protecting group of the linker. Macrocycles <b>10j</b>–<b>l</b> were synthesized according to this latter route (not shown).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>10a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, THF, H<sub>2</sub>O, MeOH, RT (95%). (b) 2,2′-Oxybis(<i>N</i>-methylethanamine) (5 equiv), HATU, DIPEA, THF. (c) Sulfamide, dioxane, 100 °C. (d) TFA/DCM. (e) (i) CDI, dry THF, RT; (ii) DBU, THF.</p></p></figure><div class="NLM_p">Upon catalytic hydrogenation, compound <b>10a</b> gave a mixture of enantiomers that could be separated by chiral chromatography, yielding the enantiomerically pure macrocycles <b>11a</b> and <b>12a</b> containing a saturated bridge (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The enantiomeric excesses were 100% and 99.1%, respectively.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of <b>11a</b> and <b>12a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Derivatives with the cyclopropyl bridge were obtained by cyclopropanation of bisester indole <b>7</b> using trimethylsulfoxonium chloride in the presence of sodium hydride followed by enantiomeric separation of the pair of enantiomers obtained with the chiral auxiliary (<i>S</i>)-4-benzyl-2-oxazolidinone by column chromatography, which yielded diastereoisomers <b>14</b> and <b>15</b>, as depicted in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. After removal of the chiral auxiliary under basic conditions, the reaction sequence used for the preparation of macrocyclic derivative <b>10a</b> was applied to carboxylic acids <b>16</b> and <b>17</b>, yielding the cyclopropyl-bridged macrocycles <b>18a</b> and <b>19a</b> with 100% ee. For the two pairs of enantiomers <b>11a</b>/<b>12a</b> and <b>18a</b>/<b>19a</b>, assignment of stereochemistry was based on antiviral data in conjunction with conformational analysis and modeled binding modes predicated on earlier NS5B–inhibitor complexes.<a onclick="showRef(event, 'ref28 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref31">(28, 31)</a> The rich set of available and relevant public structural data allowed for the straightforward construction of what were deemed to be relatively reliable binding models on the basis of the assumption of common binding modes for the corresponding features of the new inhibitors. This approach, while based on modeled structures, seemed quite reliable, and our later results with a macrocyclic inhibitor complex (discussed below) proved to be fully consistent with our earlier speculations on both stereochemical preference and macrocycle design.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>18a</b> and <b>19a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) Trimethylsulfoxonium chloride, NaH, DMSO, RT; (ii) <b>7</b>, 50 °C. (b) NaOH, H<sub>2</sub>O/THF/MeOH, RT. (c) (COCl)<sub>2</sub>, DMF, THF, 0 °C. (d) (<i>S</i>)-4-Benzyl-2-oxazolidinone (1.1 equiv), <i>n</i>-BuLi (1.1 equiv), THF, −78 °C. (e) NaOH (1 N), MeOH/THF, RT. (f) 2,2′-Oxybis(<i>N</i>-methylethanamine) (5 equiv), HATU, DIPEA,THF. (g) (i) Sulfamide, dioxane, 100 °C; (ii) TFA/DCM. (h) (i) CDI, dry THF, RT; (ii) DBU, THF.</p></p></figure><div class="NLM_p">The synthesis of macrocycle <b>25</b> with a “reduced” amide bond is outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. A one-pot procedure involving the conversion of carboxylic acid <b>20</b> to the corresponding isobutyl carbonate followed by sodium borohydride reduction afforded alcohol <b>21</b>. Subsequent introduction of the mesylate leaving group and its displacement by symmetrical <i>N</i>,<i>N</i>′-dimethyl-1,4-butanediamine allowed for the synthesis of intermediate <b>23</b>, which then underwent the same sequence of reactions as previously to yield the “reduced” macrocycle <b>25</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N</i>-Methylmorpholine, isobutyl chloroformate, THF, −15 °C, then NaBH<sub>4</sub>, 0 °C. (b) Et<sub>3</sub>N, MeSO<sub>2</sub>Cl, THF, 0 °C. (c) <i>N</i>,<i>N</i>′-Dimethyl-1,4-butanediamine, THF, RT. (d) Sulfamide, dioxane, 105 °C. (e) (i) TFA, DCM, RT; (ii) CDI, acetonitrile, 60 °C; (iii) DBU, acetonitrile, RT.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">SAR and PK Properties Leading to the Selection of TMC647055</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The anti-HCV potencies (EC<sub>50</sub>’s) of compounds <b>10a</b>–<b>l</b>, <b>11a</b>, <b>12a</b>, <b>18a</b>, <b>19a</b>, and <b>25</b> were determined in the Huh-7 replicon cell line containing the subgenomic bicistronic HCV genotype 1b replicon clone ET and luciferase readout<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In an effort to better understand the observed structure–activity relationship (SAR), and in the absence of a reliable permeability determination for this class of macrocycles,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> binding affinities on the 1b polymerase were measured by surface plasmon resonance (SPR)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Cytotoxicity was measured in MT4 and Huh-7 cell lines and was minimal for all the compounds tested (CC<sub>50</sub> > 25 μM). Studies with the unsaturated-bridged macrocyclic series revealed several structure–activity trends. The 16- and 17-membered macrocycles were optimal. An 18-membered analogue (<b>10b</b>) suffered a 2-fold decrease in replicon potency (cf. <b>10a</b> and <b>10c)</b> despite improved binding affinity (<i>K</i><sub>d</sub> = 0.8 nM). Smaller ring size (compound <b>10d</b>, 15-membered ring) led to decreased binding affinity and replicon potency. Ether and alkyl linkers were similarly potent, while the presence of a basic nitrogen in the linker decreased the activity (<b>10f</b> and the piperazine derivatives <b>10g</b> and <b>10l</b>), contrasting with earlier reports on non-macrocyclic indoles.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Substitution of the linker nitrogens had dramatic effects. Two methyl substituents proved optimal, while monomethyl analogues (<b>10j</b> and <b>10k</b>) were less potent in both binding and cellular assays, with an additional effect of decreased permeability for macrocycle <b>10j</b>. Derivatives with R<sup>1</sup> = methoxy (<b>10a</b>) and fluoro (<b>10i</b>) showed similar potencies, while R<sup>1</sup> = chloro (<b>10h</b>) gave a 4-fold loss of potency in the replicon assay, likely attributable to high lipophilicity in view of the good binding affinity (<i>K</i><sub>d</sub> = 1.5 nM) observed for this compound. While keeping the ether linker constant, the nature and stereospecificity of the seven-membered bridge was evaluated with the saturated analogues <b>11a</b> and <b>12a</b> and cyclopropyl-bridged macrocycles <b>18a</b> and <b>19a</b>. For these two subseries, only the <i>R</i> enantiomers (<b>12a</b> and <b>19a</b>) showed good antiviral activity, with 20- and 40-fold losses of potency for the less active enantiomers <b>11a</b> and <b>18a</b>, respectively. Saturation of the double bond yielded a compound with potency similar to that of the unsaturated analogue <b>10a</b> (EC<sub>50</sub> = 79 and 77 nM for <b>12a</b> and <b>10a</b>, respectively), while cyclopropanation gave a 2-fold improvement (<b>19a</b>, EC<sub>50</sub> = 40 nM). Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> shows models of both enantiomers of a simple non-macrocyclic <i>N</i>,<i>N</i>-dimethylamide, highlighting the different trajectories accessible to this pair. In this case, the models have been adjusted to closely mimic the bound conformation observed for <b>10c</b> on which they are overlaid; under these (idealized) conditions it is clear that while the <i>R</i> amide overlays closely with that of bound <b>10c</b>, such a trajectory is not possible for the <i>S</i> enantiomer. Thus, we speculate that the less active <i>S</i> enantiomers are unable to adopt the optimal binding conformation within the constraint imposed by the 17-membered macrocycle. Extensive conformational adjustment involving the core indole–phenyl system of the inhibitor would be expected to have a profound and likely negative effect on the binding affinity. Additional changes in binding contacts could reasonably be expected for the contact with Arg503 as well as the contact with His34, which has been observed for bound <b>10c</b> (discussed below in <a class="ref internalNav" href="#sec4" aria-label="Crystallography and Modeling">Crystallography and Modeling</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of the Subseries, Linker, And Phenyl Substitution on Replicon Potency and Binding Affinity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Replicon potency.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Dissociation constant determined by surface plasmon resonance with NS5B con1b(Δ21).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></p></div></div><div></div></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stereospecificity of the saturated bridged system. Depicted are conformers of non-macrocyclic <i>N</i>,<i>N</i>-dimethylamide (<i>R</i>, green; <i>S</i>, purple), showing the stereospecific difference in the trajectory from the bridge, overlaid onto the NS5B-bound conformation of <b>10c</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, the carbonyl of the amide group proved to be critical for potency, since the “reduced” macrocycle <b>25</b> exhibited a 30-fold decrease in cellular anti-HCV replicon activity relative to amide <b>10c</b> (EC<sub>50</sub> = 2.34 μM versus 0.075 μM). The antiviral potency in the presence of 40% human serum was also measured, since this series of macrocycles generally exhibited high binding to plasma proteins in vitro (e.g., the free fraction of <b>10a</b> in the presence of plasma is 0.3%), which could limit the in vivo efficacy. The resulting serum shifts were generally 10–15-fold (9-fold for <b>10a</b>), with no clear SAR for this parameter. Rather than trying to decrease the serum shift, our strategy focused on the selection of compounds exhibiting high distribution to the liver, since HCV replication takes place almost exclusively in hepatocytes. We anticipated that this parameter could be an important contributor to the efficacy of compounds in patients<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> and that it may correspond to a more therapeutically relevant way of discriminating among inhibitors with relatively good anti-HCV replicon activities compared with the common strategy of minimizing the serum shift. Ultimately, a concentration in the liver at 7 h postdose that was higher than the serum-shifted EC<sub>50</sub> was used as a criterion to select the most promising compounds.</div><div class="NLM_p">A panel of analogues chosen for their good antiviral potency, acceptable in vitro metabolic stability, and chemical diversity, were then evaluated in vivo in Sprague–Dawley rats after IV and oral administration at 2 and 10 mg/kg, respectively. In addition to the classical PK parameters, concentrations in the liver at 7 h postdose were also measured (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Parameters of Selected Macrocyclic Analogues (2 mg/kg IV, 10 mg/kg PO; Vehicle 70:30 PEG400/Saline IV, PEG400/2% vitE-TPGS PO; <i>n</i> = 3)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Cl (L h<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">[liver] (ng/g)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">L/P<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">F (%)<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">7800</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">>66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">5000</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">6317</td><td class="colsep0 rowsep0" align="char" char=".">341</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10i</b></td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">6560</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10l</b></td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="char" char=".">299</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">898</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">3200</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Human liver microsomes stability, expressed as percentage of compound metabolized after 15 min at a concentration of 5 μM.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Plasma clearance.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Liver concentration after oral administration 7 h postdose.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Liver/plasma ratio after oral administration 7 h postdose.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Oral bioavailability.</p></div></div></div><div class="NLM_p last">The nature of the bridge had a profound impact on the PK parameters, with the unsaturated analogue <b>10a</b> exhibiting the best overall profile, including good systemic absorption (bioavailability higher than 66%), high distribution to the liver (7800 ng/g, 7 h postdose), and moderate clearance. The saturated derivative <b>12a</b> showed clearance similar to that of <b>10a</b> but had low bioavailability and low distribution to the liver (15% and 898 ng/g, respectively), while the cyclopropyl derivative <b>19a</b> showed a relatively high clearance of 5.2 L h<sup>–1</sup> kg<sup>–1</sup>, in agreement with its low in vitro liver microsome stability (70% of the compound metabolized after 15 min in rat liver microsomes). The nature of the linker was also important: the unsubstituted amide derivative <b>10e</b> had good distribution to the liver but a poor absolute bioavailability of only 6%, highlighting the role of the amide substituent on permeability, while macrocycle <b>10l</b> with a basic piperazine moiety showed an extremely poor overall profile, combining high clearance (despite good in vitro liver microsome metabolic stability), low absorption, and poor distribution to the liver. Finally, replacement of the methoxy group by a fluoro substituent (<b>10i</b>) led to PK properties similar to those of <b>10a</b>, as did replacement of the ether-containing linker by the alkyl linker (<b>10c</b>). On the basis of the overall good in vitro and in vivo properties, <b>10a</b> was further evaluated in dogs and showed an acceptable PK profile characterized by high oral bioavailability (F = 87%) and high systemic exposure (<i>C</i><sub>max</sub> = 10.2 μM and AUC<sub>0–∞</sub> = 25.8 μM h) after a single 10 mg/kg oral dose, combined with moderate plasma clearance (Cl = 0.54 L h<sup>–1</sup> kg<sup>–1</sup>) and a low volume of distribution (Vd<sub>ss</sub> = 0.32 L/kg).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Crystallography and Modeling</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Macrocycle <b>10c</b>, a close structural analogue of TMC647055, was successfully cocrystallized with a ΔC<sub>21</sub> construct of genotype 1b strain J4 NS5B (Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>–<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The observed binding mode for the tetracyclic core and pendant cyclohexyl moiety of <b>10c</b> bound to the NNI-1 site of NS5B is consistent with those of the equivalent moieties of the previously published structures (PDB IDs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRK">2BRK</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRL">2BRL</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2DXS">2DXS</a><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>) that were used to guide our design strategy. The cyclohexyl ring and the corresponding hydrophobic edge of the relatively rigid indole–phenyl ring system sit in a hydrophobic pocket, while the opposite and relatively flexible side of the macrocycle (the macrocycle linker) is largely solvent-exposed. The acyl sulfamide moiety forms two hydrogen bonds with the guanidine of Arg503. Distinctively, the <b>10c</b> complex resolves additional N-terminal residues of the NNI-1 site in comparison with other published NNI-1 complexes (e.g., Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>);<a onclick="showRef(event, 'ref15 ref26'); return false;" href="javascript:void(0);" class="ref ref15 ref26">(15, 26)</a> interestingly, this difference may be due to a (weak) binding contact between the amide carbonyl of the macrocycle and His34 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Observed and modeled binding modes. (A) Crystal structure of <b>10c</b> (orange) bound at the NNI-1 site, showing the pocket surface and details of contacts with His34 and Arg503. (B) Overlay of bound <b>10c</b> (orange) and the modeled low-energy conformer of <b>10a</b> (purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular modeling analysis suggested that <b>10a</b> should be able to adopt a binding mode essentially identical to that of <b>10c</b>, possibly involving slight conformational adjustments in parts of the flexible macrocycle linker, which is one atom longer in <b>10a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b). The occupancy of the hydrophobic regions of the binding site and the multiple contacts with Arg503 are expected to be essentially identical to those described above for <b>10c</b>, whereas the contact with His34 is less clear because of the difference in the macrocycle linker lengths of <b>10c</b> and <b>10a</b>.</div><div class="NLM_p">Binding of inhibitors at both the NNI-1 and NNI-2 sites displaces the fingertip Λ1 loop, a change that is thought to lock the enzyme in an inactive “open” state and thus lead to inhibition.<a onclick="showRef(event, 'ref15 ref36'); return false;" href="javascript:void(0);" class="ref ref15 ref36">(15, 36)</a><b>10c</b> bound in the NNI-1 site closely mimics features of the fingertip Λ1 loop, positioning hydrophobic aryl groups similarly to the side chains of Leu30 and Leu31 of the bound loop (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) and effectively competing with the native intramolecular protein–protein interaction.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of bound inhibitors with the native NNI-1 site protein–protein interaction. Shown are bound <b>10c</b> and a model of <b>10a</b> (as in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b) overlaid on the NS5B loop that occupies NNI-1 in the absence of bound inhibitor [protein of the NNI-1 site is not shown; the loop is from monomer B of the <b>10c</b>–NS5B complex structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DRU">4DRU</a>)].<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since the original formulation of our macrocycle design strategy,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> additional structures detailing indoles bound at the NNI-1 site have been disclosed.<a onclick="showRef(event, 'ref20 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref20 ref37 ref38">(20, 37, 38)</a> These structures reveal additional information about feasible binding interactions in the NNI-1 site and are also consistent with previous structures. Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> shows overlays of bound <b>10c</b> with two examples of these more recent indole inhibitors, and in both cases we see a tight overlay with the tetracyclic cyclohexyl–indole–phenyl core of bound <b>10c</b>. Similar to <b>10c</b>, the new structures show multiple hydrogen-bonding contacts with the guanidine of Arg503. The importance of this interaction was noted previously,<a onclick="showRef(event, 'ref15 ref26 ref31'); return false;" href="javascript:void(0);" class="ref ref15 ref26 ref31">(15, 26, 31)</a> with earlier structures incorporating a carboxylate for this contact; one key element of our macrocycle design strategy was the replacement of this carboxylate. In our original report, we described the more buried pocket where the methoxyphenyl moiety of bound <b>10c</b> sits, compared with the more exposed regions seen in earlier structures. This difference persists in the more recent structures, the two examples of which both show the more exposed pocket in this region of the binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). The reason(s) for the observation of the more enclosed pocket in this region of the binding site in our structure remains unclear, but it may be due to the methoxyphenyl group that protrudes more deeply into the pocket and/or the weak contact between the inhibitor amide carbonyl and His34 mentioned above. Both of these chemical features are relatively unique to <b>10c</b> in comparison with the inhibitors bound at this site in other published structures.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison with recent NS5B NNI-1 complex structures. (A) <b>10c</b> with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z">3Q0Z</a> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z">3Q0Z</a> protein shown).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (B) <b>10c</b> with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC">4GMC</a> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC">4GMC</a> protein shown).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Preclinical Characterization of TMC647055 (<b>10a</b>)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of the promising anti-HCV replicon activity and PK profiles in preclinical species, <b>10a</b> was selected as a candidate for clinical development, and its biological profile with respect to binding kinetics, genotypic coverage, resistance and mutant selection, combination with other DAAs, and preliminary safety were further characterized.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p"><b>10a</b> elicited a mean IC<sub>50</sub> of 34 nM in an RNA-dependent, RNA polymerase primer-dependent transcription assay and inhibited the replication of a genotype 1b replicon (clone ET) in the Huh7-Luc cell line with a median EC<sub>50</sub> of 77 nM (luciferase readout). In Huh7-SG-1a, a stable genotype 1a cell line, the median EC<sub>50</sub> value was 166 nM (qRT-PCR readout). The mean 50% cytotoxic concentrations in Huh7 and MT4 cells in luciferase reporter assays were 42.1 μM (<i>n</i> = 5) and 28.9 μM (<i>n</i> = 16), respectively. Cytotoxicity measurements on a panel of additional cell lines (MRC-5, HEK-293T, HepG2, and VeroE6 cells) all resulted in CC<sub>50</sub> values in excess of 50 μM.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">The binding kinetics of <b>10a</b> were measured by SPR and showed a high-affinity interaction with NS5B across all genotypes (i.e., median <i>K</i><sub>d</sub> < 35 nM), except for genotype 2b, for which a more than 20-fold decrease in <i>K</i><sub>d</sub> was observed, mainly because of a higher dissociation rate (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). For genotype 1b, the association and dissociation constants were 2.2 × 10<sup>4</sup> M<sup>–1</sup> s<sup>–1</sup> and 8.9 × 10<sup>–5</sup> s<sup>–1</sup>, respectively, resulting in a <i>K</i><sub>d</sub> of 4 nM and a half-life of 130 min. This rather long inhibitor residence time may represent a distinctive advantage over other indole derivatives with regard to in vivo efficacy and target selectivity.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> Broad cross-genotypic coverage of <b>10a</b> was also confirmed in a transient replicon assay using chimeric replicons containing the NS5B region derived from patient isolates (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), with <b>10a</b> showing consistently high potencies against genotypes 1a, 1b, 3a, 4a, and 6a. Similar to previous reports describing NNI-1 inhibitors,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> we observed a >200-fold reduction in potency against genotypes 2a and 2b (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Median Binding Affinities and Antiviral Activities of <b>10a</b> against Different Genotypes, Using NS5B Purified Proteins from Clinical Isolates and a Transient Replicon Assay with Chimeric Replicons Containing the NS5B Region Derived from Patient Isolates, Respectively</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="×" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">genotype</th><th class="colsep0 rowsep0" align="center" char="×"><i>K</i><sub>d</sub> (M)</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wild-type 1b</td><td class="colsep0 rowsep0" align="char" char="×">4.1 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.051</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1a</td><td class="colsep0 rowsep0" align="char" char="×">7.3 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.048</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1b</td><td class="colsep0 rowsep0" align="char" char="×">3.9 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2a</td><td class="colsep0 rowsep0" align="char" char="×">–</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">12.530</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2b</td><td class="colsep0 rowsep0" align="char" char="×">8.8 × 10<sup>–7</sup></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">>28.000</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3a</td><td class="colsep0 rowsep0" align="char" char="×">6.1 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.088</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4a</td><td class="colsep0 rowsep0" align="char" char="×">2.0 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.097</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5a</td><td class="colsep0 rowsep0" align="char" char="×">2.1 × 10<sup>–8</sup></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6a</td><td class="colsep0 rowsep0" align="char" char="×">3.0 × 10<sup>–8</sup></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.113</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Number of isolates. For <i>n</i> = 1 or 2, the observed value or the mean of the two observed values, respectively, is reported.</p></div></div></div><div class="NLM_p">The susceptibility of <b>10a</b> was tested on different genotype 1b replicons harboring mutations in the NS5B polymerase located in the NNI-1 pocket (L392I, V494A, and P495L), also identified during in vitro resistance selection experiments with <b>10a</b>, and on other mutations outside of the NNI-1 pocket. The greatest decrease in antiviral potency, a 371-fold reduction in susceptibility relative to that of the wild-type genotype 1b replicon, was observed for the P495L mutant, consistent with previous reports identifying this position as a key mutation for NNI-1 site inhibitors.<a onclick="showRef(event, 'ref16 ref33 ref42'); return false;" href="javascript:void(0);" class="ref ref16 ref33 ref42">(16, 33, 42)</a> The L392I and V494A mutations resulted in 9- and 3-fold median decreases, respectively, in anti-HCV replicon activity. Overall, these results mirror those of past resistance studies. Residues 392, 494, and 495 contribute to the NNI-1 site binding surface, making direct binding contacts with bound <b>10c</b>, <b>10a</b> (model shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), and other indoles that bind at this site.<a onclick="showRef(event, 'ref15 ref20 ref26 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref15 ref20 ref26 ref37 ref38">(15, 20, 26, 37, 38)</a> Residue 392 contributes to the deepest part of the hydrophobic pocket occupied by the cyclohexyl moiety, while residue 494 contacts both the cyclohexyl ring and the face of the indole–phenyl system. Residue 495 packs against the face of the indole and is also near the critical acyl sulfamide moiety of the bound inhibitor; changes at this position are also likely to impact the positioning of Arg503, which forms multiple hydrogen bonds with bound <b>10c</b> and <b>10a</b> and makes similar interactions with other NNI-1 compounds. Thus, the resistance results seem consistent with the observed and modeled binding modes presented here. Additionally, the activity of <b>10a</b> was not affected by mutations associated with reduced sensitivity to NNI-2 (M423T), NNI-3 (M414T), NNI-4 (C316Y), HCV NS5B nucleoside/nucleotide inhibitors (S96T and S282T), HCV NS3/4A protease inhibitors (R155K, A156V, and D168V), and HCV NS5A inhibitors (L31V and Y93H).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> NS3/4a inhibitors (e.g., TMC435) and NS5A inhibitors maintained full inhibitory potency against the NNI-1 mutants. This lack of cross-resistance suggested that combination therapy with other DAAs may be fruitful.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. NS5B resistance mutations for <b>10a</b>. The <b>10a</b>–NS5B complex was modeled by superimposing a low-energy conformer of <b>10a</b> onto bound <b>10c</b> from the <b>10c</b>–NS5B complex, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b. Positions 392 (light teal), 494 (dark teal), and 495 (red) are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further explore the effect of a combination of an NNI and a protease inhibitor on virus suppression and resistance development, an in vitro clearance and rebound experiment and a colony formation experiment were carried out with <b>10a</b> and TMC435 (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) using Huh7-Luc replicon cells.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In the clearance and rebound experiment, a 14 day incubation of the cells with the two inhibitors alone and in combination was followed by a 3 week “rebound” phase in the absence of inhibitor. Complete clearance of replicon cells was achieved using the combination of 1.5 μM <b>10a</b> and 0.10 μM TMC435, while for each of these inhibitors alone, even at higher concentrations (3.75 and 0.25 μM for the NNI and protease inhibitors, respectively), incomplete clearance and rebound of replicon RNA was observed. In addition, in the colony formation experiments, in which Huh7-Luc replicon cells were incubated for 2–3 weeks with either TMC435 or <b>10a</b> or a combination of the two, the combination of these two inhibitors suppressed the formation of resistant colonies at low concentrations (0.75 and 0.08 μM for the NNI and protease inhibitor, respectively). At a higher concentration of 1.5 μM, <b>10a</b> alone led to a similar result, while the protease inhibitor (0.20 μM) alone did not.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure of the HCV NS3/4A protease inhibitor TMC435 (simeprevir, Sovriad).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The in vitro preliminary safety of <b>10a</b> was found to be acceptable in a battery of assays assessing cytotoxicity toward six different cell lines, genotoxicity, cardiovascular toxicity, selectivity versus human polymerases and a panel of enzymes and receptors, and potential reactivity with regard to glutathione adduct formation and acyl glucuronide formation. In addition, no systemic adverse effects were observed in a 5 day tolerance study with up to 1000 mg kg<sup>–1</sup> day<sup>–1</sup> in rat, except for a small decrease in body weight.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Early Clinical Development of TMC647055 (<b>10a</b>)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The safety and tolerability of <b>10a</b> after repeated administrations during 5 days and a morning dose at day 6 was demonstrated in healthy volunteers given oral b.i.d. doses of 300 mg, 1000 mg, and 1250 mg as well as in HCV genotype 1-infected patients given oral b.i.d. doses of 500 mg and 1000 mg. The most commonly reported adverse events were gastrointestinal (nausea, vomiting, loose stools, diarrhea, and abdominal cramps/discomfort), probably related to the hydroxypropyl-β-cyclodextrin vehicle. There were no serious adverse events (SAEs), no grade 3 or 4 AEs, and no clinically significant effects on laboratory parameters, vital signs, food consumption, appetite, or ECG profile. The main pharmacokinetic observations were (i) a marginal food effect, (ii) a slightly greater than dose-proportional increase in plasma concentrations in healthy volunteers and a dose-proportional increase in HCV-infected patients, (iii) an approximately 2-fold higher exposure in infected patients relative to healthy volunteers, and (iv) a decrease in exposure during the treatment. The plasma concentrations of 4-β-hydroxycholesterol, the endogenous biomarker for CYP3A4 induction, increased with increasing TMC647055 dose in healthy volunteers, indicating that TMC647055 induced CYP3A4 and its own metabolism. Mean trough concentrations in patients exceeded the replicon genotype 1a/1b EC<sub>50</sub> values at both 500 and 1000 mg b.i.d. The antiviral response showed dose-dependent median maximum decreases in HCV RNA from baseline of 1.4 log<sub>10</sub> and 2.4 log<sub>10</sub> in GT1a patients with HCV RNA data available up to Day 6 at 500 and 1000 mg b.i.d., respectively. In GT1b patients, the median maximum decreases in HCV RNA were similar at the two dose levels (3.3 log<sub>10</sub> at 500 mg b.i.d. and 3.4 log<sub>10</sub> at 1000 mg b.i.d.).</div><div class="NLM_p">These results encouraged further assessment of the combination of <b>10a</b> with the protease inhibitor TMC435, which had previously shown improved results in vitro relative to each of these compounds alone with regard to virus suppression and resistance development. The combination of <b>10a</b> (1000 mg b.i.d.) and TMC435 (150 mg q.d.) was given to HCV genotype 1a- and 1b-infected patients for 10 days and found to be safe and well-tolerated. Potent antiviral activity was measured, with a median HCV RNA decrease of 4.64 log<sub>10</sub> IU/mL at day 11. The decline in plasma HCV RNA was substantially better than observed with either <b>10a</b> or TMC435 alone. Importantly, no viral breakthrough was detected, and no emerging mutations in the NNI-1 pocket of the polymerase associated with reduced in vitro sensitivity to <b>10a</b> were seen. However, emergence of the R155K mutation in the NS3/4A protease, which leads to a 30-fold decrease in susceptibility to TMC435,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> was detected in six/seven genotype 1a-infected patients during dosing or at follow-up.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Finally, this combination was characterized by a decrease of the mean exposures of the two compounds upon repeated dosing, attributable to CYP3A4 induction by <b>10a</b>.</div><div class="NLM_p last">Because of the good safety and tolerability combined with potent antiviral activity, the combination of <b>10a</b> and TMC435 is being evaluated in an all-oral once-daily regimen with low-dose ritonavir to counterbalance the CYP3A4 induction, with and without ribavirin b.i.d., in a phase 2 interferon-free study.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A structure-based macrocyclization strategy was applied to a known 6-carboxylic acid indole chemotype, leading to the discovery of potent and selective inhibitors of HCV NS5B polymerase devoid of the undesirable features characterizing non-macrocyclic analogues (potential for acyl glucuronide formation and presence of zwitterions). Lead optimization focused on the subseries containing the more rigid bridged-indole macrocycles, in combination with early in vivo evaluation in rats, culminated rapidly in the discovery of the clinical candidate <b>10a</b>. This 17-membered-ring macrocycle is characterized by high affinity for and persistent binding to NS5B polymerase, encouraging in vivo properties in preclinical species (most notably high distribution to the liver in rats), and an acceptable preliminary safety profile. Furthermore, <b>10a</b> exhibits a favorable in vitro antiviral profile with respect to cross-genotypic coverage, virus suppression, and resistance selection, alone or in combination with the HCV NS3 protease inhibitor TMC435. These encouraging results translated to safe and well-tolerated treatment for HCV genotype 1-infected patients, demonstrating a strong antiviral effect that was more pronounced in combination treatment with TMC435. These results warrant further assessment of this combination in an all-oral once-daily interferon-free regimen with a low dose of ritonavir to optimize the pharmacokinetic–pharmacodynamic parameters.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Information</h3><div class="NLM_p last">NMR spectra were recorded on a Bruker Avance 400 spectrometer operating at 400 MHz for <sup>1</sup>H. Chemical shifts are given in parts per million and <i>J</i> values in hertz. Multiplicities are indicated using the following abbreviations: s for singlet, d for doublet, t for triplet, m for multiplet, etc. Details on the different LC–MS methods used for the characterization of the new compounds described in this section (designated as LCMS-1 to LCMS-6 and HPLC-chiral) can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Chemical purities were >95% for all final compounds, as assessed by two LC–MS analysis methods.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 1,1-Dimethylethyl 6-[[[2-[2-[(Aminosulfonyl)methylamino]ethoxy]ethyl]methylamino]carbonyl]-13-cyclohexyl-3-methoxy-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>9a</b>)</h3><div class="NLM_p last">A solution of NaOH (6.38 g) in 25 mL of water was added to a stirred solution of bisester <b>7</b> (2 g, 3.9 mmol, synthesized as reported in ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>) in THF (100 mL) and MeOH (150 mL). After 1 h, the reaction mixture (RM) was concentrated under reduced pressure and then diluted with ice-cold water (150 mL). The pH of the resulting solution was adjusted to 6 with acetic acid. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum to give 1.90 g (98% yield) of 10-(1,1-dimethylethoxycarbonyl)-13-cyclohexyl-3-methoxy-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-6-carboxylic acid (<b>20</b>) as a yellowish powder. To a stirred solution of carboxylic acid <b>20</b> (1.00 g, 2.05 mmol), DIPEA (1.07 mL, 6.15 mmol), and 2,2′-oxybis(<i>N</i>-methylethanamine) (1.08 g, 8.20 mmol) in 30 mL of dry THF was added HATU (1.17 g, 3.08 mmol) under nitrogen. After 1 h, the RM was quenched with water (100 mL) and extracted with ethyl acetate (75 mL). The organic layer was successively dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The residue was triturated in water, filtered off, and dried in a high-vacuum oven to give 1.15 g (93% yield) of 1,1-dimethylethyl 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>8a</b>) as a yellowish powder, which was used without any further purification in the next step. LCMS-1 95% pure, <i>t</i><sub>R</sub> = 3.03 min, <i>m</i>/<i>z</i> 602.4 [M + H]<sup>+</sup>; HRMS (APPI+) calcd for C<sub>36</sub>H<sub>48</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup> 602.3594, found 602.3578. A solution of <b>8a</b> (1.15 g, 1.91 mmol) and sulfamide (1.84 g, 19.1 mmol) in dioxane (10 mL) was heated at 100 °C in a microwave oven for 20 min. The RM was then cooled to RT and evaporated under vacuum. The residue was triturated in water, filtered off, and washed with water. The powder was redissolved in EtOAc, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give 1.15 g (88% yield) of the desired product <b>9a</b> as a yellowish powder. LCMS-1 100%, <i>t</i><sub>R</sub> = 3.37 min, <i>m</i>/<i>z</i> 681.3 [M + H]<sup>+</sup>; HRMS (APPI+) calcd for C<sub>36</sub>H<sub>49</sub>N<sub>4</sub>O<sub>7</sub> [M + H]<sup>+</sup> 681.3322, found 681.3314; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26–1.44 (m, 4H) 1.61 (s, 9H) 1.75 (d, <i>J</i> = 13.35 Hz, 2H) 1.84 (d, <i>J</i> = 13.35 Hz, 2H) 2.04 (qd, <i>J</i> = 12.55, 3.15 Hz, 2H) 2.70 (s, 3H) 2.86 (tt, <i>J</i> = 12.20, 3.60 Hz, 1H), 2.95 (s, 3H) 3.13 (t, <i>J</i> = 5.79 Hz, 2H) 3.49–3.56 (m, 6H) 3.91 (s, 3H) 4.69 (br s, 2H) 6.31 (br s, 2H) 6.97 (s, 1H) 7.13 (d, <i>J</i> = 2.77 Hz, 1H) 7.16 (dd, <i>J</i> = 8.56, 2.77 Hz, 1H) 7.55 (d, <i>J</i> = 8.56 Hz, 1H) 7.58 (dd, <i>J</i> = 8.56, 1.51 Hz, 1H) 7.84 (d, <i>J</i> = 8.31 Hz, 1H) 8.05 (d, <i>J</i> = 1.01 Hz, 1H).</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 2,19-Methano-3,7:4,1-dimetheno-1<i>H</i>,11<i>H</i>-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9<i>H</i>,15<i>H</i>)-dione 27-Cyclohexyl-12,13,16,17-tetrahydro-22-methoxy-11,17-dimethyl-10,10-dioxide (<b>10a</b>)</h3><div class="NLM_p last">TFA (3.0 g, 26.3 mmol) was added to a solution of <b>9a</b> (1.15 g, 1.70 mmol) in dichloromethane (30 mL). After 1 h, the RM was concentrated under vacuum. The residue was triturated in ether, filtered, washed with ether, and then purified by chromatography (gradient EtOAc to EtOAc/EtOH 9:1) to give 802 mg (76% yield) of the carboxylic acid intermediate. LCMS-1 96%, <i>t</i><sub>R</sub> = 2.72 min, <i>m</i>/<i>z</i> 625 [M + H]<sup>+</sup>; HRMS (APPI+) calcd for C<sub>32</sub>H<sub>41</sub>N<sub>4</sub>O<sub>7</sub>S [M + H]<sup>+</sup> 625.2696, found 625.2683; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 1.22–1.50 (m, 4H) 1.75 (m, 3H) 1.83 (m, 2H) 1.96–2.12 (m, 2H) 2.70 (s, 3H) 2.80–2.91 (m, 1H) 2.94 (s, 3H) 3.13 (t, <i>J</i> = 5.92 Hz, 2H) 3.47–3.58 (m, 6H) 3.90 (s, 3H) 4.68 (br s, 2H) 6.32 (br s, 2H) 6.96 (s, 1H) 7.12 (d, <i>J</i> = 2.77 Hz, 1H) 7.16 (dd, <i>J</i> = 8.56, 2.77 Hz, 1H) 7.54 (d, <i>J</i> = 8.56 Hz, 1H) 7.63 (dd, <i>J</i> = 8.31, 1.26 Hz, 1H) 7.83 (d, <i>J</i> = 8.31 Hz, 1H) 8.10 (s, 1H). Carbonyldiimidazole (389 mg, 2.40 mmol) was added to a stirred solution of the previous intermediate (500 mg, 0.80 mmol) in dry THF (8 mL). The RM was stirred at RT for 1 h and then concentrated, and the resulting residue was purified by flash chromatography (gradient EtOAc to CH<sub>3</sub>CN 1:0 to 0:1) to give 550 mg of the acylimidazole intermediate as a slightly yellow solid. HRMS (APPI+) calcd for C<sub>35</sub>H<sub>43</sub>N<sub>6</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 675.2965, found 675.2950. DBU (244 mg, 0.32 mmol) was added to a solution of the acylimidazole (550 mg) in acetonitrile (25 mL). The RM was stirred overnight at RT and then concentrated under reduced pressure. The residue was dissolved in water (30 mL), and the pH of the resulting solution was adjusted to 5 with acetic acid. The precipitate was collected by filtration, washed with water, and dried. Recrystallization from ethanol followed by column chromatography purification (gradient EtOAc to EtOAc/EtOH 9:1) provided 380 mg (78% yield) of the title product <b>10a</b> as a white powder. LCMS-1 99.6%, <i>t</i><sub>R</sub> = 3.81 min, <i>m</i>/<i>z</i> 607 [M + H]<sup>+</sup>, LCMS-2 100%, <i>t</i><sub>R</sub> = 1.02 min; HRMS (APPI<sup>+</sup>) calcd for C<sub>32</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 607.2590, found 607.2609; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.15 (m, 1H) 1.40 (m, 3H) 1.71 (m, 2H) 1.88 (m, 1H) 2.01 (m, 3H) 2.56 (m, 3H) 2.77 (m, 1H) 2.99 (s, 3H) 3.26 (m, 2H) 3.50–3.71 (m, 6H) 3.87 (s, 3H) 4.44 (d, <i>J</i> = 14.1 Hz, 1H) 5.09 (d, <i>J</i> = 15.0 Hz, 1H) 6.95 (s, 1H) 7.13 (s, 1H) 7.19 (d, <i>J</i> = 8.6 Hz, 1H) 7.47 (d, <i>J</i> = 8.0 Hz, 1H) 7.54 (d, <i>J</i> = 8.3 Hz, 1H) 7.88 (d, <i>J</i> = 7.8 Hz, 1H) 8.33 (s, 1H) 11.40 (s, 1H).</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (19<i>S</i>)-2,19-Methano-3,7:4,1-dimetheno-1<i>H</i>,11<i>H</i>-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9<i>H</i>,15<i>H</i>)-dione 27-Cyclohexyl-12,13,16,17,19,20-hexahydro-22-methoxy-11,17-dimethyl-10,10-dioxide (<b>11a</b>) and (19<i>R</i>)-2,19-Methano-3,7:4,1-dimetheno-1<i>H</i>,11<i>H</i>-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9<i>H</i>,15<i>H</i>)-dione 27-Cyclohexyl-12,13,16,17,19,20-hexahydro-22-methoxy-11,17-dimethyl-10,10-dioxide (<b>12a</b>)</h3><div class="NLM_p last">A solution of <b>10a</b> (56 mg, 0.092 mmol) in MeOH (15 mL) and THF (5 mL) was hydrogenated in an H-cube apparatus using a 10% Pd on carbon cartridge. Then the solvent was evaporated, and the residue was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>CN 9:1) to give 23 mg (41% yield) of the desired saturated product as a racemic mixture, which was further separated by SFC using a 6.5 min run on a chiral CHIRALCEL OD-H column (250 × 10 mm, coated on 5 μm silica gel) with 55% methanol/45% CO<sub>2</sub> as the mobile phase at a flow rate of 10 mL/min to give the two pure enantiomers <b>11a</b> and <b>12a</b>. Retention times under these conditions were observed at 4.25 and 5.54 min, respectively. Compound <b>11a</b>: HPLC-chiral 99.57%, <i>t</i><sub>R</sub> = 2.80 min, ee = 99.1%; LCMS-3 99.7%, <i>t</i><sub>R</sub> = 5.12 min, <i>m</i>/<i>z</i> 609 [M + H]<sup>+</sup>. Compound <b>12a</b>: HPLC-chiral 100%, <i>t</i><sub>R</sub> = 2.27 min, ee = 100%; LCMS-3 99.7%, <i>t</i><sub>R</sub> = 5.12 min, <i>m</i>/<i>z</i> 609 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.15–1.30 (m, 1H) 1.32–1.46 (m, 2H) 1.55–1.81 (m, 3H) 1.82–2.09 (m, 4H) 2.54–2.59 (m, 1H) 2.79–2.91 (m, 1H) 2.92–3.09 (m, 5H) 3.34–3.49 (m, 6H) 3.51–3.60 (m, 1H) 3.64–3.74 (m, 2H) 3.76–3.96 (m, 6H) 4.53 (d, <i>J</i> = 14.81 Hz, 1H) 6.98–7.11 (m, 2H) 7.32 (m, 2H) 7.75–7.88 (m, 2H) 11.30 (br s, 1H).</div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (4b<i>S</i>,5a<i>R</i>)-<i>tert</i>-Butyl 5a-((<i>S</i>)-4-Benzyl-2-oxooxazolidine-3-carbonyl)-12-cyclohexyl-3-methoxy-4b,5,5a,6-tetrahydrobenzo[3,4]cyclopropa[5,6]azepino[1,2-<i>a</i>]indole-9-carboxylate (<b>14</b>) and (4b<i>R</i>,5a<i>S</i>)-<i>tert</i>-Butyl 5a-((<i>S</i>)-4-Benzyl-2-oxooxazolidine-3-carbonyl)-12-cyclohexyl-3-methoxy-4b,5,5a,6-tetrahydrobenzo[3,4]cyclopropa[5,6]azepino[1,2-<i>a</i>]indole-9-carboxylate (<b>15</b>)</h3><div class="NLM_p last">Sodium hydride (1.54 g, 64 mmol) was added to a stirred suspension of trimethylsulfoxonium chloride (9.07 g, 2.2 equiv) in anhydrous DMSO (100 mL) under nitrogen. After 30 min at RT, 16 g (32 mmol, 1 equiv) of neat bisester <b>7</b> was added portionwise. After 2 h at RT, TLC showed completion of the reaction, and the RM was quenched with water. The resulting precipitate was filtered off, washed with water, and dried in the vacuum oven. Purification by flash chromatography on silica gel (gradient of MeOH in DCM) provided 9.5 g (57% yield) of the desired cyclopropyl intermediate <b>13</b> as a racemic mixture. Subsequent cleavage of the methyl ester using the same procedure as described for the synthesis of <b>20</b> gave the corresponding carboxylic acid in 95% yield as a light-yellow solid. At 0 °C under a protective atmosphere, oxalyl chloride (4.07 mL, 47.4 mmol) was added to a solution of the previous carboxylic acid intermediate (19.83 g, 39.5 mmol) and DMF (5 drops) in dry tetrahydrofuran (100 mL). Upon addition of oxalyl chloride, the immediate formation of gas was observed. The RM was stirred at 0 °C for 1.5 h. Then an additional 0.5 equiv of oxalyl chloride was added, and the RM was stirred for 1 h (repeated once until full conversion was obtained). The RM was evaporated to dryness in vacuo to afford 20.5 g (97% yield) of the acid chloride as a white solid, which was used directly in the next step. To a solution of (<i>S</i>)-4-benzyl-2-oxazolidinone (7.50 g, 42.3 mmol) in dry tetrahydrofuran (60 mL) under a nitrogen atmosphere, <i>n</i>-butyllithium (26.4 mL, 42.3 mmol) was added slowly at −78 °C. The RM was stirred for 40 min at −78 °C. After 40 min, the anion solution was added via a cannula to a solution of the acid chloride (20 g, 38.5 mmol) in 60 mL of THF at −78 °C. The RM was stirred for 1.5 h at −78 °C. When the reaction was finished, it was quenched with an ammonium chloride solution at −70 °C. The RM was then warmed to RT, extracted with EtOAc, washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic layer was filtered and concentrated to afford 26.34 g of a yellow solid. The two enantiomers <b>14</b> and <b>15</b> were separated by flash column chromatography using 5:1 heptane/EtOAc (the faster-running spot corresponded to <b>15</b>) and were obtained as light-yellow solids with a purity of 97%  in yields of 85% (11.17 g) and 81% (10.6 g), respectively; <i>m</i>/<i>z</i> 661 [M + H]<sup>+</sup>.</div></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (4b<i>R</i>,5a<i>S</i>)-9-(<i>tert</i>-Butoxycarbonyl)-12-cyclohexyl-3-methoxy-4b,5,5a,6-tetrahydrobenzo[3,4]cyclopropa[5,6]azepino[1,2-<i>a</i>]indole-5a-carboxylic Acid (<b>17</b>)</h3><div class="NLM_p last">Diastereoisomer <b>15</b> (11.17 g, 16.90 mmol) was first dissolved in THF (130 mL), and then methanol (130 mL) was added. A 1 N NaOH solution (101 mL, 101 mmol) was added slowly to keep the temperature below 30 °C. The RM was stirred at RT for 2 h. When the reaction was finished, 1 N HCl solution was added until the pH reached 2. Water (500 mL) was then added, and the RM was extracted with EtOAc, washed with brine, and concentrated. Purification by flash column chromatography using 1:1 heptane/EtOAc afforded 5.24 g (60% yield) of the desired carboxylic acid <b>17</b> with an ee of 97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, mixture of rotamers, 60/40 major/minor) δ 1.08–1.26 (m, 2H) 1.27–1.48 (m, 8H) 1.51–1.62 (m, 20H) 1.66–1.79 (m, 4H) 1.81–2.11 (m, 8H) 2.65–2.92 (m, 4H) 3.41–3.44 (m, 1H major) 3.85 (s, 3H major) 3.86 (s, 3H minor) 3.95 (d, <i>J</i> = 15.19 Hz, 1H minor) 5.12 (d, <i>J</i> = 15.19 Hz, 1H minor) 5.35 (d, <i>J</i> = 14.74 Hz, 1H major) 6.99–7.08 (m, 2H) 7.17–7.31 (m, 4H) 7.52 (dd, <i>J</i> = 8.47, 1.43 Hz, 1H major) 7.60 (dd, <i>J</i> = 8.58, 1.32 Hz, 1H minor) 7.79 (d, <i>J</i> = 8.58 Hz, 1H major) 7.85 (d, <i>J</i> = 8.36 Hz, 1H minor) 7.97 (d, <i>J</i> = 0.88 Hz, 1H minor) 8.26 (d, <i>J</i> = 1.10 Hz, 1H major).</div></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (1a<i>R</i>,12b<i>S</i>)-8-Cyclohexyl-11-methoxy-16,22-dimethyl-1,12b-dihydro-5,1a-(methanoiminothioiminoethanooxyethanoiminomethano)cyclopropa[<i>d</i>]indolo[2,1-<i>a</i>][2]benzazepine-13,23(2<i>H</i>)-dione 15,15-Dioxide (<b>19a</b>)</h3><div class="NLM_p last">This macrocycle was synthesized following the same sequence of reactions as described for the synthesis of the unsaturated macrocyclic analogue <b>10a</b>, starting from carboxylic acid <b>17</b> instead of <b>20</b>, and was obtained as a white solid. LCMS-5 100%, <i>t</i><sub>R</sub> = 6.57 min; LCMS-6 100%, <i>t</i><sub>R</sub> = 1.90 min; HPLC-chiral 100%, <i>t</i><sub>R</sub> = 5.00 min, ee = 100%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 100 °C) δ 1.21–2.08 (m, 12H) 2.48–2.51 (m, 1H) 2.82–3.90 (m, 16H) 5.13 (d, <i>J</i> = 15.34 Hz, 1H) 7.01 (dd, <i>J</i> = 8.48, 2.83 Hz, 1H) 7.08–7.17 (m, 1H) 7.28 (d, <i>J</i> = 8.48 Hz, 1H) 7.38 (dd, <i>J</i> = 8.48, 1.21 Hz, 1H) 7.77 (d, <i>J</i> = 8.48 Hz, 1H) 8.04 (d, <i>J</i> = 1.21 Hz, 1H) 10.93 (br s, 1H).</div></div><div id="sec8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (1a<i>S</i>,12b<i>R</i>)-8-Cyclohexyl-11-methoxy-16,22-dimethyl-1,12b-dihydro-5,1a-(methanoiminothioiminoethanooxyethanoiminomethano)cyclopropa[<i>d</i>]indolo [2,1-<i>a</i>][2]benzazepine-13,23(2<i>H</i>)-dione 15,15-Dioxide (<b>18a</b>)</h3><div class="NLM_p last">This macrocycle was synthesized following the same sequence of reactions as described for the synthesis of the other enantiomer <b>19a</b>, starting from diastereoisomer <b>14</b> instead of <b>15</b>, and was obtained as a white solid. LCMS-5 100%, <i>t</i><sub>R</sub> = 6.56 min; LCMS-6 100%, <i>t</i><sub>R</sub> = 1.90 min; HPLC-chiral 100%, <i>t</i><sub>R</sub> = 4.62 min, ee = 100%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.13–2.14 (m, 12H) 2.45 (t, <i>J</i> = 7.26 Hz, 1H) 2.75–3.90 (m, 16H) 5.11 (d, <i>J</i> = 15.19 Hz, 1H) 7.05 (dd, <i>J</i> = 8.47, 2.53 Hz, 1H) 7.13 (d, <i>J</i> = 2.20 Hz, 1H) 7.26 (d, <i>J</i> = 8.36 Hz, 1H) 7.28–7.35 (m, 1H) 7.79 (d, <i>J</i> = 8.36 Hz, 1H) 8.01–8.22 (m, 1H) 11.34 (s, 1H).</div></div><div id="sec8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1,1-Dimethylethyl 13-Cyclohexyl-6-hydroxymethyl-3-methoxy-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>21</b>)</h3><div class="NLM_p last">To a stirred solution of acid <b>20</b> (1300 mg, 2.67 mmol) and <i>N</i>-methylmorpholine (270 mg, 2.67 mmol) in dry THF (10 mL) was added dropwise at −15 °C isobutyl chloroformate (364 mg, 2.67 mmol), and the mixture was stirred at −15 °C for 15 min. The RM turned from yellow to orange. The suspension was filtered, and NaBH<sub>4</sub> (202 mg, 5.33 mmol) was added at 0 °C to the filtrate, followed by 2 drops of water. The RM was stirred in an ice bath for 2 h and then diluted with water and extracted with EtOAc. The organic phase was washed with water until neutral, dried (MgSO<sub>4</sub>), filtered, and evaporated under vacuum. Purification by flash chromatography (heptane/EtOAc 9:1 to 1:1) gave 1 g (78% yield) of the desired alcohol <b>21</b> as a slightly yellow solid. LCMS-1 99.17%, <i>t</i><sub>R</sub> = 3.58 min, <i>m</i>/<i>z</i> 474 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.24–1.29 (m, 1H) 1.32–1.46 (m, 2H) 1.63 (s, 9H) 1.66–1.72 (m, 1H) 1.73–1.82 (m, 2H) 1.87–2.17 (m, 4H) 2.76–2.93 (m, 1H) 3.89 (s, 3H) 4.10–4.28 (m, 1H) 4.35 (br s, 2H) 4.74–4.99 (m, 1H) 6.68 (s, 1H) 6.88 (d, <i>J</i> = 2.35 Hz, 1H) 6.99 (dd, <i>J</i> = 8.61, 2.54 Hz, 1H) 7.48 (d, <i>J</i> = 8.61 Hz, 1H) 7.68 (d, <i>J</i> = 8.41 Hz, 1H) 7.83 (d, <i>J</i> = 8.41 Hz, 1H) 8.12 (s, 1H).</div></div><div id="sec8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1,1-Dimethylethyl 13-Cyclohexyl-3-methoxy-6-[[(methylsulfonyl)oxy]methyl]-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>22</b>)</h3><div class="NLM_p last">To a solution of alcohol <b>21</b> (500 mg, 1.056 mmol, 1.0 equiv) in THF (10 mL) were added Et<sub>3</sub>N (160 mg, 1.5 equiv) and methanesulfonyl chloride (181 mg, 1.5 equiv) at 0 °C. The resulting solution was stirred at 0 °C for 2 h. The RM was then quenched with water and extracted with EtOAc. The organic layer was washed with water two times, dried over MgSO<sub>4</sub>, filtered, and concentrated to give 555 mg (90% yield) of mesyl alcohol <b>22</b> as a yellow solid, which was used without further purification in the next step. LCMS-3 99%, <i>t</i><sub>R</sub> = 6.46 min, <i>m</i>/<i>z</i> 552 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.22–1.29 (m, 1H) 1.31–1.47 (m, 2H) 1.53–1.67 (m, 10H) 1.70–1.82 (m, 2H) 1.90–2.15 (m, 4H) 2.72–2.90 (m, 4H) 3.89 (br s, 3H) 4.19–4.41 (m, 1H) 4.77–4.87 (m, 1H) 4.92 (br s, 2H) 6.84 (br s, 1H) 6.89 (br s, 1H) 6.99–7.10 (m, 1H) 7.49 (d, <i>J</i> = 8.61 Hz, 1H) 7.70 (d, <i>J</i> = 8.41 Hz, 1H) 7.80–7.87 (m, 1H) 8.15 (br s, 1H).</div></div><div id="sec8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1,1-Dimethylethyl 13-Cyclohexyl-6-[methyl[4-(methylamino)butyl]amino]methyl-3-methoxy-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>23</b>)</h3><div class="NLM_p last">To <i>N</i>,<i>N</i>′-dimethyl-1,4-butanediamine (105 mg, 5 equiv) dissolved in THF (5 mL) was added mesyl alcohol <b>22</b> (100 mg, 0.181 mmol) at RT. The RM was stirred at RT for 48 h and then diluted with water and extracted with EtOAc. The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated to give 450 mg (96% yield) of compound <b>23</b> as a slightly yellow solid, which was used without further purification in the next step. LCMS-1 99%, <i>t</i><sub>R</sub> = 3.64 min (broad peak), <i>m</i>/<i>z</i> 572 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.20–1.26 (m, 1H) 1.36–1.40 (m, 2H) 1.59 (s, 12H) 1.68–1.80 (m, 2H) 1.81–1.97 (m, 2H) 1.97–2.14 (m, 7H) 2.18–2.33 (m, 2H) 2.41 (s, 3H) 2.44–2.58 (m, 2H) 2.74–2.93 (m, 1H) 3.10 (br s, 2H) 3.90 (s, 3H) 3.99–4.11 (m, 1H) 4.94–5.19 (m, 1H) 6.55 (s, 1H) 6.81–6.90 (m, 1H) 6.91–7.02 (m, 1H) 7.48 (d, <i>J</i> = 8.41 Hz, 1H) 7.67 (d, <i>J</i> = 8.61 Hz, 1H) 7.76–7.85 (m, 1H) 8.16 (s, 1H).</div></div><div id="sec8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1,1-Dimethylethyl 13-Cyclohexyl-6-[[methyl[4-[(aminosulfonyl)methylamino]butyl]amino]methyl]-3-methoxy-7<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylate (<b>24</b>)</h3><div class="NLM_p last">A mixture of compound <b>23</b> (400 mg, 0.7 mmol) and sulfamide (336 mg, 5 equiv) in dioxane (20 mL) was heated at 105 °C. After 3 h, the RM was cooled to RT, concentrated in vacuum, redissolved in DCM, extracted with water, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography (DCM to EtOAc) gave 350 mg (63%) of compound <b>24</b> as a white foam. LCMS-1 100%, <i>t</i><sub>R</sub> = 3.18 min, <i>m</i>/<i>z</i> 651 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.22–1.52 (m, 7H) 1.62 (s, 9H) 1.69–1.82 (m, 2H) 1.83–2.15 (m, 8H) 2.21–2.34 (m, 2H) 2.78 (s, 3H) 2.80–2.91 (m, 1H) 3.01–3.18 (m, 4H) 3.90 (s, 3H) 4.01–4.16 (m, 1H) 4.64 (br s, 2H) 5.08 (m, 1H) 6.55 (s, 1H) 6.87 (s, 1H) 6.93–7.02 (m, 1H) 7.47 (d, <i>J</i> = 8.61 Hz, 1H) 7.65 (d, <i>J</i> = 7.82 Hz, 1H) 7.82 (d, <i>J</i> = 8.61 Hz, 1H) 8.10–8.17 (m, 1H).</div></div><div id="sec8_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 11<i>H</i>-2,18-Methano-3,7:4,1-dimetheno-10,2,9,11,16-benzothiatetraazacycloheneicosine-8(9<i>H</i>,12<i>H</i>)-one 26-Cyclohexyl-13,14,15,16,17-pentahydro-21-methoxy-11,16-dimethyl-10,10-dioxide (<b>25</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl ester <b>24</b> (310 mg, 0.476 mmol) in DCM was added TFA (3.2 g, 60 equiv) at RT. The RM immediately turned yellow upon addition of TFA. After 2 h, the RM was concentrated to dryness, and the residue was triturated in diisopropyl ether. The resulting cream solid was filtered off and dried under high vacuum to give 350 mg (100% yield) of the corresponding carboxylic acid, which was used directly in the next step as a TFA salt. LCMS-1 98.5%, <i>t</i><sub>R</sub> = 2.39 min, <i>m</i>/<i>z</i> 595 [M + H]<sup>+</sup>. To the carboxylic acid intermediate (TFA salt) dissolved in acetonitrile (20 mL) was added CDI (88 mg, 1.1 equiv) at RT. The RM was then heated at 50 °C for 2 h, at which time LC–MS showed complete conversion of the carboxylic acid to the acylimidazole intermediate. The RM was then diluted with ACN (50 mL), and DBU (225 mg, 3 equiv) was added at RT. After 16 h, the RM was quenched with diluted HCl (pH 2), concentrated in vacuum, and extracted with DCM. The organic layer was washed with water (until the water layer reached neutral pH), dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was triturated in DCM, and the resulting cream solid was filtered off to give 146 mg (46% yield) of compound <b>25</b>. LCMS-2 98%, <i>t</i><sub>R</sub> = 1.28 min, <i>m</i>/<i>z</i> 577 [M + H]<sup>+</sup>; LCMS-4 100%, <i>t</i><sub>R</sub> = 1.51 min; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.06–1.21 (m, 1H) 1.24–1.51 (m, 8H) 1.60–2.09 (m, 8H) 2.13–2.28 (m, 1H) 2.55–2.68 (m, 1H) 2.70–2.84 (m, 2H) 3.02 (s, 3H) 3.10–3.22 (m, 1H) 3.36–3.49 (m, 2H) 3.85 (s, 3H) 4.08 (d, <i>J</i> = 13.80 Hz, 1H) 5.11 (d, <i>J</i> = 13.80 Hz, 1H) 6.65 (s, 1H) 7.02 (d, <i>J</i> = 2.51 Hz, 1H) 7.10 (dd, <i>J</i> = 8.78, 2.76 Hz, 1H) 7.35 (d, <i>J</i> = 8.28 Hz, 1H) 7.49 (d, <i>J</i> = 8.53 Hz, 1H) 7.82 (d, <i>J</i> = 8.53 Hz, 1H) 8.14 (s, 1H) 11.50 (br s, 1H).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28"><a href="/doi/suppl/10.1021/jm401396p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Details of LCMS and chiral HPLC methods. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401396p/suppl_file/jm401396p_si_001.pdf">jm401396p_si_001.pdf (163.1 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401396p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandrine Vendeville</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c8bbbeada6acadbef988a1bcbbe6a2a6a2e6aba7a5"><span class="__cf_email__" data-cfemail="116267747f75746720517865623f7b7f7b3f727e7c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maxwell D. Cummings</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tse-I Lin</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lili Hu</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdellah Tahri</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David McGowan</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katie Amssoms</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefaan Last</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoit Devogelaere</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie-Claude Rouan</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leen Vijgen</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Martin Berke</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascale Dehertogh</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Els Fransen</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erna Cleiren</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liesbet van der Helm</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Fanning</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Origène Nyanguile</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenny Simmen</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pieter Van Remoortere</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Raboisson</span> - <span class="hlFld-Affiliation affiliation">Janssen Infectious Diseases
BVBA (formerly Tibotec BVBA), Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2701e2959-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the analytical chemistry team for their technical assistance.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">El-Serag, H. B.</span><span> </span><span class="NLM_article-title">Hepatocellular carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMra1001683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21992124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1118-1127&author=H.+B.+El-Serag&title=Hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocellular carcinoma</span></div><div class="casAuthors">El-Serag, Hashem B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1118-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9eGOw4kyT7Vg90H21EOLACvtfcHk0ljfXFEiUrPq5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqtrnL&md5=3fb4250042385c5e29a189df86aea635</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001683%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Serag%26aufirst%3DH.%2BB.%26atitle%3DHepatocellular%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1118%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ghany, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strader, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">American Association for the Study of Liver, D. Diagnosis, management, and treatment of hepatitis C: An update</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">–</span> <span class="NLM_lpage">1374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1335-1374&author=M.+G.+Ghanyauthor=D.+B.+Straderauthor=D.+L.+Thomasauthor=L.+B.+Seeff&title=American+Association+for+the+Study+of+Liver%2C+D.+Diagnosis%2C+management%2C+and+treatment+of+hepatitis+C%3A+An+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhany%26aufirst%3DM.%2BG.%26aulast%3DStrader%26aufirst%3DD.%2BB.%26aulast%3DThomas%26aufirst%3DD.%2BL.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DAmerican%2520Association%2520for%2520the%2520Study%2520of%2520Liver%252C%2520D.%2520Diagnosis%252C%2520management%252C%2520and%2520treatment%2520of%2520hepatitis%2520C%253A%2520An%2520update%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D1335%26epage%3D1374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span> </span><span class="NLM_article-title">The Global Burden of Hepatitis, C. W. G. Global Burden of Disease (GBD) for Hepatitis C</span>.  <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1177%2F0091270003258669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14681338" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Global+Burden+of+Hepatitis%2C+C.+W.+G.+Global+Burden+of+Disease+%28GBD%29+for+Hepatitis+C.+J.+Clin.+Pharmacol.+2004%2C+44%2C+20%E2%80%9329."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F0091270003258669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270003258669%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Global%2520Burden%2520of%2520Hepatitis%252C%2520C.%2520W.%2520G.%2520Global%2520Burden%2520of%2520Disease%2520%2528GBD%2529%2520for%2520Hepatitis%2520C%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D44%26spage%3D20%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sings, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burroughs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, R.</span><span> </span><span class="NLM_article-title">Boceprevir for previously treated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1009482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21449784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1207-1217&author=B.+R.+Baconauthor=S.+C.+Gordonauthor=E.+Lawitzauthor=P.+Marcellinauthor=J.+M.+Vierlingauthor=S.+Zeuzemauthor=F.+Poordadauthor=Z.+D.+Goodmanauthor=H.+L.+Singsauthor=N.+Boparaiauthor=M.+Burroughsauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=R.+Esteban&title=Boceprevir+for+previously+treated+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for previously treated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Bacon, Bruce R.; Gordon, Stuart C.; Lawitz, Eric; Marcellin, Patrick; Vierling, John M.; Zeuzem, Stefan; Poordad, Fred; Goodman, Zachary D.; Sings, Heather L.; Boparai, Navdeep; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.; Esteban, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal.  Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an addnl. treatment.  To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 infection, we randomly assigned patients (in a 1:2:2 ratio) to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead-in period).  Subsequently, group 1 (control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 32 wk, and patients with a detectable HCV RNA level at week 8 received placebo plus peginterferon-ribavirin for an addnl. 12 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  A total of 403 patients were treated.  The rate of sustained virol. response was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in the control group (21%, P < 0.001).  Among patients with an undetectable HCV RNA level at week 8, the rate of sustained virol. response was 86% after 32 wk of triple therapy and 88% after 44 wk of triple therapy.  Among the 102 patients with a decrease in the HCV RNA level of less than 1 log10 IU per mL at treatment week 4, the rates of sustained virol. response were 0%, 33%, and 34% in groups 1, 2, and 3, resp.  Anemia was significantly more common in the boceprevir groups than in the control group, and erythropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.  The addn. of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virol. response in previously treated patients with chronic HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjykaE3KIqArVg90H21EOLACvtfcHk0lga0SQStqEszw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D&md5=402802777ab3a369c71332a84a8b40e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009482%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DSings%26aufirst%3DH.%2BL.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DBurroughs%26aufirst%3DM.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DBoceprevir%2520for%2520previously%2520treated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1207%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sniukiene, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span> </span><span class="NLM_article-title">Boceprevir for untreated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1010494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21449783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1195-1206&author=F.+Poordadauthor=J.+McConeauthor=B.+R.+Baconauthor=S.+Brunoauthor=M.+P.+Mannsauthor=M.+S.+Sulkowskiauthor=I.+M.+Jacobsonauthor=K.+R.+Reddyauthor=Z.+D.+Goodmanauthor=N.+Boparaiauthor=M.+J.+DiNubileauthor=V.+Sniukieneauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=J.-P.+Bronowicki&title=Boceprevir+for+untreated+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for untreated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Poordad, Fred; McCone, Jonathan, Jr.; Bacon, Bruce; Bruno, Savino; Manns, Michael P.; Sulkowski, Mark S.; Jacobson, Ira M.; Rajender Reddy, K.; Goodman, Zachary D.; Boparai, Navdeep; DiNubile, Mark J.; Sniukiene, Vilma; Brass, Clifford A.; Albrecht, Janice K.; Bronowicki, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1195-1206</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Peginterferon-ribavirin therapy is the current std. of care for chronic infection with hepatitis C virus (HCV).  The rate of sustained virol. response has been below 50% in cases of HCV genotype 1 infection.  Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an addnl. treatment in phase 1 and phase 2 studies.  We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead- in period).  Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 24 wk, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an addnl. 20 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  Non-black patients and black patients were enrolled and analyzed sep.  A total of 938 non-black and 159 black patients were treated.  In the non-black cohort, a sustained virol. response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P < 0.001), and in 213 of the 311 patients (68%) in group 3 (P < 0.001).  In the black cohort, a sustained virol. response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004).  In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 wk.  Anemia led to dose redns. in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, resp.  The addn. of boceprevir to std. therapy with peginterferon-ribavirin, as compared with std. therapy alone, significantly increased the rates of sustained virol. response in previously untreated adults with chronic HCV genotype 1 infection.  The rates were similar with 24 wk and 44 wk of boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCdL0rY0lmGrVg90H21EOLACvtfcHk0lga0SQStqEszw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D&md5=47ea838a941fdf7f9a27350a403e794e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1010494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1010494%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DMcCone%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DSniukiene%26aufirst%3DV.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26atitle%3DBoceprevir%2520for%2520untreated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1195%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusheiko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bzowej, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flisiak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankoh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">Telaprevir for previously untreated chronic hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1012912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21696307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2405-2416&author=I.+M.+Jacobsonauthor=J.+G.+McHutchisonauthor=G.+Dusheikoauthor=A.+M.+Di+Bisceglieauthor=K.+R.+Reddyauthor=N.+H.+Bzowejauthor=P.+Marcellinauthor=A.+J.+Muirauthor=P.+Ferenciauthor=R.+Flisiakauthor=J.+Georgeauthor=M.+Rizzettoauthor=D.+Shouvalauthor=R.+Solaauthor=R.+A.+Tergauthor=E.+M.+Yoshidaauthor=N.+Addaauthor=L.+Bengtssonauthor=A.+J.+Sankohauthor=T.+L.+Kiefferauthor=S.+Georgeauthor=R.+S.+Kauffmanauthor=S.+Zeuzem&title=Telaprevir+for+previously+untreated+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for previously untreated chronic hepatitis C virus infection</span></div><div class="casAuthors">Jacobson, Ira M.; McHutchison, John G.; Dusheiko, Geoffrey; Di Bisceglie, Adrian M.; Reddy, K. Rajender; Bzowej, Natalie H.; Marcellin, Patrick; Muir, Andrew J.; Ferenci, Peter; Flisiak, Robert; George, Jacob; Rizzetto, Mario; Shouval, Daniel; Sola, Ricard; Terg, Ruben A.; Yoshida, Eric M.; Adda, Nathalie; Bengtsson, Leif; Sankoh, Abdul J.; Kieffer, Tara L.; George, Shelley; Kauffman, Robert S.; Zeuzem, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2405-2416</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients.  METHODS: In this international, phase 3, randomized, double-blind, placebo-controlled trial, we assigned 1088 patients with HCV genotype 1 infection who had not received previous treatment for the infection to one of three groups: a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 wk (T12PR group), followed by peginterferon-ribavirin alone for 12 wk if HCV RNA was undetectable at weeks 4 and 12 or for 36 wk if HCV RNA was detectable at either time point; a group receiving telaprevir with peginterferon-ribavirin for 8 wk and placebo with peginterferon-ribavirin for 4 wk (T8PR group), followed by 12 or 36 wk of peginterferon-ribavirin on the basis of the same HCV RNA criteria; or a group receiving placebo with peginterferon-ribavirin for 12 wk, followed by 36 wk of peginterferon-ribavirin (PR group).  The primary end point was the proportion of patients who had undetectable plasma HCV RNA 24 wk after the last planned dose of study treatment (sustained virol. response).  RESULTS: Significantly more patients in the T12PR or T8PR group than in the PR group had a sustained virol. response (75% and 69%, resp., vs. 44%; P < 0.001 for the comparison of the T12PR or T8PR group with the PR group).  A total of 58% of the patients treated with telaprevir were eligible to receive 24 wk of total treatment.  Anemia, gastrointestinal side effects, and skin rashes occurred at a higher incidence among patients receiving telaprevir than among those receiving peginterferon-ribavirin alone.  The overall rate of discontinuation of the treatment regimen owing to adverse events was 10% in the T12PR and T8PR groups and 7% in the PR group.  CONCLUSIONS: Telaprevir with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was assocd. with significantly improved rates of sustained virol. response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 wk of therapy administered in the majority of patients. (Funded by Vertex Pharmaceuticals and Tibotec; ADVANCE ClinicalTrials.gov no., NCT00627926.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcImqLMQ63DLVg90H21EOLACvtfcHk0lga0SQStqEszw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCku7Y%253D&md5=16aff3164348c2bfe80fc14121eb7b93</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1012912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1012912%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DBzowej%26aufirst%3DN.%2BH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DRizzetto%26aufirst%3DM.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3DSola%26aufirst%3DR.%26aulast%3DTerg%26aufirst%3DR.%2BA.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DAdda%26aufirst%3DN.%26aulast%3DBengtsson%26aufirst%3DL.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DTelaprevir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2405%26epage%3D2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaccia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Heeswijk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont, M.</span><span> </span><span class="NLM_article-title">Telaprevir for retreatment of HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2417</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1013086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21696308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2417-2428&author=S.+Zeuzemauthor=P.+Andreoneauthor=S.+Polauthor=E.+Lawitzauthor=M.+Diagoauthor=S.+Robertsauthor=R.+Focacciaauthor=Z.+Younossiauthor=G.+R.+Fosterauthor=A.+Horbanauthor=P.+Ferenciauthor=F.+Nevensauthor=B.+Mullhauptauthor=P.+Pockrosauthor=R.+Tergauthor=D.+Shouvalauthor=B.+van+Hoekauthor=O.+Weilandauthor=R.+Van+Heeswijkauthor=S.+De+Meyerauthor=D.+Luoauthor=G.+Boogaertsauthor=R.+Poloauthor=G.+Picchioauthor=M.+Beumont&title=Telaprevir+for+retreatment+of+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for retreatment of HCV infection</span></div><div class="casAuthors">Zeuzem, Stefan; Andreone, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, Moises; Roberts, Stuart; Focaccia, Roberto; Younossi, Zobair; Foster, Graham R.; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Mullhaupt, Beat; Pockros, Paul; Terg, Ruben; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; Van Heeswijk, Rolf; De Meyer, Sandra; Luo, Don; Boogaerts, Griet; Polo, Ramon; Picchio, Gaston; Beumont, Maria</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2428</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virol. response to therapy with peginterferon alfa plus ribavirin.  METHODS: In this randomized, phase 3 trial, we evaluated the addn. of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous therapy or who had a relapse after an initial response.  A total of 663 patients were assigned to one of three groups: the T12PR48 group, which received telaprevir for 12 wk and peginterferon plus ribavirin for a total of 48 wk; the lead-in T12PR48 group, which received 4 wk of peginterferon plus ribavirin followed by 12 wk of telaprevir and peginterferon plus ribavirin for a total of 48 wk; and the control group (PR48), which received peginterferon plus ribavirin for 48 wk.  The primary end point was the rate of sustained virol. response, which was defined as undetectable HCV RNA 24 wk after the last planned dose of a study drug.  RESULTS: Rates of sustained virol. response were significantly higher in the two telaprevir groups than in the control group among patients who had a previous relapse (83% in the T12PR48 group, 88% in the lead-in T12PR48 group, and 24% in the PR48 group), a partial response (59%, 54%, and 15%, resp.), and no response (29%, 33%, and 5%, resp.) (P < 0.001 for all comparisons).  Grade 3 adverse events (mainly anemia, neutropenia, and leukopenia) were more frequent in the telaprevir groups than in the control group (37% vs. 22%).  CONCLUSIONS: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virol. response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase. (Funded by Tibotec and Vertex Pharmaceuticals; REALIZE ClinicalTrials.gov no., NCT00703118.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzx61JZTi22bVg90H21EOLACvtfcHk0lipl6g2GpSY_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D&md5=de254ca59467daf5259a3dff8d2d831a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013086%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DDiago%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFocaccia%26aufirst%3DR.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3Dvan%2BHoek%26aufirst%3DB.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DVan%2BHeeswijk%26aufirst%3DR.%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DBoogaerts%26aufirst%3DG.%26aulast%3DPolo%26aufirst%3DR.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBeumont%26aufirst%3DM.%26atitle%3DTelaprevir%2520for%2520retreatment%2520of%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2417%26epage%3D2428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Behrens, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=12-22&author=S.+E.+Behrensauthor=L.+Tomeiauthor=R.+De+Francesco&title=Identification+and+properties+of+the+RNA-dependent+RNA+polymerase+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DS.%2BE.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520properties%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D12%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">8416</span><span class="NLM_x">–</span> <span class="NLM_lpage">8428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=9343198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=8416-8428&author=V.+Lohmannauthor=F.+Kornerauthor=U.+Herianauthor=R.+Bartenschlager&title=Biochemical+properties+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA+polymerase+and+identification+of+amino+acid+sequence+motifs+essential+for+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymic activity</span></div><div class="casAuthors">Lohmann, Volker; Korner, Frank; Herian, Ulrike; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8416-8428</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5B protein of the hepatitis C virus (HCV) is an RNA-dependent RNA polymerase (RdRp) (S.-E. Behrens, L. Tomei, and R. De Francesco, EMBO J. 15:12-22, 1996) that is assumed to be required for replication of the viral genome.  To further study the biochem. and structural properties of this enzyme, an NS5B-hexahistidine fusion protein was expressed with recombinant baculoviruses in insect cells and purified to near homogeneity.  The enzyme was found to have a primer-dependent RdRp activity that was able to copy a complete in vitro-transcribed HCV genome in the absence of addnl. viral or cellular factors.  Filter binding assays and competition expts. showed that the purified enzyme binds RNA with no clear preference for HCV 3'-end sequences.  Binding to homopolymeric RNAs was also examd., and the following order of specificity was obsd.: poly(U) > poly(G) > poly(A) > poly(C).  An inverse order was found for the RdRp activity, which used poly(C) most efficiently as a template but was inactive on poly(U) and poly(G), suggesting that a high binding affinity between polymerase and template interferes with processivity.  By using a mutational anal., four amino acid sequence motifs crucial for RdRp activity were identified.  While most substitutions of conserved residues within these motifs severely reduced the enzymic activities, a single substitution in motif D which enhanced the RdRp activity by about 50% was found.  Deletion studies indicate that amino acid residues at the very termini, in particular the amino terminus, are important for RdRp activity but not for RNA binding.  Finally, we found a terminal transferase activity assocd. with the purified enzyme.  However, this activity was also detected with NS5B proteins with an inactive RdRp, with an NS4B protein purified in the same way, and with wild-type baculovirus, suggesting that it is not an inherent activity of NS5B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdCeTDzvlRArVg90H21EOLACvtfcHk0lipl6g2GpSY_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D&md5=98640d185270f0b331db0fa0624865cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DKorner%26aufirst%3DF.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520properties%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520and%2520identification%2520of%2520amino%2520acid%2520sequence%2520motifs%2520essential%2520for%2520enzymatic%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D8416%26epage%3D8428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span> </span><span class="NLM_article-title">Nucleoside analog inhibitors of hepatitis C virus replication</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.2174%2F187152606776056698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16787301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=17-29&author=S.+S.+Carrollauthor=D.+B.+Olsen&title=Nucleoside+analog+inhibitors+of+hepatitis+C+virus+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analog inhibitors of hepatitis C virus replication</span></div><div class="casAuthors">Carroll, S. S.; Olsen, D. B.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Of the 30 compds. currently marketed in the United States for treatment of viral infections, 15 are nucleoside analogs, demonstrating the utility of this class of compd. as a source of antiviral drugs.  The success of nucleoside analogs in treating other viral infections provides a compelling rationale for the significant effort that is currently being devoted to the discovery and development of nucleoside analogs to treat infection by hepatitis C virus (HCV) that may lead to improvements in response rates compared to currently available therapies.  Several different approaches were adopted to identify promising analogs, including the use of surrogate viruses in cell culture assays, screening in the cell-based bicistronic HCV replicon assay, and screening nucleoside triphosphates for the ability to inhibit the activity of the HCV RNA-dependent RNA polymerase in vitro.  Several classes of ribonucleoside analogs with modifications of the ribose inhibit HCV replication.  Nucleoside analogs incorporating a 2'-C-Me modification are potent inhibitors in the replicon assay in the absence of cytotoxicity, and appear to exert their inhibition by acting as functional chain terminators of RNA synthesis.  NM283, a prodrug of 2'-C-methylcytidine, has entered clin. trials and demonstrated viral load redns. in subjects infected with genotype 1 HCV, a genotype known to be difficult to treat effectively with currently approved therapies.  Overall, results to date offer encouragement that improved therapies to treat HCV infection including newly developed nucleoside analogs may become available within the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVhFYWU3S1hbVg90H21EOLACvtfcHk0lgAQJQzFuvwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7Y%253D&md5=27a3f74bc6da7bfd4ce02a1266511f5c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F187152606776056698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056698%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26atitle%3DNucleoside%2520analog%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D17%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Jonckers, T. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buyck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachau-Durand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoof, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandekerckhove, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillen, L. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rydegard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">2′-Deoxy-2′-spirocyclopropylcytidine revisited: A new and selective inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8150</span><span class="NLM_x">–</span> <span class="NLM_lpage">8160</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101050a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8150-8160&author=T.+H.+M.+Jonckersauthor=T.-I.+Linauthor=C.+Buyckauthor=S.+Lachau-Durandauthor=K.+Vandyckauthor=S.+Van+Hoofauthor=L.+A.+M.+Vandekerckhoveauthor=L.+Huauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=L.+L.+A.+Dillenauthor=M.+D.+Cummingsauthor=H.+de+Kockauthor=M.+Nilssonauthor=C.+Sundauthor=C.+Rydegardauthor=B.+Samuelssonauthor=A.+Rosenquistauthor=G.+Fanningauthor=K.+Van+Emelenauthor=K.+Simmenauthor=P.+Raboisson&title=2%E2%80%B2-Deoxy-2%E2%80%B2-spirocyclopropylcytidine+revisited%3A+A+new+and+selective+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm101050a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101050a%26sid%3Dliteratum%253Aachs%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DBuyck%26aufirst%3DC.%26aulast%3DLachau-Durand%26aufirst%3DS.%26aulast%3DVandyck%26aufirst%3DK.%26aulast%3DVan%2BHoof%26aufirst%3DS.%26aulast%3DVandekerckhove%26aufirst%3DL.%2BA.%2BM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDillen%26aufirst%3DL.%2BL.%2BA.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSund%26aufirst%3DC.%26aulast%3DRydegard%26aufirst%3DC.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3D2%25E2%2580%25B2-Deoxy-2%25E2%2580%25B2-spirocyclopropylcytidine%2520revisited%253A%2520A%2520new%2520and%2520selective%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8150%26epage%3D8160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of the HCV NS5B polymerase: Progress in the discovery and development of novel agents for the treatment of HCV infections</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=614-634&author=P.+L.+Beaulieu&title=Non-nucleoside+inhibitors+of+the+HCV+NS5B+polymerase%3A+Progress+in+the+discovery+and+development+of+novel+agents+for+the+treatment+of+HCV+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520the%2520HCV%2520NS5B%2520polymerase%253A%2520Progress%2520in%2520the%2520discovery%2520and%2520development%2520of%2520novel%2520agents%2520for%2520the%2520treatment%2520of%2520HCV%2520infections%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D614%26epage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.2174%2F187152606776056724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16787302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=31-41&author=U.+Kochauthor=F.+Narjes&title=Allosteric+inhibition+of+the+hepatitis+C+virus+NS5B+RNA+dependent+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase</span></div><div class="casAuthors">Koch, Uwe; Narjes, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human and monetary costs of chronic hepatitis C and the complications arising from this disease emphasize the urgency to find a treatment for Hepatitis C Virus (HCV) infected patients.  The current std. of treatment for patients chronically infected with HCV is combination therapy with pegylated interferon plus ribavirin.  Recently, viral enzymes have become the target of efforts to develop small mol. inhibitors interfering with the essential steps in the life cycle of the virus.  Amongst these enzymes the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) is essential for viral replication and has been recognized as a prime target for therapeutic intervention.  Several distinct classes of inhibitors of NS5B RdRp have been disclosed in the literature, including active site inhibitors such as nucleosides and pyrophosphate mimetics, as well as nonnucleoside inhibitors.  The latter, based on the success of allosteric inhibitors in the treatment of HIV infection, have been developed into compds. which show activity in the subgenomic cell-culture assay of HCV replication.  This review provides an account of the recent developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbJzS0wn4zMLVg90H21EOLACvtfcHk0lgAQJQzFuvwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7c%253D&md5=d299870b484180aa4f9e179cb96eabe2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187152606776056724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056724%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DAllosteric%2520inhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520dependent%2520RNA%2520polymerase%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D31%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Tramontano, E.</span><span> </span><span class="NLM_article-title">The exploding field of the HCV polymerase non-nucleoside inhibitors: Summary of first generation compounds</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1298-1310&author=E.+Tramontano&title=The+exploding+field+of+the+HCV+polymerase+non-nucleoside+inhibitors%3A+Summary+of+first+generation+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTramontano%26aufirst%3DE.%26atitle%3DThe%2520exploding%2520field%2520of%2520the%2520HCV%2520polymerase%2520non-nucleoside%2520inhibitors%253A%2520Summary%2520of%2520first%2520generation%2520compounds%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1298%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carfi, A.</span><span> </span><span class="NLM_article-title">Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">29765</span><span class="NLM_x">–</span> <span class="NLM_lpage">29770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1074%2Fjbc.M505423200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=15955819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=29765-29770&author=S.+Di+Marcoauthor=C.+Volpariauthor=L.+Tomeiauthor=S.+Altamuraauthor=S.+Harperauthor=F.+Narjesauthor=U.+Kochauthor=M.+Rowleyauthor=R.+De+Francescoauthor=G.+Migliaccioauthor=A.+Carfi&title=Interdomain+communication+in+hepatitis+C+virus+polymerase+abolished+by+small+molecule+inhibitors+bound+to+a+novel+allosteric+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site</span></div><div class="casAuthors">Di Marco, Stefania; Volpari, Cinzia; Tomei, Licia; Altamura, Sergio; Harper, Steven; Narjes, Frank; Koch, Uwe; Rowley, Michael; De Francesco, Raffaele; Migliaccio, Giovanni; Carfi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">29765-29770</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase is required for replication of the viral genome and is a key target for therapeutic intervention against HCV.  We have detd. the crystal structures of the HCV polymerase complexed with two indole-based allosteric inhibitors at 2.3- and 2.4-Å resoln.  The structures show that these inhibitors bind to a site on the surface of the thumb domain.  A cyclohexyl and Ph ring substituents, bridged by an indole moiety, fill two closely spaced pockets, whereas a carboxylate substituent forms a salt bridge with an exposed arginine side chain.  Interestingly, in the apoenzyme, the inhibitor binding site is occupied by a small α-helix at the tip of the N-terminal loop that connects the fingers and thumb domains.  Thus, these mols. inhibit the enzyme by preventing formation of intramol. contacts between these two domains and consequently precluding their coordinated movements during RNA synthesis.  Our structures identify a novel mechanism by which a new class of allosteric inhibitors inhibits the HCV polymerase and open the way to the development of novel antiviral agents against this clin. relevant human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWHS1-2Y1C8LVg90H21EOLACvtfcHk0lg7nFX3q3lUKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Sltr0%253D&md5=1192532b3624ec0032d9dff24c19a704</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M505423200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M505423200%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DCarfi%26aufirst%3DA.%26atitle%3DInterdomain%2520communication%2520in%2520hepatitis%2520C%2520virus%2520polymerase%2520abolished%2520by%2520small%2520molecule%2520inhibitors%2520bound%2520to%2520a%2520novel%2520allosteric%2520site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D29765%26epage%3D29770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGibbon, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">39260</span><span class="NLM_x">–</span> <span class="NLM_lpage">39267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=39260-39267&author=G.+Kukoljauthor=G.+A.+McGibbonauthor=G.+McKercherauthor=M.+Marquisauthor=S.+Lefebvreauthor=L.+Thauvetteauthor=J.+Gauthierauthor=S.+Gouletauthor=M.-A.+Poupartauthor=P.+L.+Beaulieu&title=Binding+site+characterization+and+resistance+to+a+class+of+non-nucleoside+inhibitors+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMcGibbon%26aufirst%3DG.%2BA.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DM.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DGauthier%26aufirst%3DJ.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DBinding%2520site%2520characterization%2520and%2520resistance%2520to%2520a%2520class%2520of%2520non-nucleoside%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D39260%26epage%3D39267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroccio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gennari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisbocci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Incitti, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stansfield, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span> </span><span class="NLM_article-title">Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">13225</span><span class="NLM_x">–</span> <span class="NLM_lpage">13231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1128%2FJVI.77.24.13225-13231.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14645579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslSmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=13225-13231&author=L.+Tomeiauthor=S.+Altamuraauthor=L.+Bartholomewauthor=A.+Biroccioauthor=A.+Ceccacciauthor=L.+Paciniauthor=F.+Narjesauthor=N.+Gennariauthor=M.+Bisbocciauthor=I.+Incittiauthor=L.+Orsattiauthor=S.+Harperauthor=I.+Stansfieldauthor=M.+Rowleyauthor=R.+De+Francescoauthor=G.+Migliaccio&title=Mechanism+of+action+and+antiviral+activity+of+benzimidazole-based+allosteric+inhibitors+of+the+hepatitis+C+virus+RNA-dependent+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase</span></div><div class="casAuthors">Tomei, Licia; Altamura, Sergio; Bartholomew, Linda; Biroccio, Antonino; Ceccacci, Alessandra; Pacini, Laura; Narjes, Frank; Gennari, Nadia; Bisbocci, Monica; Incitti, Ilario; Orsatti, Laura; Harper, Steven; Stansfield, Ian; Rowley, Michael; De Francesco, Raffaele; Migliaccio, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">13225-13231</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The RNA-dependent RNA polymerase of hepatitis C virus (HCV) is the catalytic subunit of the viral RNA amplification machinery and is an appealing target for the development of new therapeutic agents against HCV infection.  Nonnucleoside inhibitors based on a benzimidazole scaffold have been recently reported.  Compds. of this class are efficient inhibitors of HCV RNA replication in cell culture, thus providing attractive candidates for further development.  Here we report the detailed anal. of the mechanism of action of selected benzimidazole inhibitors.  Kinetic data and binding expts. indicated that these compds. act as allosteric inhibitors that block the activity of the polymerase prior to the elongation step.  Escape mutations that confer resistance to these compds. map to proline 495, a residue located on the surface of the polymerase thumb domain and away from the active site.  Substitution of this residue is sufficient to make the HCV enzyme and replicons resistant to the inhibitors.  Interestingly, proline 495 lies in a recently identified noncatalytic GTP-binding site, thus validating it as a potential allosteric site that can be targeted by small-mol. inhibitors of HCV polymerase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLeqFmAyaoXrVg90H21EOLACvtfcHk0lg7nFX3q3lUKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslSmsrY%253D&md5=05154e4c748a15ecdb96bc5fa2a4f6cb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.24.13225-13231.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.24.13225-13231.2003%26sid%3Dliteratum%253Aachs%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DCeccacci%26aufirst%3DA.%26aulast%3DPacini%26aufirst%3DL.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DGennari%26aufirst%3DN.%26aulast%3DBisbocci%26aufirst%3DM.%26aulast%3DIncitti%26aufirst%3DI.%26aulast%3DOrsatti%26aufirst%3DL.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DStansfield%26aufirst%3DI.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26atitle%3DMechanism%2520of%2520action%2520and%2520antiviral%2520activity%2520of%2520benzimidazole-based%2520allosteric%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520RNA-dependent%2520RNA%2520polymerase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D13225%26epage%3D13231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hache, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.+S.+Duceppeauthor=B.+Hacheauthor=A.+Jakalianauthor=L.+Lagaceauthor=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+From+benzimidazole+to+indole+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.%2BS.%26aulast%3DHache%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520From%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7650</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3006788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7650-7666&author=P.+L.+Beaulieuauthor=M.+Bosauthor=M.+G.+Cordingleyauthor=C.+Chabotauthor=G.+Fazalauthor=M.+Garneauauthor=J.+R.+Gillardauthor=E.+Jolicoeurauthor=S.+LaPlanteauthor=G.+McKercherauthor=M.+Poirierauthor=M.+A.+Poupartauthor=Y.+S.+Tsantrizosauthor=J.+Duanauthor=G.+Kukolj&title=Discovery+of+the+first+thumb+pocket+1+NS5B+polymerase+inhibitor+%28BILB+1941%29+with+demonstrated+antiviral+activity+in+patients+chronically+infected+with+genotype+1+hepatitis+C+virus+%28HCV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm3006788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3006788%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520the%2520first%2520thumb%2520pocket%25201%2520NS5B%2520polymerase%2520inhibitor%2520%2528BILB%25201941%2529%2520with%2520demonstrated%2520antiviral%2520activity%2520in%2520patients%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7650%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, M. d. R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stansfield, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercolani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaramella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuleman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux-Roels, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baiocco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of (7<i>R</i>)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl)amino}-7,8-dihydro-6<i>H</i>-indolo[1,2-<i>e</i>][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=289-301&author=F.+Narjesauthor=B.+Crescenziauthor=M.+Ferraraauthor=J.+Habermannauthor=S.+Colarussoauthor=M.+d.+R.+R.+Ferreiraauthor=I.+Stansfieldauthor=A.+C.+Mackayauthor=I.+Conteauthor=C.+Ercolaniauthor=S.+Zaramellaauthor=M.-C.+Palumbiauthor=P.+Meulemanauthor=G.+Leroux-Roelsauthor=C.+Giulianoauthor=F.+Fioreauthor=S.+Di+Marcoauthor=P.+Baioccoauthor=U.+Kochauthor=G.+Migliaccioauthor=S.+Altamuraauthor=R.+Lauferauthor=R.+De+Francescoauthor=M.+Rowley&title=Discovery+of+%287R%29-14-cyclohexyl-7-%7B%5B2-%28dimethylamino%29ethyl%5D%28methyl%29amino%7D-7%2C8-dihydro-6H-indolo%5B1%2C2-e%5D%5B1%2C5%5Dbenzoxazocine-11-carboxylic+acid+%28MK-3281%29%2C+a+potent+and+orally+bioavailable+finger-loop+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm1013105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013105%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DHabermann%26aufirst%3DJ.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DFerreira%26aufirst%3DM.%2Bd.%2BR.%2BR.%26aulast%3DStansfield%26aufirst%3DI.%26aulast%3DMackay%26aufirst%3DA.%2BC.%26aulast%3DConte%26aufirst%3DI.%26aulast%3DErcolani%26aufirst%3DC.%26aulast%3DZaramella%26aufirst%3DS.%26aulast%3DPalumbi%26aufirst%3DM.-C.%26aulast%3DMeuleman%26aufirst%3DP.%26aulast%3DLeroux-Roels%26aufirst%3DG.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DBaiocco%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25287R%2529-14-cyclohexyl-7-%257B%255B2-%2528dimethylamino%2529ethyl%255D%2528methyl%2529amino%257D-7%252C8-dihydro-6H-indolo%255B1%252C2-e%255D%255B1%252C5%255Dbenzoxazocine-11-carboxylic%2520acid%2520%2528MK-3281%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520finger-loop%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D289%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padron Velazquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Paz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1035-1054&author=C.+Giulianoauthor=F.+Fioreauthor=A.+Di+Marcoauthor=J.+Padron+Velazquezauthor=A.+Bishopauthor=F.+Bonelliauthor=O.+Gonzalez-Pazauthor=I.+Marcucciauthor=S.+Harperauthor=F.+Narjesauthor=B.+Paciniauthor=E.+Monteagudoauthor=G.+Migliaccioauthor=M.+Rowleyauthor=R.+Laufer&title=Preclinical+pharmacokinetics+and+metabolism+of+a+potent+non-nucleoside+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DDi%2BMarco%26aufirst%3DA.%26aulast%3DPadron%2BVelazquez%26aufirst%3DJ.%26aulast%3DBishop%26aufirst%3DA.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DGonzalez-Paz%26aufirst%3DO.%26aulast%3DMarcucci%26aufirst%3DI.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DR.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520metabolism%2520of%2520a%2520potent%2520non-nucleoside%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DXenobiotica%26date%3D2005%26volume%3D35%26spage%3D1035%26epage%3D1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bailey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. G.</span><span> </span><span class="NLM_article-title">Acyl glucuronide reactivity in perspective: Biological consequences</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1016%2FS0009-2797%2803%2900020-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=12686489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis12jt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2003&pages=117-137&author=M.+J.+Baileyauthor=R.+G.+Dickinson&title=Acyl+glucuronide+reactivity+in+perspective%3A+Biological+consequences"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronide reactivity in perspective: biological consequences</span></div><div class="casAuthors">Bailey, Mark J.; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-137</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The metabolic conjugation of exogenous and endogenous carboxylic acid substrates with endogenous glucuronic acid, mediated by the uridine diphosphoglucuronosyl transferase (UGT) superfamily of enzymes, leads to the formation of acyl glucuronide metabolites.  Since the late 1970s, acyl glucuronides have been increasingly identified as reactive electrophilic metabolites, capable of undergoing three reactions: intramol. rearrangement, hydrolysis, and intermol. reactions with proteins leading to covalent drug-protein adducts.  This essential dogma has been accepted for over a decade.  The key question proposed by researchers, and now the pharmaceutical industry, is: does or can the covalent modification of endogenous proteins, mediated by reactive acyl glucuronide metabolites, lead to adverse drug reactions, perhaps idiosyncratic in nature This review evaluates the evidence for acyl glucuronide-derived perturbation of homeostasis, particularly that which might result from the covalent modification of endogenous proteins and other macromols.  Because of the availability of acyl glucuronides for test tube/in vitro expts., there is now a substantial literature documenting their rearrangement, hydrolysis and covalent modification of proteins in vitro.  It is certain from in vitro expts. that serum albumin, dipeptidyl peptidase IV, tubulin and UGTs are covalently modified by acyl glucuronides.  However, these in vitro expts. have been specifically designed to amplify any interference with a biol. process in order to find biol. effects.  The in vivo situation is not at all clear.  Certainly it must be concluded that all humans taking carboxylate drugs that form reactive acyl glucuronides will form covalent drug-protein adducts, and it must also be concluded that this in itself is normally benign.  However, there is enough in vivo evidence implicating acyl glucuronides, which, when backed up by in vivo circumstantial and documented in vitro evidence, supports the view that reactive acyl glucuronides may initiate toxicity/immune responses.  In summary, though acyl glucuronide-derived covalent modification of endogenous macromols. is well-defined, the work ahead needs to provide detailed links between such modification and its possible biol. consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5i99kMJKu1LVg90H21EOLACvtfcHk0lh43ED5Ya9W9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis12jt7k%253D&md5=20e8f673b5abfa0974a1d32bfb38e01d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2803%2900020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252803%252900020-6%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BJ.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DAcyl%2520glucuronide%2520reactivity%2520in%2520perspective%253A%2520Biological%2520consequences%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2003%26volume%3D145%26spage%3D117%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Castillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. C.</span><span> </span><span class="NLM_article-title">Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=7587932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADyaK2MXlslSjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=566-572&author=M.+Castilloauthor=P.+C.+Smith&title=Disposition+and+reactivity+of+ibuprofen+and+ibufenac+acyl+glucuronides+in+vivo+in+the+rhesus+monkey+and+in+vitro+with+human+serum+albumin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin</span></div><div class="casAuthors">Castillo, Marta; Smith, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">566-72</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The disposition of ibuprofen and ibufenac, an analog of ibuprofen with a history of severe adverse reactions, was investigated in rhesus monkeys after oral administration.  Plasma concns. of the parent drugs and their glucuronides were measured by a direct HPLC method.  Ibuprofen and ibufenac exhibited notable inter-animal variability.  Ibufenac tended to have a higher area under the plasma concn. vs. time curve (AUC), and its apparent clearance was lower.  The plasma levels of acyl glucuronides were lower than parent drugs; the ratio of AUC in plasma for glucuronide/parent drug was 22.8% and 10.5% for ibuprofen and ibufenac, resp.  The degrdn. of ibufenac glucuronide in vitro was faster than ibuprofen glucuronide in aq. buffer, human serum albumin, and human plasma solns.  Covalent binding of parent drug to protein via the acyl glucuronides was obsd. both in vitro and in vivo.  The max. protein adduct formed in vivo with ibufenac was 60% higher than found for ibuprofen, although exposure in plasma to its reactive acyl glucuronide, as measured by AUC, was lower.  These data indicate that ibufenac glucuronide is a more reactive metabolite than ibuprofen glucuronide in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooBktMPhPzn7Vg90H21EOLACvtfcHk0lhxNlw74CxdPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlslSjs7k%253D&md5=4835a6931c79f31cfde06c873481fbbe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26atitle%3DDisposition%2520and%2520reactivity%2520of%2520ibuprofen%2520and%2520ibufenac%2520acyl%2520glucuronides%2520in%2520vivo%2520in%2520the%2520rhesus%2520monkey%2520and%2520in%2520vitro%2520with%2520human%2520serum%2520albumin%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D566%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Skonberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillo, M. P.</span><span> </span><span class="NLM_article-title">Metabolic activation of carboxylic acids</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1517%2F17425255.4.4.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=18433345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=425-438&author=C.+Skonbergauthor=J.+Olsenauthor=K.+G.+Madsenauthor=S.+H.+Hansenauthor=M.+P.+Grillo&title=Metabolic+activation+of+carboxylic+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of carboxylic acids</span></div><div class="casAuthors">Skonberg, Christian; Olsen, Jorgen; Madsen, Kim Grimstrup; Hansen, Steen Honore; Grillo, Mark P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-438</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Carboxylic acids constitute a large and heterogeneous class of both endogenous and xenobiotic compds.  A no. of carboxylic acid drugs have been assocd. with adverse reactions, linked to the metabolic activation of the carboxylic acid moiety of the compds., i.e., formation of acyl-glucuronides and acyl-CoA thioesters.  Objective: The objective is to give an overview of the current knowledge on metabolic activation of carboxylic acids and how such metabolites may play a role in adverse reactions and toxicity.  Methods: Literature concerning the formation and disposition of acyl glucuronides and acyl-CoA thioesters was searched.  Also included were papers on the chem. reactivity of acyl glutathione-thioesters, and literature concerning possible links between metabolic activation of carboxylic acids and reported cellular and clin. effects.  Results/conclusion: This review demonstrates that metabolites of carboxylic acid drugs must be considered chem. reactive, and that the current knowledge about metabolic activation of this compd. class can be a good starting-point for further studies on the consequences of chem. reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdB7y_4L2TirVg90H21EOLACvtfcHk0lhxNlw74CxdPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D&md5=fec1dbee0f4e4bf93c95ba2441b48004</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.4.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.4.425%26sid%3Dliteratum%253Aachs%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%2BG.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26atitle%3DMetabolic%2520activation%2520of%2520carboxylic%2520acids%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D425%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherborne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, I.</span><span> </span><span class="NLM_article-title">Rate-limited steps of human oral absorption and QSAR studies</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1446-1457&author=Y.+H.+Zhaoauthor=M.+H.+Abrahamauthor=J.+Leauthor=A.+Herseyauthor=C.+N.+Luscombeauthor=G.+Beckauthor=B.+Sherborneauthor=I.+Cooper&title=Rate-limited+steps+of+human+oral+absorption+and+QSAR+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DI.%26atitle%3DRate-limited%2520steps%2520of%2520human%2520oral%2520absorption%2520and%2520QSAR%2520studies%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D1446%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ikegashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruha, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span> </span><span class="NLM_article-title">Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6950</span><span class="NLM_x">–</span> <span class="NLM_lpage">6953</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0610245" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6950-6953&author=K.+Ikegashiraauthor=T.+Okaauthor=S.+Hirashimaauthor=S.+Nojiauthor=H.+Yamanakaauthor=Y.+Haraauthor=T.+Adachiauthor=J.-I.+Tsuruhaauthor=S.+Doiauthor=Y.+Haseauthor=T.+Noguchiauthor=I.+Andoauthor=N.+Oguraauthor=S.+Ikedaauthor=H.+Hashimoto&title=Discovery+of+conformationally+constrained+tetracyclic+compounds+as+potent+hepatitis+C+virus+NS5B+RNA+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors</span></div><div class="casAuthors">Ikegashira, Kazutaka; Oka, Takahiro; Hirashima, Shintaro; Noji, Satoru; Yamanaka, Hiroshi; Hara, Yoshinori; Adachi, Tsuyoshi; Tsuruha, Jun-Ichiro; Doi, Satoki; Hase, Yasunori; Noguchi, Toru; Ando, Izuru; Ogura, Naoki; Ikeda, Satoru; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6950-6953</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a new series of hepatitis C virus NS5B RNA polymerase inhibitors contg. a conformationally constrained tetracyclic scaffold.  SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (I and II) bearing a basic pendent group with high biochem. and cellular potencies.  These compds. displayed a very small shift in cellular potency when the replicon assay was performed in the presence of human serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF0S142h4FZLVg90H21EOLACvtfcHk0lhxNlw74CxdPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKrs7rF&md5=18234c5535779cf60484899c6e63770f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0610245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0610245%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHirashima%26aufirst%3DS.%26aulast%3DNoji%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DTsuruha%26aufirst%3DJ.-I.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DNoguchi%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DI.%26aulast%3DOgura%26aufirst%3DN.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520conformationally%2520constrained%2520tetracyclic%2520compounds%2520as%2520potent%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6950%26epage%3D6953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Helm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4431</span><span class="NLM_x">–</span> <span class="NLM_lpage">4436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4431-4436&author=D.+McGowanauthor=S.+Vendevilleauthor=T.+I.+Linauthor=A.+Tahriauthor=L.+Huauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=J.+M.+Berkeauthor=M.+Canardauthor=E.+Cleirenauthor=P.+Dehertoghauthor=S.+Lastauthor=E.+Fransenauthor=E.+Van+Der+Helmauthor=I.+Van+den+Steenauthor=L.+Vijgenauthor=M.+C.+Rouanauthor=G.+Fanningauthor=O.+Nyanguileauthor=K.+Van+Emelenauthor=K.+Simmenauthor=P.+Raboisson&title=Finger-loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+1%3A+Discovery+and+optimization+of+novel+1%2C6-+and+2%2C6-macrocyclic+indole+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DVan%2BDer%2BHelm%26aufirst%3DE.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger-loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%25201%253A%2520Discovery%2520and%2520optimization%2520of%2520novel%25201%252C6-%2520and%25202%252C6-macrocyclic%2520indole%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4431%26epage%3D4436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger-loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4437</span><span class="NLM_x">–</span> <span class="NLM_lpage">4443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4437-4443&author=S.+Vendevilleauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=M.+Canardauthor=S.+Lastauthor=I.+Van+den+Steenauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboisson&title=Finger-loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+II.+Optimization+of+tetracyclic+indole-based+macrocycle+leading+to+the+discovery+of+TMC647055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger-loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%2520II.%2520Optimization%2520of%2520tetracyclic%2520indole-based%2520macrocycle%2520leading%2520to%2520the%2520discovery%2520of%2520TMC647055%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4437%26epage%3D4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1377-1385&author=T.-I.+Linauthor=O.+Lenzauthor=G.+Fanningauthor=T.+Verbinnenauthor=F.+Delouvroyauthor=A.+Scholliersauthor=K.+Vermeirenauthor=A.+Rosenquistauthor=M.+Edlundauthor=B.+Samuelssonauthor=L.+Vrangauthor=H.+de+Kockauthor=P.+Wigerinckauthor=P.+Raboissonauthor=K.+Simmen&title=In+vitro+activity+and+preclinical+profile+of+TMC435350%2C+a+potent+hepatitis+C+virus+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520activity%2520and%2520preclinical%2520profile%2520of%2520TMC435350%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1377%26epage%3D1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=A.+Rosenquistauthor=M.+Nilssonauthor=L.+Salvador-Odenauthor=T.-I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+Wahlingauthor=K.+Wickstromauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure%E2%80%93activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3%2F4A+protease+leading+to+the+discovery+of+TMC435350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DWahling%26aufirst%3DH.%26aulast%3DWickstrom%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span> </span><span class="NLM_article-title">Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4637</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1002%2Fanie.201200110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4637-4640&author=M.+D.+Cummingsauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=K.+Amssomsauthor=S.+Lastauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboissonauthor=S.+Vendeville&title=Structure-based+macrocyclization+yields+hepatitis+C+virus+NS5B+inhibitors+with+improved+binding+affinities+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Macrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved Binding Affinities and Pharmacokinetic Properties</span></div><div class="casAuthors">Cummings, Maxwell D.; Lin, Tse-I.; Hu, Lili; Tahri, Abdellah; McGowan, David; Amssoms, Katie; Last, Stefaan; Devogelaere, Benoit; Rouan, Marie-Claude; Vijgen, Leen; Berke, Jan Martin; Dehertogh, Pascale; Fransen, Els; Cleiren, Erna; van der Helm, Liesbet; Fanning, Gregory; Van Emelen, Kristof; Nyanguile, Origene; Simmen, Kenny; Raboisson, Pierre; Vendeville, Sandrine</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4637-4640, S4637/1-S4637/20</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocyclization is one mol. design strategy that can be used to improve the drug-related characteristics of small mols. and peptides,'1"4' and thus may provide a route to a less restrictive "drug-likeness space".  Structure-based design is typically focused on the optimization of a chem. series to increase affinity toward a target protein: modification to gain addnl. binding contacts and rigidification to favor a bio-active conformation are two common strategies.  In addn. to affinity for the primary target, a 3D structure of a relevant protein-small mol. complex can be used to guide the optimization of other pharmaceutical properties.  Substituent positions that project away from the binding site may be chem. exploited to alter one or more PK- or ADME-related properties (e.g. "solubilizing groups") while having minimal effect on the therapeutically relevant binding interaction (PK = pharmacokinetics; ADME = absorption, distribution, metab., and excretion).  Pursuing a design strategy based on publicly available 3D structures, we combined rigidification and the introduction of a PK-enhancing group in a single modification by forming a macrocycle between two solvent-exposed substituent positions of a small-mol. inhibitor of an essential viral enzyme.  In the present work we have used structure-based design to guide macrocyclization, leading to the discovery of new inhibitors that maintain potency while showing substantially improved pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70QpVIVUDr7Vg90H21EOLACvtfcHk0lgmMFYMyS9MeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGltLc%253D&md5=1dc1c86dcc8f22d406256e4a779e9e6e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200110%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DVendeville%26aufirst%3DS.%26atitle%3DStructure-based%2520macrocyclization%2520yields%2520hepatitis%2520C%2520virus%2520NS5B%2520inhibitors%2520with%2520improved%2520binding%2520affinities%2520and%2520pharmacokinetic%2520properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D4637%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">Apparent permeability was assessed in caco-2 cells and was found to be unpredictive for in vivo absorption. For example, <b>10a</b> was predicted to be poorly absorbed with a <i>P</i><sub>AB</sub> of 2.8 cm/s but showed a very good exposure in rats and dogs. We postulate that our acyl sulfamide derivatives are mostly present in a charged form (anion) at the pH of the caco-2 cells experiment (pH 7.4), thus underestimating their permeability in the stomach and intestines where the pH is lower. For <b>10a</b>, the measured p<i>K</i><sub>a</sub> of the acidic acyl sulfamide moiety was 5.7.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span> </span><span class="NLM_article-title">TMC647055, a potent non-nucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4676-4684&author=B.+Devogelaereauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=O.+Nyanguileauthor=A.+Tahriauthor=K.+Amssomsauthor=O.+Lenzauthor=M.+D.+Cummingsauthor=R.+F.+Claytonauthor=S.+Vendevilleauthor=P.+Raboissonauthor=K.+A.+Simmenauthor=G.+C.+Fanningauthor=T.-I.+Lin&title=TMC647055%2C+a+potent+non-nucleoside+hepatitis+C+virus+NS5B+polymerase+inhibitor+with+cross-genotypic+coverage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DClayton%26aufirst%3DR.%2BF.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DLin%26aufirst%3DT.-I.%26atitle%3DTMC647055%252C%2520a%2520potent%2520non-nucleoside%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520with%2520cross-genotypic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4676%26epage%3D4684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+Bosauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.-M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.-A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.-L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0liYqxzbkKEMCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2–P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2%E2%80%93P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2%25E2%2580%2593P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Biswal, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yannopoulos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilimoria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. N.</span><span> </span><span class="NLM_article-title">Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">18202</span><span class="NLM_x">–</span> <span class="NLM_lpage">18210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=18202-18210&author=B.+K.+Biswalauthor=M.+M.+Cherneyauthor=M.+Wangauthor=L.+Chanauthor=C.+G.+Yannopoulosauthor=D.+Bilimoriaauthor=O.+Nicolasauthor=J.+Bedardauthor=M.+N.+James&title=Crystal+structures+of+the+RNA-dependent+RNA+polymerase+genotype+2a+of+hepatitis+C+virus+reveal+two+conformations+and+suggest+mechanisms+of+inhibition+by+non-nucleoside+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiswal%26aufirst%3DB.%2BK.%26aulast%3DCherney%26aufirst%3DM.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DYannopoulos%26aufirst%3DC.%2BG.%26aulast%3DBilimoria%26aufirst%3DD.%26aulast%3DNicolas%26aufirst%3DO.%26aulast%3DBedard%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DM.%2BN.%26atitle%3DCrystal%2520structures%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520genotype%25202a%2520of%2520hepatitis%2520C%2520virus%2520reveal%2520two%2520conformations%2520and%2520suggest%2520mechanisms%2520of%2520inhibition%2520by%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D18202%26epage%3D18210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thavonekham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Allosteric <i>N</i>-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase—Acylsulfonamides and acyl sulfamides as carboxylic acid replacements</span> <span class="citation_source-journal">Can. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=66-81&author=P.+L.+Beaulieuauthor=R.+Coulombeauthor=J.+Gillardauthor=C.+Brochuauthor=J.+Duanauthor=M.+Garneauauthor=E.+Jolicoeurauthor=P.+Kuhnauthor=M.-A.+Poupartauthor=J.+Rancourtauthor=T.+A.+Stammersauthor=B.+Thavonekhamauthor=G.+Kukolj&title=Allosteric+N-acetamide-indole-6-carboxylic+acid+thumb+pocket+1+inhibitors+of+hepatitis+C+virus+NS5B+polymerase%E2%80%94Acylsulfonamides+and+acyl+sulfamides+as+carboxylic+acid+replacements"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DStammers%26aufirst%3DT.%2BA.%26aulast%3DThavonekham%26aufirst%3DB.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DAllosteric%2520N-acetamide-indole-6-carboxylic%2520acid%2520thumb%2520pocket%25201%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%25E2%2580%2594Acylsulfonamides%2520and%2520acyl%2520sulfamides%2520as%2520carboxylic%2520acid%2520replacements%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D2013%26volume%3D91%26spage%3D66%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0ljjSN6tNyi_Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">An optimized indole acetamide lead from the acyclic series (see ref  <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>) was found to have a half-life of 3 min in our in-house SPR experiment.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Pauwels, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostmans, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirynen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span> </span><span class="NLM_article-title">Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">6909</span><span class="NLM_x">–</span> <span class="NLM_lpage">6919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1128%2FJVI.01543-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=17459932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVOisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=6909-6919&author=F.+Pauwelsauthor=W.+Mostmansauthor=L.+M.+Quirynenauthor=L.+van+der+Helmauthor=C.+W.+Bouttonauthor=A.+S.+Rueffauthor=E.+Cleirenauthor=P.+Raboissonauthor=D.+Surlerauxauthor=O.+Nyanguileauthor=K.+A.+Simmen&title=Binding-site+identification+and+genotypic+profiling+of+hepatitis+C+virus+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors</span></div><div class="casAuthors">Pauwels, Frederik; Mostmans, Wendy; Quirynen, Ludo M. M.; van der Helm, Liesbet; Boutton, Carlo W.; Rueff, Anne-Stephanie; Cleiren, Erna; Raboisson, Pierre; Surleraux, Dominique; Nyanguile, Origene; Simmen, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6909-6919</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The search for hepatitis C virus polymerase inhibitors has resulted in the identification of several nonnucleoside binding pockets.  The shape and nature of these binding sites differ across and even within diverse hepatitis C virus genotypes.  These differences confront antiviral drug discovery with the challenge of finding compds. that are capable of inhibition in variable binding pockets.  To address this, we have established a hepatitis C virus mutant and genotypic recombinant polymerase panel as a means of guiding medicinal chem. through the elucidation of the site of action of novel inhibitors and profiling against genotypes.  Using a genotype 1b backbone, we demonstrate that the recombinant P495L, M423T, M414T, and S282T mutant enzymes can be used to identify the binding site of an acyl pyrrolidine analog.  We assess the inhibitory activity of this analog and other nonnucleoside inhibitors with our panel of enzyme isolates generated from clin. sera representing genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpujEe1PIq2rLVg90H21EOLACvtfcHk0ljjSN6tNyi_Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVOisL8%253D&md5=cfc408253bdf44eff2d8f6dd3e47b2dc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FJVI.01543-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01543-06%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DQuirynen%26aufirst%3DL.%2BM.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%2BW.%26aulast%3DRueff%26aufirst%3DA.%2BS.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26atitle%3DBinding-site%2520identification%2520and%2520genotypic%2520profiling%2520of%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D6909%26epage%3D6919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Rydberg, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paonessa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carfi, A.</span><span> </span><span class="NLM_article-title">Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">390</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2009&pages=1048-1059&author=E.+H.+Rydbergauthor=A.+Cellucciauthor=L.+Bartholomewauthor=M.+Mattuauthor=G.+Barbatoauthor=S.+W.+Ludmererauthor=D.+J.+Grahamauthor=S.+Altamuraauthor=G.+Paonessaauthor=R.+De+Francescoauthor=G.+Migliaccioauthor=A.+Carfi&title=Structural+basis+for+resistance+of+the+genotype+2b+hepatitis+C+virus+NS5B+polymerase+to+site+A+non-nucleoside+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRydberg%26aufirst%3DE.%2BH.%26aulast%3DCellucci%26aufirst%3DA.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DMattu%26aufirst%3DM.%26aulast%3DBarbato%26aufirst%3DG.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DPaonessa%26aufirst%3DG.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DCarfi%26aufirst%3DA.%26atitle%3DStructural%2520basis%2520for%2520resistance%2520of%2520the%2520genotype%25202b%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520to%2520site%2520A%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D390%26spage%3D1048%26epage%3D1059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span> </span><span class="NLM_article-title">In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1878</span><span class="NLM_x">–</span> <span class="NLM_lpage">1887</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1878-1887&author=O.+Lenzauthor=T.+Verbinnenauthor=T.-I.+Linauthor=L.+Vijgenauthor=M.+D.+Cummingsauthor=J.+Lindbergauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=A.+Scholliersauthor=K.+Vermeirenauthor=T.+Ivensauthor=P.+Raboissonauthor=M.+Edlundauthor=S.+Stormauthor=L.+Vrangauthor=H.+de+Kockauthor=G.+C.+Fanningauthor=K.+A.+Simmen&title=In+vitro+resistance+profile+of+the+hepatitis+C+virus+NS3%2F4A+protease+inhibitor+TMC435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DIvens%26aufirst%3DT.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DS.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26atitle%3DIn%2520vitro%2520resistance%2520profile%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitor%2520TMC435%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D1878%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Bourgeois, S.; Reesink, H. W.; Leempoels, J.; Vijgen, L.; Rouan, M.-C.; Marien, K.; Remoortere, P. V.; Fanning, G.; Picchio, G.; Simmen, K.; Verloes, R.</span> Combination Therapy of TMC647055 with Simeprevir (TMC435) in Genotype 1 HCV Patients. EASL, The International Liver Conference, Amsterdam,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bourgeois%2C+S.%3B+Reesink%2C+H.+W.%3B+Leempoels%2C+J.%3B+Vijgen%2C+L.%3B+Rouan%2C+M.-C.%3B+Marien%2C+K.%3B+Remoortere%2C+P.+V.%3B+Fanning%2C+G.%3B+Picchio%2C+G.%3B+Simmen%2C+K.%3B+Verloes%2C+R.+Combination+Therapy+of+TMC647055+with+Simeprevir+%28TMC435%29+in+Genotype+1+HCV+Patients.+EASL%2C+The+International+Liver+Conference%2C+Amsterdam%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBourgeois%26aufirst%3DS.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':[],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Dan Liu, Nan Jiang, Wen Dou Huang, Ji Wen Li, Wen Jing Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Ren Xiang Tan</span>. </span><span class="cited-content_cbyCitation_article-title">Ionic-Liquid-Catalyzed Access to CTr: An Antitumor Agent. </span><span class="cited-content_cbyCitation_journal-name">ACS Sustainable Chemistry & Engineering</span><span> <strong>2021,</strong> <em>9 </em>
                                    (14)
                                     , 5138-5147. <a href="https://doi.org/10.1021/acssuschemeng.1c00191" title="DOI URL">https://doi.org/10.1021/acssuschemeng.1c00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssuschemeng.1c00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssuschemeng.1c00191%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Sustainable%2520Chemistry%2520%2526%2520Engineering%26atitle%3DIonic-Liquid-Catalyzed%252BAccess%252Bto%252BCTr%25253A%252BAn%252BAntitumor%252BAgent%26aulast%3DLiu%26aufirst%3DDan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10012021%26date%3D17022021%26date%3D26032021%26volume%3D9%26issue%3D14%26spage%3D5138%26epage%3D5147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maxwell D. Cummings, <span class="NLM_string-name hlFld-ContribAuthor">Sivakumar Sekharan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6843-6853. <a href="https://doi.org/10.1021/acs.jmedchem.8b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BMacrocycle%252BDesign%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%252Band%252BSimple%252BMetrics%252BTo%252BIdentify%252BOpportunities%252Bfor%252BMacrocyclization%252Bof%252BSmall-Molecule%252BLigands%26aulast%3DCummings%26aufirst%3DMaxwell%2BD.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D18122018%26date%3D22032019%26date%3D12032019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice  Romeo</span>, <span class="hlFld-ContribAuthor ">Federico  Iacovelli</span>, <span class="hlFld-ContribAuthor ">Mattia  Falconi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Virus Research</span><span> <strong>2020,</strong> <em>286 </em>, 198068. <a href="https://doi.org/10.1016/j.virusres.2020.198068" title="DOI URL">https://doi.org/10.1016/j.virusres.2020.198068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.virusres.2020.198068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.virusres.2020.198068%26sid%3Dliteratum%253Aachs%26jtitle%3DVirus%2520Research%26atitle%3DTargeting%252Bthe%252BSARS-CoV-2%252Bspike%252Bglycoprotein%252Bprefusion%252Bconformation%25253A%252Bvirtual%252Bscreening%252Band%252Bmolecular%252Bdynamics%252Bsimulations%252Bapplied%252Bto%252Bthe%252Bidentification%252Bof%252Bpotential%252Bfusion%252Binhibitors%26aulast%3DRomeo%26aufirst%3DAlice%26date%3D2020%26volume%3D286%26spage%3D198068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Watkins</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of HCV NS5B Non-nucleoside Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 171-191. <a href="https://doi.org/10.1007/7355_2018_35" title="DOI URL">https://doi.org/10.1007/7355_2018_35</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_35%26sid%3Dliteratum%253Aachs%26atitle%3DEvolution%252Bof%252BHCV%252BNS5B%252BNon-nucleoside%252BInhibitors%26aulast%3DWatkins%26aufirst%3DWilliam%2BJ.%26date%3D2019%26date%3D2019%26spage%3D171%26epage%3D191%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guglielmo  Borgia</span>, <span class="hlFld-ContribAuthor ">Alberto Enrico  Maraolo</span>, <span class="hlFld-ContribAuthor ">Salvatore  Nappa</span>, <span class="hlFld-ContribAuthor ">Ivan  Gentile</span>, <span class="hlFld-ContribAuthor ">Antonio Riccardo  Buonomo</span>. </span><span class="cited-content_cbyCitation_article-title">NS5B polymerase inhibitors in phase II clinical trials for HCV infection. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2018,</strong> <em>27 </em>
                                    (3)
                                     , 243-250. <a href="https://doi.org/10.1080/13543784.2018.1420780" title="DOI URL">https://doi.org/10.1080/13543784.2018.1420780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2018.1420780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2018.1420780%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DNS5B%252Bpolymerase%252Binhibitors%252Bin%252Bphase%252BII%252Bclinical%252Btrials%252Bfor%252BHCV%252Binfection%26aulast%3DBorgia%26aufirst%3DGuglielmo%26date%3D2018%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D243%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sulejman  Alihodžić</span>, <span class="hlFld-ContribAuthor ">Mirjana  Bukvić</span>, <span class="hlFld-ContribAuthor ">Ivaylo J.  Elenkov</span>, <span class="hlFld-ContribAuthor ">Antun  Hutinec</span>, <span class="hlFld-ContribAuthor ">Sanja  Koštrun</span>, <span class="hlFld-ContribAuthor ">Dijana  Pešić</span>, <span class="hlFld-ContribAuthor ">Gordon  Saxty</span>, <span class="hlFld-ContribAuthor ">Linda  Tomašković</span>, <span class="hlFld-ContribAuthor ">Dinko  Žiher</span>. </span><span class="cited-content_cbyCitation_article-title">Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 113-233. <a href="https://doi.org/10.1016/bs.pmch.2018.01.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2018.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2018.01.002%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BTrends%252Bin%252BMacrocyclic%252BDrug%252BDiscovery%252Band%252Bbeyond%252B-Ro5%26aulast%3DAlihod%25C5%25BEi%25C4%2587%26aufirst%3DSulejman%26date%3D2018%26spage%3D113%26epage%3D233%26pub%3DElsevier%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Noritaka  Abe</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress of the Chemistry of Azaazulenes and Related Compounds. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2018,</strong> <em>97 </em>
                                    (1)
                                     , 43. <a href="https://doi.org/10.3987/REV-18-SR(T)1" title="DOI URL">https://doi.org/10.3987/REV-18-SR(T)1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/REV-18-SR(T)1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FREV-18-SR%28T%291%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DRecent%252BProgress%252Bof%252Bthe%252BChemistry%252Bof%252BAzaazulenes%252Band%252BRelated%252BCompounds%26aulast%3DAbe%26aufirst%3DNoritaka%26date%3D2018%26volume%3D97%26issue%3D1%26spage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Bourgeois</span>, <span class="hlFld-ContribAuthor ">Hans  Van Vlierberghe</span>, <span class="hlFld-ContribAuthor ">Christophe  Moreno</span>, <span class="hlFld-ContribAuthor ">Hans  Orlent</span>, <span class="hlFld-ContribAuthor ">Frederik  Nevens</span>, <span class="hlFld-ContribAuthor ">Keikawus  Arastéh</span>, <span class="hlFld-ContribAuthor ">Yves  Horsmans</span>, <span class="hlFld-ContribAuthor ">Jörn M.  Schattenberg</span>, <span class="hlFld-ContribAuthor ">Peter  Buggisch</span>, <span class="hlFld-ContribAuthor ">Sven  Francque</span>, <span class="hlFld-ContribAuthor ">Leen  Vijgen</span>, <span class="hlFld-ContribAuthor ">Thomas N.  Kakuda</span>, <span class="hlFld-ContribAuthor ">Eva  Hoeben</span>, <span class="hlFld-ContribAuthor ">Donghan  Luo</span>, <span class="hlFld-ContribAuthor ">An  Vandebosch</span>, <span class="hlFld-ContribAuthor ">Bert  Jacquemyn</span>, <span class="hlFld-ContribAuthor ">Pieter  Van Remoortere</span>, <span class="hlFld-ContribAuthor ">René  Verloes</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. </span><span class="cited-content_cbyCitation_journal-name">BMC Gastroenterology</span><span> <strong>2017,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12876-017-0580-2" title="DOI URL">https://doi.org/10.1186/s12876-017-0580-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12876-017-0580-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12876-017-0580-2%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Gastroenterology%26atitle%3DEfficacy%25252C%252Bsafety%252Band%252Bpharmacokinetics%252Bof%252Bsimeprevir%252Band%252BTMC647055%25252Fritonavir%252Bwith%252Bor%252Bwithout%252Bribavirin%252Band%252BJNJ-56914845%252Bin%252BHCV%252Bgenotype%252B1%252Binfection%26aulast%3DBourgeois%26aufirst%3DStefan%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangdi  Li</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current therapy for chronic hepatitis C: The role of direct-acting antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2017,</strong> <em>142 </em>, 83-122. <a href="https://doi.org/10.1016/j.antiviral.2017.02.014" title="DOI URL">https://doi.org/10.1016/j.antiviral.2017.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2017.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DCurrent%252Btherapy%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BThe%252Brole%252Bof%252Bdirect-acting%252Bantivirals%26aulast%3DLi%26aufirst%3DGuangdi%26date%3D2017%26volume%3D142%26spage%3D83%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Persich</span>, <span class="hlFld-ContribAuthor ">Steven  Hostyn</span>, <span class="hlFld-ContribAuthor ">Céline  Joie</span>, <span class="hlFld-ContribAuthor ">Guy  Winderickx</span>, <span class="hlFld-ContribAuthor ">Jeroen  Pikkemaat</span>, <span class="hlFld-ContribAuthor ">Edwin P.  Romijn</span>, <span class="hlFld-ContribAuthor ">Bert U.W.  Maes</span>. </span><span class="cited-content_cbyCitation_article-title">“Dark” Singlet Oxygen and Electron Paramagnetic Resonance Spin Trapping as Convenient Tools to Assess Photolytic Drug Degradation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2017,</strong> <em>106 </em>
                                    (5)
                                     , 1310-1316. <a href="https://doi.org/10.1016/j.xphs.2017.01.015" title="DOI URL">https://doi.org/10.1016/j.xphs.2017.01.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2017.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2017.01.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3D%2525E2%252580%25259CDark%2525E2%252580%25259D%252BSinglet%252BOxygen%252Band%252BElectron%252BParamagnetic%252BResonance%252BSpin%252BTrapping%252Bas%252BConvenient%252BTools%252Bto%252BAssess%252BPhotolytic%252BDrug%252BDegradation%26aulast%3DPersich%26aufirst%3DPeter%26date%3D2017%26volume%3D106%26issue%3D5%26spage%3D1310%26epage%3D1316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddappa A.  Patil</span>, <span class="hlFld-ContribAuthor ">Shivaputra A.  Patil</span>, <span class="hlFld-ContribAuthor ">Renukadevi  Patil</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal applications of (benz)imidazole- and indole-based macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>89 </em>
                                    (4)
                                     , 639-649. <a href="https://doi.org/10.1111/cbdd.12802" title="DOI URL">https://doi.org/10.1111/cbdd.12802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12802%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DMedicinal%252Bapplications%252Bof%252B%252528benz%252529imidazole-%252Band%252Bindole-based%252Bmacrocycles%26aulast%3DPatil%26aufirst%3DSiddappa%2BA.%26date%3D2017%26date%3D2017%26volume%3D89%26issue%3D4%26spage%3D639%26epage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Herman  van Vlijmen</span>, <span class="hlFld-ContribAuthor ">Renee L.  Desjarlais</span>, <span class="hlFld-ContribAuthor ">Tara  Mirzadegan</span>. </span><span class="cited-content_cbyCitation_article-title">Computational chemistry at Janssen. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2017,</strong> <em>31 </em>
                                    (3)
                                     , 267-273. <a href="https://doi.org/10.1007/s10822-016-9998-9" title="DOI URL">https://doi.org/10.1007/s10822-016-9998-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-016-9998-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-016-9998-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DComputational%252Bchemistry%252Bat%252BJanssen%26aulast%3Dvan%2BVlijmen%26aufirst%3DHerman%26date%3D2017%26date%3D2016%26volume%3D31%26issue%3D3%26spage%3D267%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bianca  Heinrich</span>, <span class="hlFld-ContribAuthor ">John P.  Bilello</span>. </span><span class="cited-content_cbyCitation_article-title">HCV Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 579-609. <a href="https://doi.org/10.1007/978-3-319-46718-4_39" title="DOI URL">https://doi.org/10.1007/978-3-319-46718-4_39</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-46718-4_39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-46718-4_39%26sid%3Dliteratum%253Aachs%26atitle%3DHCV%252BDrug%252BResistance%26aulast%3DHeinrich%26aufirst%3DBianca%26date%3D2017%26date%3D2017%26spage%3D579%26epage%3D609%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntimicrobial%252BDrug%252BResistance%26aulast%3DMayers%26aufirst%3DDouglas%2BL.%26date%3D2017%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 553-627. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12406-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12406-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12406-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12406-0%26sid%3Dliteratum%253Aachs%26atitle%3DDirect-Acting%252BAntiviral%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D553%26epage%3D627%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2016,</strong> <em>26 </em>
                                    (9)
                                     , 979-986. <a href="https://doi.org/10.1080/13543776.2016.1210127" title="DOI URL">https://doi.org/10.1080/13543776.2016.1210127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2016.1210127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2016.1210127%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPyrazolo%25255B1%25252C5-a%25255Dpyrimidine-based%252Bmacrocycles%252Bas%252Bnovel%252BHIV-1%252Binhibitors%25253A%252Ba%252Bpatent%252Bevaluation%252Bof%252BWO2015123182%26aulast%3DSun%26aufirst%3DLin%26date%3D2016%26date%3D2016%26volume%3D26%26issue%3D9%26spage%3D979%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiqun  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Cui</span>, <span class="hlFld-ContribAuthor ">Chenchen  Guo</span>, <span class="hlFld-ContribAuthor ">Bo-Zhen  Chen</span>, <span class="hlFld-ContribAuthor ">Mingjuan  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry and Cell Biology</span><span> <strong>2016,</strong> <em>94 </em>
                                    (2)
                                     , 147-158. <a href="https://doi.org/10.1139/bcb-2015-0109" title="DOI URL">https://doi.org/10.1139/bcb-2015-0109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1139/bcb-2015-0109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1139%2Fbcb-2015-0109%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520and%2520Cell%2520Biology%26atitle%3DMolecular%252Bmodeling%252Bstudy%252Bon%252Bthe%252Bdrug%252Bresistance%252Bmechanism%252Bof%252BNS5B%252Bpolymerase%252Bto%252BTMC647055%26aulast%3DWang%26aufirst%3DHuiqun%26date%3D2016%26volume%3D94%26issue%3D2%26spage%3D147%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean  Ekins</span>, <span class="hlFld-ContribAuthor ">John  Liebler</span>, <span class="hlFld-ContribAuthor ">Bruno J.  Neves</span>, <span class="hlFld-ContribAuthor ">Warren G.  Lewis</span>, <span class="hlFld-ContribAuthor ">Megan  Coffee</span>, <span class="hlFld-ContribAuthor ">Rachelle  Bienstock</span>, <span class="hlFld-ContribAuthor ">Christopher  Southan</span>, <span class="hlFld-ContribAuthor ">Carolina H.  Andrade</span>. </span><span class="cited-content_cbyCitation_article-title">Illustrating and homology modeling the proteins of the Zika virus. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2016,</strong> <em>5 </em>, 275. <a href="https://doi.org/10.12688/f1000research.8213.1" title="DOI URL">https://doi.org/10.12688/f1000research.8213.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.8213.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.8213.1%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DIllustrating%252Band%252Bhomology%252Bmodeling%252Bthe%252Bproteins%252Bof%252Bthe%252BZika%252Bvirus%26aulast%3DEkins%26aufirst%3DSean%26date%3D2016%26date%3D2016%26volume%3D5%26spage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Can  Zhao</span>, <span class="hlFld-ContribAuthor ">Yinhu  Wang</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>102 </em>, 188-214. <a href="https://doi.org/10.1016/j.ejmech.2015.07.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.07.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.07.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.07.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bon%252Bthe%252Bsynthesis%252Bof%252Bhepatitis%252BC%252Bvirus%252BNS5B%252BRNA-dependent%252BRNA-polymerase%252Binhibitors%26aulast%3DZhao%26aufirst%3DCan%26date%3D2015%26volume%3D102%26spage%3D188%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabao  Zhao</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xuemei  Jiang</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>94 </em>, 218-228. <a href="https://doi.org/10.1016/j.ejmech.2015.03.012" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BHCV%252BNS5B%252Bthumb%252Bsite%252BI%252Binhibitors%25253A%252BCore-refining%252Bfrom%252Bbenzimidazole%252Bto%252Bindole%252Bscaffold%26aulast%3DZhao%26aufirst%3DFabao%26date%3D2015%26volume%3D94%26spage%3D218%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Zhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiong  Chen</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">A review on recent developments of indole-containing antiviral agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 421-441. <a href="https://doi.org/10.1016/j.ejmech.2014.10.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Brecent%252Bdevelopments%252Bof%252Bindole-containing%252Bantiviral%252Bagents%26aulast%3DZhang%26aufirst%3DMing-Zhi%26date%3D2015%26volume%3D89%26spage%3D421%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amir  Taheri</span>, <span class="hlFld-ContribAuthor ">Bingbing  Lai</span>, <span class="hlFld-ContribAuthor ">Cheng  Cheng</span>, <span class="hlFld-ContribAuthor ">Yanlong  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Brønsted acid ionic liquid-catalyzed reductive Friedel–Crafts alkylation of indoles and cyclic ketones without using an external reductant. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2015,</strong> <em>17 </em>
                                    (2)
                                     , 812-816. <a href="https://doi.org/10.1039/C4GC01299B" title="DOI URL">https://doi.org/10.1039/C4GC01299B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4GC01299B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4GC01299B%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DBr%2525C3%2525B8nsted%252Bacid%252Bionic%252Bliquid-catalyzed%252Breductive%252BFriedel%2525E2%252580%252593Crafts%252Balkylation%252Bof%252Bindoles%252Band%252Bcyclic%252Bketones%252Bwithout%252Busing%252Ban%252Bexternal%252Breductant%26aulast%3DTaheri%26aufirst%3DAmir%26date%3D2015%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D812%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaihana  Abdulrahman Almatrrouk</span>, <span class="hlFld-ContribAuthor ">Anthony W  Oliver</span>, <span class="hlFld-ContribAuthor ">Lynne  Hampson</span>, <span class="hlFld-ContribAuthor ">Ian N  Hampson</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis. </span><span class="cited-content_cbyCitation_journal-name">Future Virology</span><span> <strong>2014,</strong> <em>9 </em>
                                    (7)
                                     , 679-692. <a href="https://doi.org/10.2217/fvl.14.50" title="DOI URL">https://doi.org/10.2217/fvl.14.50</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fvl.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffvl.14.50%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Virology%26atitle%3DTargeting%252Bgap%252Bjunction%252Bintercellular%252Bcommunication%252Bas%252Ba%252Bpotential%252Btherapy%252Bfor%252BHCV-related%252Bcarcinogenesis%26aulast%3DAbdulrahman%2BAlmatrrouk%26aufirst%3DShaihana%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D679%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current race in the development of DAAs (direct-acting antivirals) against HCV. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2014,</strong> <em>89 </em>
                                    (4)
                                     , 441-452. <a href="https://doi.org/10.1016/j.bcp.2014.04.005" title="DOI URL">https://doi.org/10.1016/j.bcp.2014.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2014.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DCurrent%252Brace%252Bin%252Bthe%252Bdevelopment%252Bof%252BDAAs%252B%252528direct-acting%252Bantivirals%252529%252Bagainst%252BHCV%26aulast%3DDe%2BClercq%26aufirst%3DErik%26date%3D2014%26volume%3D89%26issue%3D4%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean–Michel  Pawlotsky</span>. </span><span class="cited-content_cbyCitation_article-title">New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. </span><span class="cited-content_cbyCitation_journal-name">Gastroenterology</span><span> <strong>2014,</strong> <em>146 </em>
                                    (5)
                                     , 1176-1192. <a href="https://doi.org/10.1053/j.gastro.2014.03.003" title="DOI URL">https://doi.org/10.1053/j.gastro.2014.03.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1053/j.gastro.2014.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1053%2Fj.gastro.2014.03.003%26sid%3Dliteratum%253Aachs%26jtitle%3DGastroenterology%26atitle%3DNew%252BHepatitis%252BC%252BTherapies%25253A%252BThe%252BToolbox%25252C%252BStrategies%25252C%252Band%252BChallenges%26aulast%3DPawlotsky%26aufirst%3DJean%25E2%2580%2593Michel%26date%3D2014%26volume%3D146%26issue%3D5%26spage%3D1176%26epage%3D1192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the early lead compound <b>1</b>, the clinical candidates <b>2</b> (BILB1941) and <b>3</b> (MK-3281), and initial 1,6- and 2,6-indole-based macrocycles <b>4</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>10a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, THF, H<sub>2</sub>O, MeOH, RT (95%). (b) 2,2′-Oxybis(<i>N</i>-methylethanamine) (5 equiv), HATU, DIPEA, THF. (c) Sulfamide, dioxane, 100 °C. (d) TFA/DCM. (e) (i) CDI, dry THF, RT; (ii) DBU, THF.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of <b>11a</b> and <b>12a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>18a</b> and <b>19a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) Trimethylsulfoxonium chloride, NaH, DMSO, RT; (ii) <b>7</b>, 50 °C. (b) NaOH, H<sub>2</sub>O/THF/MeOH, RT. (c) (COCl)<sub>2</sub>, DMF, THF, 0 °C. (d) (<i>S</i>)-4-Benzyl-2-oxazolidinone (1.1 equiv), <i>n</i>-BuLi (1.1 equiv), THF, −78 °C. (e) NaOH (1 N), MeOH/THF, RT. (f) 2,2′-Oxybis(<i>N</i>-methylethanamine) (5 equiv), HATU, DIPEA,THF. (g) (i) Sulfamide, dioxane, 100 °C; (ii) TFA/DCM. (h) (i) CDI, dry THF, RT; (ii) DBU, THF.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N</i>-Methylmorpholine, isobutyl chloroformate, THF, −15 °C, then NaBH<sub>4</sub>, 0 °C. (b) Et<sub>3</sub>N, MeSO<sub>2</sub>Cl, THF, 0 °C. (c) <i>N</i>,<i>N</i>′-Dimethyl-1,4-butanediamine, THF, RT. (d) Sulfamide, dioxane, 105 °C. (e) (i) TFA, DCM, RT; (ii) CDI, acetonitrile, 60 °C; (iii) DBU, acetonitrile, RT.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stereospecificity of the saturated bridged system. Depicted are conformers of non-macrocyclic <i>N</i>,<i>N</i>-dimethylamide (<i>R</i>, green; <i>S</i>, purple), showing the stereospecific difference in the trajectory from the bridge, overlaid onto the NS5B-bound conformation of <b>10c</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Observed and modeled binding modes. (A) Crystal structure of <b>10c</b> (orange) bound at the NNI-1 site, showing the pocket surface and details of contacts with His34 and Arg503. (B) Overlay of bound <b>10c</b> (orange) and the modeled low-energy conformer of <b>10a</b> (purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of bound inhibitors with the native NNI-1 site protein–protein interaction. Shown are bound <b>10c</b> and a model of <b>10a</b> (as in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b) overlaid on the NS5B loop that occupies NNI-1 in the absence of bound inhibitor [protein of the NNI-1 site is not shown; the loop is from monomer B of the <b>10c</b>–NS5B complex structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DRU">4DRU</a>)].<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison with recent NS5B NNI-1 complex structures. (A) <b>10c</b> with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z">3Q0Z</a> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z">3Q0Z</a> protein shown).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (B) <b>10c</b> with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC">4GMC</a> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC">4GMC</a> protein shown).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. NS5B resistance mutations for <b>10a</b>. The <b>10a</b>–NS5B complex was modeled by superimposing a low-energy conformer of <b>10a</b> onto bound <b>10c</b> from the <b>10c</b>–NS5B complex, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b. Positions 392 (light teal), 494 (dark teal), and 495 (red) are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/medium/jm-2013-01396p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure of the HCV NS3/4A protease inhibitor TMC435 (simeprevir, Sovriad).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401396p/production/images/large/jm-2013-01396p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401396p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">El-Serag, H. B.</span><span> </span><span class="NLM_article-title">Hepatocellular carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMra1001683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21992124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1118-1127&author=H.+B.+El-Serag&title=Hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocellular carcinoma</span></div><div class="casAuthors">El-Serag, Hashem B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1118-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9eGOw4kyT7Vg90H21EOLACvtfcHk0liggfmrigyaxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqtrnL&md5=3fb4250042385c5e29a189df86aea635</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001683%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Serag%26aufirst%3DH.%2BB.%26atitle%3DHepatocellular%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1118%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ghany, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strader, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">American Association for the Study of Liver, D. Diagnosis, management, and treatment of hepatitis C: An update</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">–</span> <span class="NLM_lpage">1374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1335-1374&author=M.+G.+Ghanyauthor=D.+B.+Straderauthor=D.+L.+Thomasauthor=L.+B.+Seeff&title=American+Association+for+the+Study+of+Liver%2C+D.+Diagnosis%2C+management%2C+and+treatment+of+hepatitis+C%3A+An+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhany%26aufirst%3DM.%2BG.%26aulast%3DStrader%26aufirst%3DD.%2BB.%26aulast%3DThomas%26aufirst%3DD.%2BL.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DAmerican%2520Association%2520for%2520the%2520Study%2520of%2520Liver%252C%2520D.%2520Diagnosis%252C%2520management%252C%2520and%2520treatment%2520of%2520hepatitis%2520C%253A%2520An%2520update%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D1335%26epage%3D1374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span> </span><span class="NLM_article-title">The Global Burden of Hepatitis, C. W. G. Global Burden of Disease (GBD) for Hepatitis C</span>.  <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1177%2F0091270003258669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14681338" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Global+Burden+of+Hepatitis%2C+C.+W.+G.+Global+Burden+of+Disease+%28GBD%29+for+Hepatitis+C.+J.+Clin.+Pharmacol.+2004%2C+44%2C+20%E2%80%9329."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F0091270003258669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270003258669%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Global%2520Burden%2520of%2520Hepatitis%252C%2520C.%2520W.%2520G.%2520Global%2520Burden%2520of%2520Disease%2520%2528GBD%2529%2520for%2520Hepatitis%2520C%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D44%26spage%3D20%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sings, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burroughs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, R.</span><span> </span><span class="NLM_article-title">Boceprevir for previously treated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1009482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21449784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1207-1217&author=B.+R.+Baconauthor=S.+C.+Gordonauthor=E.+Lawitzauthor=P.+Marcellinauthor=J.+M.+Vierlingauthor=S.+Zeuzemauthor=F.+Poordadauthor=Z.+D.+Goodmanauthor=H.+L.+Singsauthor=N.+Boparaiauthor=M.+Burroughsauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=R.+Esteban&title=Boceprevir+for+previously+treated+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for previously treated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Bacon, Bruce R.; Gordon, Stuart C.; Lawitz, Eric; Marcellin, Patrick; Vierling, John M.; Zeuzem, Stefan; Poordad, Fred; Goodman, Zachary D.; Sings, Heather L.; Boparai, Navdeep; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.; Esteban, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal.  Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an addnl. treatment.  To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 infection, we randomly assigned patients (in a 1:2:2 ratio) to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead-in period).  Subsequently, group 1 (control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 32 wk, and patients with a detectable HCV RNA level at week 8 received placebo plus peginterferon-ribavirin for an addnl. 12 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  A total of 403 patients were treated.  The rate of sustained virol. response was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in the control group (21%, P < 0.001).  Among patients with an undetectable HCV RNA level at week 8, the rate of sustained virol. response was 86% after 32 wk of triple therapy and 88% after 44 wk of triple therapy.  Among the 102 patients with a decrease in the HCV RNA level of less than 1 log10 IU per mL at treatment week 4, the rates of sustained virol. response were 0%, 33%, and 34% in groups 1, 2, and 3, resp.  Anemia was significantly more common in the boceprevir groups than in the control group, and erythropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.  The addn. of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virol. response in previously treated patients with chronic HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjykaE3KIqArVg90H21EOLACvtfcHk0lh3UhiB9viNjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D&md5=402802777ab3a369c71332a84a8b40e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009482%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DSings%26aufirst%3DH.%2BL.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DBurroughs%26aufirst%3DM.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DBoceprevir%2520for%2520previously%2520treated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1207%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sniukiene, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span> </span><span class="NLM_article-title">Boceprevir for untreated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1010494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21449783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1195-1206&author=F.+Poordadauthor=J.+McConeauthor=B.+R.+Baconauthor=S.+Brunoauthor=M.+P.+Mannsauthor=M.+S.+Sulkowskiauthor=I.+M.+Jacobsonauthor=K.+R.+Reddyauthor=Z.+D.+Goodmanauthor=N.+Boparaiauthor=M.+J.+DiNubileauthor=V.+Sniukieneauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=J.-P.+Bronowicki&title=Boceprevir+for+untreated+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for untreated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Poordad, Fred; McCone, Jonathan, Jr.; Bacon, Bruce; Bruno, Savino; Manns, Michael P.; Sulkowski, Mark S.; Jacobson, Ira M.; Rajender Reddy, K.; Goodman, Zachary D.; Boparai, Navdeep; DiNubile, Mark J.; Sniukiene, Vilma; Brass, Clifford A.; Albrecht, Janice K.; Bronowicki, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1195-1206</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Peginterferon-ribavirin therapy is the current std. of care for chronic infection with hepatitis C virus (HCV).  The rate of sustained virol. response has been below 50% in cases of HCV genotype 1 infection.  Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an addnl. treatment in phase 1 and phase 2 studies.  We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead- in period).  Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 24 wk, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an addnl. 20 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  Non-black patients and black patients were enrolled and analyzed sep.  A total of 938 non-black and 159 black patients were treated.  In the non-black cohort, a sustained virol. response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P < 0.001), and in 213 of the 311 patients (68%) in group 3 (P < 0.001).  In the black cohort, a sustained virol. response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004).  In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 wk.  Anemia led to dose redns. in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, resp.  The addn. of boceprevir to std. therapy with peginterferon-ribavirin, as compared with std. therapy alone, significantly increased the rates of sustained virol. response in previously untreated adults with chronic HCV genotype 1 infection.  The rates were similar with 24 wk and 44 wk of boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCdL0rY0lmGrVg90H21EOLACvtfcHk0lh3UhiB9viNjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D&md5=47ea838a941fdf7f9a27350a403e794e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1010494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1010494%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DMcCone%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DSniukiene%26aufirst%3DV.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26atitle%3DBoceprevir%2520for%2520untreated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1195%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusheiko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bzowej, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flisiak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankoh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">Telaprevir for previously untreated chronic hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1012912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21696307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2405-2416&author=I.+M.+Jacobsonauthor=J.+G.+McHutchisonauthor=G.+Dusheikoauthor=A.+M.+Di+Bisceglieauthor=K.+R.+Reddyauthor=N.+H.+Bzowejauthor=P.+Marcellinauthor=A.+J.+Muirauthor=P.+Ferenciauthor=R.+Flisiakauthor=J.+Georgeauthor=M.+Rizzettoauthor=D.+Shouvalauthor=R.+Solaauthor=R.+A.+Tergauthor=E.+M.+Yoshidaauthor=N.+Addaauthor=L.+Bengtssonauthor=A.+J.+Sankohauthor=T.+L.+Kiefferauthor=S.+Georgeauthor=R.+S.+Kauffmanauthor=S.+Zeuzem&title=Telaprevir+for+previously+untreated+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for previously untreated chronic hepatitis C virus infection</span></div><div class="casAuthors">Jacobson, Ira M.; McHutchison, John G.; Dusheiko, Geoffrey; Di Bisceglie, Adrian M.; Reddy, K. Rajender; Bzowej, Natalie H.; Marcellin, Patrick; Muir, Andrew J.; Ferenci, Peter; Flisiak, Robert; George, Jacob; Rizzetto, Mario; Shouval, Daniel; Sola, Ricard; Terg, Ruben A.; Yoshida, Eric M.; Adda, Nathalie; Bengtsson, Leif; Sankoh, Abdul J.; Kieffer, Tara L.; George, Shelley; Kauffman, Robert S.; Zeuzem, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2405-2416</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients.  METHODS: In this international, phase 3, randomized, double-blind, placebo-controlled trial, we assigned 1088 patients with HCV genotype 1 infection who had not received previous treatment for the infection to one of three groups: a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 wk (T12PR group), followed by peginterferon-ribavirin alone for 12 wk if HCV RNA was undetectable at weeks 4 and 12 or for 36 wk if HCV RNA was detectable at either time point; a group receiving telaprevir with peginterferon-ribavirin for 8 wk and placebo with peginterferon-ribavirin for 4 wk (T8PR group), followed by 12 or 36 wk of peginterferon-ribavirin on the basis of the same HCV RNA criteria; or a group receiving placebo with peginterferon-ribavirin for 12 wk, followed by 36 wk of peginterferon-ribavirin (PR group).  The primary end point was the proportion of patients who had undetectable plasma HCV RNA 24 wk after the last planned dose of study treatment (sustained virol. response).  RESULTS: Significantly more patients in the T12PR or T8PR group than in the PR group had a sustained virol. response (75% and 69%, resp., vs. 44%; P < 0.001 for the comparison of the T12PR or T8PR group with the PR group).  A total of 58% of the patients treated with telaprevir were eligible to receive 24 wk of total treatment.  Anemia, gastrointestinal side effects, and skin rashes occurred at a higher incidence among patients receiving telaprevir than among those receiving peginterferon-ribavirin alone.  The overall rate of discontinuation of the treatment regimen owing to adverse events was 10% in the T12PR and T8PR groups and 7% in the PR group.  CONCLUSIONS: Telaprevir with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was assocd. with significantly improved rates of sustained virol. response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 wk of therapy administered in the majority of patients. (Funded by Vertex Pharmaceuticals and Tibotec; ADVANCE ClinicalTrials.gov no., NCT00627926.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcImqLMQ63DLVg90H21EOLACvtfcHk0liOiZb7UD1myg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCku7Y%253D&md5=16aff3164348c2bfe80fc14121eb7b93</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1012912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1012912%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DBzowej%26aufirst%3DN.%2BH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DRizzetto%26aufirst%3DM.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3DSola%26aufirst%3DR.%26aulast%3DTerg%26aufirst%3DR.%2BA.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DAdda%26aufirst%3DN.%26aulast%3DBengtsson%26aufirst%3DL.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DTelaprevir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2405%26epage%3D2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaccia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Heeswijk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont, M.</span><span> </span><span class="NLM_article-title">Telaprevir for retreatment of HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2417</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1056%2FNEJMoa1013086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=21696308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2417-2428&author=S.+Zeuzemauthor=P.+Andreoneauthor=S.+Polauthor=E.+Lawitzauthor=M.+Diagoauthor=S.+Robertsauthor=R.+Focacciaauthor=Z.+Younossiauthor=G.+R.+Fosterauthor=A.+Horbanauthor=P.+Ferenciauthor=F.+Nevensauthor=B.+Mullhauptauthor=P.+Pockrosauthor=R.+Tergauthor=D.+Shouvalauthor=B.+van+Hoekauthor=O.+Weilandauthor=R.+Van+Heeswijkauthor=S.+De+Meyerauthor=D.+Luoauthor=G.+Boogaertsauthor=R.+Poloauthor=G.+Picchioauthor=M.+Beumont&title=Telaprevir+for+retreatment+of+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for retreatment of HCV infection</span></div><div class="casAuthors">Zeuzem, Stefan; Andreone, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, Moises; Roberts, Stuart; Focaccia, Roberto; Younossi, Zobair; Foster, Graham R.; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Mullhaupt, Beat; Pockros, Paul; Terg, Ruben; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; Van Heeswijk, Rolf; De Meyer, Sandra; Luo, Don; Boogaerts, Griet; Polo, Ramon; Picchio, Gaston; Beumont, Maria</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2428</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virol. response to therapy with peginterferon alfa plus ribavirin.  METHODS: In this randomized, phase 3 trial, we evaluated the addn. of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous therapy or who had a relapse after an initial response.  A total of 663 patients were assigned to one of three groups: the T12PR48 group, which received telaprevir for 12 wk and peginterferon plus ribavirin for a total of 48 wk; the lead-in T12PR48 group, which received 4 wk of peginterferon plus ribavirin followed by 12 wk of telaprevir and peginterferon plus ribavirin for a total of 48 wk; and the control group (PR48), which received peginterferon plus ribavirin for 48 wk.  The primary end point was the rate of sustained virol. response, which was defined as undetectable HCV RNA 24 wk after the last planned dose of a study drug.  RESULTS: Rates of sustained virol. response were significantly higher in the two telaprevir groups than in the control group among patients who had a previous relapse (83% in the T12PR48 group, 88% in the lead-in T12PR48 group, and 24% in the PR48 group), a partial response (59%, 54%, and 15%, resp.), and no response (29%, 33%, and 5%, resp.) (P < 0.001 for all comparisons).  Grade 3 adverse events (mainly anemia, neutropenia, and leukopenia) were more frequent in the telaprevir groups than in the control group (37% vs. 22%).  CONCLUSIONS: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virol. response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase. (Funded by Tibotec and Vertex Pharmaceuticals; REALIZE ClinicalTrials.gov no., NCT00703118.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzx61JZTi22bVg90H21EOLACvtfcHk0liOiZb7UD1myg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D&md5=de254ca59467daf5259a3dff8d2d831a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013086%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DDiago%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFocaccia%26aufirst%3DR.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3Dvan%2BHoek%26aufirst%3DB.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DVan%2BHeeswijk%26aufirst%3DR.%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DBoogaerts%26aufirst%3DG.%26aulast%3DPolo%26aufirst%3DR.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBeumont%26aufirst%3DM.%26atitle%3DTelaprevir%2520for%2520retreatment%2520of%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2417%26epage%3D2428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Behrens, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=12-22&author=S.+E.+Behrensauthor=L.+Tomeiauthor=R.+De+Francesco&title=Identification+and+properties+of+the+RNA-dependent+RNA+polymerase+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DS.%2BE.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520properties%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D12%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">8416</span><span class="NLM_x">–</span> <span class="NLM_lpage">8428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=9343198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=8416-8428&author=V.+Lohmannauthor=F.+Kornerauthor=U.+Herianauthor=R.+Bartenschlager&title=Biochemical+properties+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA+polymerase+and+identification+of+amino+acid+sequence+motifs+essential+for+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymic activity</span></div><div class="casAuthors">Lohmann, Volker; Korner, Frank; Herian, Ulrike; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8416-8428</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5B protein of the hepatitis C virus (HCV) is an RNA-dependent RNA polymerase (RdRp) (S.-E. Behrens, L. Tomei, and R. De Francesco, EMBO J. 15:12-22, 1996) that is assumed to be required for replication of the viral genome.  To further study the biochem. and structural properties of this enzyme, an NS5B-hexahistidine fusion protein was expressed with recombinant baculoviruses in insect cells and purified to near homogeneity.  The enzyme was found to have a primer-dependent RdRp activity that was able to copy a complete in vitro-transcribed HCV genome in the absence of addnl. viral or cellular factors.  Filter binding assays and competition expts. showed that the purified enzyme binds RNA with no clear preference for HCV 3'-end sequences.  Binding to homopolymeric RNAs was also examd., and the following order of specificity was obsd.: poly(U) > poly(G) > poly(A) > poly(C).  An inverse order was found for the RdRp activity, which used poly(C) most efficiently as a template but was inactive on poly(U) and poly(G), suggesting that a high binding affinity between polymerase and template interferes with processivity.  By using a mutational anal., four amino acid sequence motifs crucial for RdRp activity were identified.  While most substitutions of conserved residues within these motifs severely reduced the enzymic activities, a single substitution in motif D which enhanced the RdRp activity by about 50% was found.  Deletion studies indicate that amino acid residues at the very termini, in particular the amino terminus, are important for RdRp activity but not for RNA binding.  Finally, we found a terminal transferase activity assocd. with the purified enzyme.  However, this activity was also detected with NS5B proteins with an inactive RdRp, with an NS4B protein purified in the same way, and with wild-type baculovirus, suggesting that it is not an inherent activity of NS5B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdCeTDzvlRArVg90H21EOLACvtfcHk0liOiZb7UD1myg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D&md5=98640d185270f0b331db0fa0624865cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DKorner%26aufirst%3DF.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520properties%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520and%2520identification%2520of%2520amino%2520acid%2520sequence%2520motifs%2520essential%2520for%2520enzymatic%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D8416%26epage%3D8428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span> </span><span class="NLM_article-title">Nucleoside analog inhibitors of hepatitis C virus replication</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.2174%2F187152606776056698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16787301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=17-29&author=S.+S.+Carrollauthor=D.+B.+Olsen&title=Nucleoside+analog+inhibitors+of+hepatitis+C+virus+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analog inhibitors of hepatitis C virus replication</span></div><div class="casAuthors">Carroll, S. S.; Olsen, D. B.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Of the 30 compds. currently marketed in the United States for treatment of viral infections, 15 are nucleoside analogs, demonstrating the utility of this class of compd. as a source of antiviral drugs.  The success of nucleoside analogs in treating other viral infections provides a compelling rationale for the significant effort that is currently being devoted to the discovery and development of nucleoside analogs to treat infection by hepatitis C virus (HCV) that may lead to improvements in response rates compared to currently available therapies.  Several different approaches were adopted to identify promising analogs, including the use of surrogate viruses in cell culture assays, screening in the cell-based bicistronic HCV replicon assay, and screening nucleoside triphosphates for the ability to inhibit the activity of the HCV RNA-dependent RNA polymerase in vitro.  Several classes of ribonucleoside analogs with modifications of the ribose inhibit HCV replication.  Nucleoside analogs incorporating a 2'-C-Me modification are potent inhibitors in the replicon assay in the absence of cytotoxicity, and appear to exert their inhibition by acting as functional chain terminators of RNA synthesis.  NM283, a prodrug of 2'-C-methylcytidine, has entered clin. trials and demonstrated viral load redns. in subjects infected with genotype 1 HCV, a genotype known to be difficult to treat effectively with currently approved therapies.  Overall, results to date offer encouragement that improved therapies to treat HCV infection including newly developed nucleoside analogs may become available within the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVhFYWU3S1hbVg90H21EOLACvtfcHk0ljh4AxTmLhDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7Y%253D&md5=27a3f74bc6da7bfd4ce02a1266511f5c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F187152606776056698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056698%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26atitle%3DNucleoside%2520analog%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D17%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Jonckers, T. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buyck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachau-Durand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoof, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandekerckhove, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillen, L. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rydegard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">2′-Deoxy-2′-spirocyclopropylcytidine revisited: A new and selective inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8150</span><span class="NLM_x">–</span> <span class="NLM_lpage">8160</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101050a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8150-8160&author=T.+H.+M.+Jonckersauthor=T.-I.+Linauthor=C.+Buyckauthor=S.+Lachau-Durandauthor=K.+Vandyckauthor=S.+Van+Hoofauthor=L.+A.+M.+Vandekerckhoveauthor=L.+Huauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=L.+L.+A.+Dillenauthor=M.+D.+Cummingsauthor=H.+de+Kockauthor=M.+Nilssonauthor=C.+Sundauthor=C.+Rydegardauthor=B.+Samuelssonauthor=A.+Rosenquistauthor=G.+Fanningauthor=K.+Van+Emelenauthor=K.+Simmenauthor=P.+Raboisson&title=2%E2%80%B2-Deoxy-2%E2%80%B2-spirocyclopropylcytidine+revisited%3A+A+new+and+selective+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm101050a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101050a%26sid%3Dliteratum%253Aachs%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DBuyck%26aufirst%3DC.%26aulast%3DLachau-Durand%26aufirst%3DS.%26aulast%3DVandyck%26aufirst%3DK.%26aulast%3DVan%2BHoof%26aufirst%3DS.%26aulast%3DVandekerckhove%26aufirst%3DL.%2BA.%2BM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDillen%26aufirst%3DL.%2BL.%2BA.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSund%26aufirst%3DC.%26aulast%3DRydegard%26aufirst%3DC.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3D2%25E2%2580%25B2-Deoxy-2%25E2%2580%25B2-spirocyclopropylcytidine%2520revisited%253A%2520A%2520new%2520and%2520selective%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8150%26epage%3D8160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of the HCV NS5B polymerase: Progress in the discovery and development of novel agents for the treatment of HCV infections</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=614-634&author=P.+L.+Beaulieu&title=Non-nucleoside+inhibitors+of+the+HCV+NS5B+polymerase%3A+Progress+in+the+discovery+and+development+of+novel+agents+for+the+treatment+of+HCV+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520the%2520HCV%2520NS5B%2520polymerase%253A%2520Progress%2520in%2520the%2520discovery%2520and%2520development%2520of%2520novel%2520agents%2520for%2520the%2520treatment%2520of%2520HCV%2520infections%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D614%26epage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.2174%2F187152606776056724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16787302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=31-41&author=U.+Kochauthor=F.+Narjes&title=Allosteric+inhibition+of+the+hepatitis+C+virus+NS5B+RNA+dependent+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase</span></div><div class="casAuthors">Koch, Uwe; Narjes, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human and monetary costs of chronic hepatitis C and the complications arising from this disease emphasize the urgency to find a treatment for Hepatitis C Virus (HCV) infected patients.  The current std. of treatment for patients chronically infected with HCV is combination therapy with pegylated interferon plus ribavirin.  Recently, viral enzymes have become the target of efforts to develop small mol. inhibitors interfering with the essential steps in the life cycle of the virus.  Amongst these enzymes the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) is essential for viral replication and has been recognized as a prime target for therapeutic intervention.  Several distinct classes of inhibitors of NS5B RdRp have been disclosed in the literature, including active site inhibitors such as nucleosides and pyrophosphate mimetics, as well as nonnucleoside inhibitors.  The latter, based on the success of allosteric inhibitors in the treatment of HIV infection, have been developed into compds. which show activity in the subgenomic cell-culture assay of HCV replication.  This review provides an account of the recent developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbJzS0wn4zMLVg90H21EOLACvtfcHk0ljh4AxTmLhDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Ggu7c%253D&md5=d299870b484180aa4f9e179cb96eabe2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187152606776056724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056724%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DAllosteric%2520inhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520dependent%2520RNA%2520polymerase%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D31%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Tramontano, E.</span><span> </span><span class="NLM_article-title">The exploding field of the HCV polymerase non-nucleoside inhibitors: Summary of first generation compounds</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1298-1310&author=E.+Tramontano&title=The+exploding+field+of+the+HCV+polymerase+non-nucleoside+inhibitors%3A+Summary+of+first+generation+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTramontano%26aufirst%3DE.%26atitle%3DThe%2520exploding%2520field%2520of%2520the%2520HCV%2520polymerase%2520non-nucleoside%2520inhibitors%253A%2520Summary%2520of%2520first%2520generation%2520compounds%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1298%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carfi, A.</span><span> </span><span class="NLM_article-title">Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">29765</span><span class="NLM_x">–</span> <span class="NLM_lpage">29770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1074%2Fjbc.M505423200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=15955819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=29765-29770&author=S.+Di+Marcoauthor=C.+Volpariauthor=L.+Tomeiauthor=S.+Altamuraauthor=S.+Harperauthor=F.+Narjesauthor=U.+Kochauthor=M.+Rowleyauthor=R.+De+Francescoauthor=G.+Migliaccioauthor=A.+Carfi&title=Interdomain+communication+in+hepatitis+C+virus+polymerase+abolished+by+small+molecule+inhibitors+bound+to+a+novel+allosteric+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site</span></div><div class="casAuthors">Di Marco, Stefania; Volpari, Cinzia; Tomei, Licia; Altamura, Sergio; Harper, Steven; Narjes, Frank; Koch, Uwe; Rowley, Michael; De Francesco, Raffaele; Migliaccio, Giovanni; Carfi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">29765-29770</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase is required for replication of the viral genome and is a key target for therapeutic intervention against HCV.  We have detd. the crystal structures of the HCV polymerase complexed with two indole-based allosteric inhibitors at 2.3- and 2.4-Å resoln.  The structures show that these inhibitors bind to a site on the surface of the thumb domain.  A cyclohexyl and Ph ring substituents, bridged by an indole moiety, fill two closely spaced pockets, whereas a carboxylate substituent forms a salt bridge with an exposed arginine side chain.  Interestingly, in the apoenzyme, the inhibitor binding site is occupied by a small α-helix at the tip of the N-terminal loop that connects the fingers and thumb domains.  Thus, these mols. inhibit the enzyme by preventing formation of intramol. contacts between these two domains and consequently precluding their coordinated movements during RNA synthesis.  Our structures identify a novel mechanism by which a new class of allosteric inhibitors inhibits the HCV polymerase and open the way to the development of novel antiviral agents against this clin. relevant human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWHS1-2Y1C8LVg90H21EOLACvtfcHk0lh4lUWghkE8Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Sltr0%253D&md5=1192532b3624ec0032d9dff24c19a704</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M505423200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M505423200%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DCarfi%26aufirst%3DA.%26atitle%3DInterdomain%2520communication%2520in%2520hepatitis%2520C%2520virus%2520polymerase%2520abolished%2520by%2520small%2520molecule%2520inhibitors%2520bound%2520to%2520a%2520novel%2520allosteric%2520site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D29765%26epage%3D29770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGibbon, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">39260</span><span class="NLM_x">–</span> <span class="NLM_lpage">39267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=39260-39267&author=G.+Kukoljauthor=G.+A.+McGibbonauthor=G.+McKercherauthor=M.+Marquisauthor=S.+Lefebvreauthor=L.+Thauvetteauthor=J.+Gauthierauthor=S.+Gouletauthor=M.-A.+Poupartauthor=P.+L.+Beaulieu&title=Binding+site+characterization+and+resistance+to+a+class+of+non-nucleoside+inhibitors+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMcGibbon%26aufirst%3DG.%2BA.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DM.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DGauthier%26aufirst%3DJ.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DBinding%2520site%2520characterization%2520and%2520resistance%2520to%2520a%2520class%2520of%2520non-nucleoside%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D39260%26epage%3D39267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroccio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gennari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisbocci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Incitti, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stansfield, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span> </span><span class="NLM_article-title">Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">13225</span><span class="NLM_x">–</span> <span class="NLM_lpage">13231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1128%2FJVI.77.24.13225-13231.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14645579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslSmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=13225-13231&author=L.+Tomeiauthor=S.+Altamuraauthor=L.+Bartholomewauthor=A.+Biroccioauthor=A.+Ceccacciauthor=L.+Paciniauthor=F.+Narjesauthor=N.+Gennariauthor=M.+Bisbocciauthor=I.+Incittiauthor=L.+Orsattiauthor=S.+Harperauthor=I.+Stansfieldauthor=M.+Rowleyauthor=R.+De+Francescoauthor=G.+Migliaccio&title=Mechanism+of+action+and+antiviral+activity+of+benzimidazole-based+allosteric+inhibitors+of+the+hepatitis+C+virus+RNA-dependent+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase</span></div><div class="casAuthors">Tomei, Licia; Altamura, Sergio; Bartholomew, Linda; Biroccio, Antonino; Ceccacci, Alessandra; Pacini, Laura; Narjes, Frank; Gennari, Nadia; Bisbocci, Monica; Incitti, Ilario; Orsatti, Laura; Harper, Steven; Stansfield, Ian; Rowley, Michael; De Francesco, Raffaele; Migliaccio, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">13225-13231</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The RNA-dependent RNA polymerase of hepatitis C virus (HCV) is the catalytic subunit of the viral RNA amplification machinery and is an appealing target for the development of new therapeutic agents against HCV infection.  Nonnucleoside inhibitors based on a benzimidazole scaffold have been recently reported.  Compds. of this class are efficient inhibitors of HCV RNA replication in cell culture, thus providing attractive candidates for further development.  Here we report the detailed anal. of the mechanism of action of selected benzimidazole inhibitors.  Kinetic data and binding expts. indicated that these compds. act as allosteric inhibitors that block the activity of the polymerase prior to the elongation step.  Escape mutations that confer resistance to these compds. map to proline 495, a residue located on the surface of the polymerase thumb domain and away from the active site.  Substitution of this residue is sufficient to make the HCV enzyme and replicons resistant to the inhibitors.  Interestingly, proline 495 lies in a recently identified noncatalytic GTP-binding site, thus validating it as a potential allosteric site that can be targeted by small-mol. inhibitors of HCV polymerase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLeqFmAyaoXrVg90H21EOLACvtfcHk0lh4lUWghkE8Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslSmsrY%253D&md5=05154e4c748a15ecdb96bc5fa2a4f6cb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.24.13225-13231.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.24.13225-13231.2003%26sid%3Dliteratum%253Aachs%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DCeccacci%26aufirst%3DA.%26aulast%3DPacini%26aufirst%3DL.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DGennari%26aufirst%3DN.%26aulast%3DBisbocci%26aufirst%3DM.%26aulast%3DIncitti%26aufirst%3DI.%26aulast%3DOrsatti%26aufirst%3DL.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DStansfield%26aufirst%3DI.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26atitle%3DMechanism%2520of%2520action%2520and%2520antiviral%2520activity%2520of%2520benzimidazole-based%2520allosteric%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520RNA-dependent%2520RNA%2520polymerase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D13225%26epage%3D13231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hache, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.+S.+Duceppeauthor=B.+Hacheauthor=A.+Jakalianauthor=L.+Lagaceauthor=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+From+benzimidazole+to+indole+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.%2BS.%26aulast%3DHache%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520From%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7650</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3006788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7650-7666&author=P.+L.+Beaulieuauthor=M.+Bosauthor=M.+G.+Cordingleyauthor=C.+Chabotauthor=G.+Fazalauthor=M.+Garneauauthor=J.+R.+Gillardauthor=E.+Jolicoeurauthor=S.+LaPlanteauthor=G.+McKercherauthor=M.+Poirierauthor=M.+A.+Poupartauthor=Y.+S.+Tsantrizosauthor=J.+Duanauthor=G.+Kukolj&title=Discovery+of+the+first+thumb+pocket+1+NS5B+polymerase+inhibitor+%28BILB+1941%29+with+demonstrated+antiviral+activity+in+patients+chronically+infected+with+genotype+1+hepatitis+C+virus+%28HCV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm3006788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3006788%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520the%2520first%2520thumb%2520pocket%25201%2520NS5B%2520polymerase%2520inhibitor%2520%2528BILB%25201941%2529%2520with%2520demonstrated%2520antiviral%2520activity%2520in%2520patients%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7650%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, M. d. R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stansfield, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercolani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaramella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuleman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux-Roels, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baiocco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of (7<i>R</i>)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl)amino}-7,8-dihydro-6<i>H</i>-indolo[1,2-<i>e</i>][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=289-301&author=F.+Narjesauthor=B.+Crescenziauthor=M.+Ferraraauthor=J.+Habermannauthor=S.+Colarussoauthor=M.+d.+R.+R.+Ferreiraauthor=I.+Stansfieldauthor=A.+C.+Mackayauthor=I.+Conteauthor=C.+Ercolaniauthor=S.+Zaramellaauthor=M.-C.+Palumbiauthor=P.+Meulemanauthor=G.+Leroux-Roelsauthor=C.+Giulianoauthor=F.+Fioreauthor=S.+Di+Marcoauthor=P.+Baioccoauthor=U.+Kochauthor=G.+Migliaccioauthor=S.+Altamuraauthor=R.+Lauferauthor=R.+De+Francescoauthor=M.+Rowley&title=Discovery+of+%287R%29-14-cyclohexyl-7-%7B%5B2-%28dimethylamino%29ethyl%5D%28methyl%29amino%7D-7%2C8-dihydro-6H-indolo%5B1%2C2-e%5D%5B1%2C5%5Dbenzoxazocine-11-carboxylic+acid+%28MK-3281%29%2C+a+potent+and+orally+bioavailable+finger-loop+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm1013105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013105%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DHabermann%26aufirst%3DJ.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DFerreira%26aufirst%3DM.%2Bd.%2BR.%2BR.%26aulast%3DStansfield%26aufirst%3DI.%26aulast%3DMackay%26aufirst%3DA.%2BC.%26aulast%3DConte%26aufirst%3DI.%26aulast%3DErcolani%26aufirst%3DC.%26aulast%3DZaramella%26aufirst%3DS.%26aulast%3DPalumbi%26aufirst%3DM.-C.%26aulast%3DMeuleman%26aufirst%3DP.%26aulast%3DLeroux-Roels%26aufirst%3DG.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DBaiocco%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25287R%2529-14-cyclohexyl-7-%257B%255B2-%2528dimethylamino%2529ethyl%255D%2528methyl%2529amino%257D-7%252C8-dihydro-6H-indolo%255B1%252C2-e%255D%255B1%252C5%255Dbenzoxazocine-11-carboxylic%2520acid%2520%2528MK-3281%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520finger-loop%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D289%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padron Velazquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Paz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1035-1054&author=C.+Giulianoauthor=F.+Fioreauthor=A.+Di+Marcoauthor=J.+Padron+Velazquezauthor=A.+Bishopauthor=F.+Bonelliauthor=O.+Gonzalez-Pazauthor=I.+Marcucciauthor=S.+Harperauthor=F.+Narjesauthor=B.+Paciniauthor=E.+Monteagudoauthor=G.+Migliaccioauthor=M.+Rowleyauthor=R.+Laufer&title=Preclinical+pharmacokinetics+and+metabolism+of+a+potent+non-nucleoside+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DDi%2BMarco%26aufirst%3DA.%26aulast%3DPadron%2BVelazquez%26aufirst%3DJ.%26aulast%3DBishop%26aufirst%3DA.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DGonzalez-Paz%26aufirst%3DO.%26aulast%3DMarcucci%26aufirst%3DI.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DR.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520metabolism%2520of%2520a%2520potent%2520non-nucleoside%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DXenobiotica%26date%3D2005%26volume%3D35%26spage%3D1035%26epage%3D1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bailey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. G.</span><span> </span><span class="NLM_article-title">Acyl glucuronide reactivity in perspective: Biological consequences</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1016%2FS0009-2797%2803%2900020-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=12686489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis12jt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2003&pages=117-137&author=M.+J.+Baileyauthor=R.+G.+Dickinson&title=Acyl+glucuronide+reactivity+in+perspective%3A+Biological+consequences"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronide reactivity in perspective: biological consequences</span></div><div class="casAuthors">Bailey, Mark J.; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-137</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The metabolic conjugation of exogenous and endogenous carboxylic acid substrates with endogenous glucuronic acid, mediated by the uridine diphosphoglucuronosyl transferase (UGT) superfamily of enzymes, leads to the formation of acyl glucuronide metabolites.  Since the late 1970s, acyl glucuronides have been increasingly identified as reactive electrophilic metabolites, capable of undergoing three reactions: intramol. rearrangement, hydrolysis, and intermol. reactions with proteins leading to covalent drug-protein adducts.  This essential dogma has been accepted for over a decade.  The key question proposed by researchers, and now the pharmaceutical industry, is: does or can the covalent modification of endogenous proteins, mediated by reactive acyl glucuronide metabolites, lead to adverse drug reactions, perhaps idiosyncratic in nature This review evaluates the evidence for acyl glucuronide-derived perturbation of homeostasis, particularly that which might result from the covalent modification of endogenous proteins and other macromols.  Because of the availability of acyl glucuronides for test tube/in vitro expts., there is now a substantial literature documenting their rearrangement, hydrolysis and covalent modification of proteins in vitro.  It is certain from in vitro expts. that serum albumin, dipeptidyl peptidase IV, tubulin and UGTs are covalently modified by acyl glucuronides.  However, these in vitro expts. have been specifically designed to amplify any interference with a biol. process in order to find biol. effects.  The in vivo situation is not at all clear.  Certainly it must be concluded that all humans taking carboxylate drugs that form reactive acyl glucuronides will form covalent drug-protein adducts, and it must also be concluded that this in itself is normally benign.  However, there is enough in vivo evidence implicating acyl glucuronides, which, when backed up by in vivo circumstantial and documented in vitro evidence, supports the view that reactive acyl glucuronides may initiate toxicity/immune responses.  In summary, though acyl glucuronide-derived covalent modification of endogenous macromols. is well-defined, the work ahead needs to provide detailed links between such modification and its possible biol. consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5i99kMJKu1LVg90H21EOLACvtfcHk0lhKtZElPhNWUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis12jt7k%253D&md5=20e8f673b5abfa0974a1d32bfb38e01d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2803%2900020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252803%252900020-6%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BJ.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DAcyl%2520glucuronide%2520reactivity%2520in%2520perspective%253A%2520Biological%2520consequences%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2003%26volume%3D145%26spage%3D117%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Castillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. C.</span><span> </span><span class="NLM_article-title">Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=7587932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADyaK2MXlslSjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=566-572&author=M.+Castilloauthor=P.+C.+Smith&title=Disposition+and+reactivity+of+ibuprofen+and+ibufenac+acyl+glucuronides+in+vivo+in+the+rhesus+monkey+and+in+vitro+with+human+serum+albumin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin</span></div><div class="casAuthors">Castillo, Marta; Smith, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">566-72</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The disposition of ibuprofen and ibufenac, an analog of ibuprofen with a history of severe adverse reactions, was investigated in rhesus monkeys after oral administration.  Plasma concns. of the parent drugs and their glucuronides were measured by a direct HPLC method.  Ibuprofen and ibufenac exhibited notable inter-animal variability.  Ibufenac tended to have a higher area under the plasma concn. vs. time curve (AUC), and its apparent clearance was lower.  The plasma levels of acyl glucuronides were lower than parent drugs; the ratio of AUC in plasma for glucuronide/parent drug was 22.8% and 10.5% for ibuprofen and ibufenac, resp.  The degrdn. of ibufenac glucuronide in vitro was faster than ibuprofen glucuronide in aq. buffer, human serum albumin, and human plasma solns.  Covalent binding of parent drug to protein via the acyl glucuronides was obsd. both in vitro and in vivo.  The max. protein adduct formed in vivo with ibufenac was 60% higher than found for ibuprofen, although exposure in plasma to its reactive acyl glucuronide, as measured by AUC, was lower.  These data indicate that ibufenac glucuronide is a more reactive metabolite than ibuprofen glucuronide in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooBktMPhPzn7Vg90H21EOLACvtfcHk0lhKtZElPhNWUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlslSjs7k%253D&md5=4835a6931c79f31cfde06c873481fbbe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26atitle%3DDisposition%2520and%2520reactivity%2520of%2520ibuprofen%2520and%2520ibufenac%2520acyl%2520glucuronides%2520in%2520vivo%2520in%2520the%2520rhesus%2520monkey%2520and%2520in%2520vitro%2520with%2520human%2520serum%2520albumin%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D566%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Skonberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillo, M. P.</span><span> </span><span class="NLM_article-title">Metabolic activation of carboxylic acids</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1517%2F17425255.4.4.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=18433345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=425-438&author=C.+Skonbergauthor=J.+Olsenauthor=K.+G.+Madsenauthor=S.+H.+Hansenauthor=M.+P.+Grillo&title=Metabolic+activation+of+carboxylic+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of carboxylic acids</span></div><div class="casAuthors">Skonberg, Christian; Olsen, Jorgen; Madsen, Kim Grimstrup; Hansen, Steen Honore; Grillo, Mark P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-438</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Carboxylic acids constitute a large and heterogeneous class of both endogenous and xenobiotic compds.  A no. of carboxylic acid drugs have been assocd. with adverse reactions, linked to the metabolic activation of the carboxylic acid moiety of the compds., i.e., formation of acyl-glucuronides and acyl-CoA thioesters.  Objective: The objective is to give an overview of the current knowledge on metabolic activation of carboxylic acids and how such metabolites may play a role in adverse reactions and toxicity.  Methods: Literature concerning the formation and disposition of acyl glucuronides and acyl-CoA thioesters was searched.  Also included were papers on the chem. reactivity of acyl glutathione-thioesters, and literature concerning possible links between metabolic activation of carboxylic acids and reported cellular and clin. effects.  Results/conclusion: This review demonstrates that metabolites of carboxylic acid drugs must be considered chem. reactive, and that the current knowledge about metabolic activation of this compd. class can be a good starting-point for further studies on the consequences of chem. reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdB7y_4L2TirVg90H21EOLACvtfcHk0lhKtZElPhNWUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D&md5=fec1dbee0f4e4bf93c95ba2441b48004</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.4.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.4.425%26sid%3Dliteratum%253Aachs%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%2BG.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26atitle%3DMetabolic%2520activation%2520of%2520carboxylic%2520acids%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D425%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherborne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, I.</span><span> </span><span class="NLM_article-title">Rate-limited steps of human oral absorption and QSAR studies</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1446-1457&author=Y.+H.+Zhaoauthor=M.+H.+Abrahamauthor=J.+Leauthor=A.+Herseyauthor=C.+N.+Luscombeauthor=G.+Beckauthor=B.+Sherborneauthor=I.+Cooper&title=Rate-limited+steps+of+human+oral+absorption+and+QSAR+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DI.%26atitle%3DRate-limited%2520steps%2520of%2520human%2520oral%2520absorption%2520and%2520QSAR%2520studies%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D1446%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ikegashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruha, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span> </span><span class="NLM_article-title">Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6950</span><span class="NLM_x">–</span> <span class="NLM_lpage">6953</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0610245" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6950-6953&author=K.+Ikegashiraauthor=T.+Okaauthor=S.+Hirashimaauthor=S.+Nojiauthor=H.+Yamanakaauthor=Y.+Haraauthor=T.+Adachiauthor=J.-I.+Tsuruhaauthor=S.+Doiauthor=Y.+Haseauthor=T.+Noguchiauthor=I.+Andoauthor=N.+Oguraauthor=S.+Ikedaauthor=H.+Hashimoto&title=Discovery+of+conformationally+constrained+tetracyclic+compounds+as+potent+hepatitis+C+virus+NS5B+RNA+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors</span></div><div class="casAuthors">Ikegashira, Kazutaka; Oka, Takahiro; Hirashima, Shintaro; Noji, Satoru; Yamanaka, Hiroshi; Hara, Yoshinori; Adachi, Tsuyoshi; Tsuruha, Jun-Ichiro; Doi, Satoki; Hase, Yasunori; Noguchi, Toru; Ando, Izuru; Ogura, Naoki; Ikeda, Satoru; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6950-6953</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a new series of hepatitis C virus NS5B RNA polymerase inhibitors contg. a conformationally constrained tetracyclic scaffold.  SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (I and II) bearing a basic pendent group with high biochem. and cellular potencies.  These compds. displayed a very small shift in cellular potency when the replicon assay was performed in the presence of human serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF0S142h4FZLVg90H21EOLACvtfcHk0ljvJkLEo7H3uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKrs7rF&md5=18234c5535779cf60484899c6e63770f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0610245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0610245%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHirashima%26aufirst%3DS.%26aulast%3DNoji%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DTsuruha%26aufirst%3DJ.-I.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DNoguchi%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DI.%26aulast%3DOgura%26aufirst%3DN.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520conformationally%2520constrained%2520tetracyclic%2520compounds%2520as%2520potent%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6950%26epage%3D6953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Helm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4431</span><span class="NLM_x">–</span> <span class="NLM_lpage">4436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4431-4436&author=D.+McGowanauthor=S.+Vendevilleauthor=T.+I.+Linauthor=A.+Tahriauthor=L.+Huauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=J.+M.+Berkeauthor=M.+Canardauthor=E.+Cleirenauthor=P.+Dehertoghauthor=S.+Lastauthor=E.+Fransenauthor=E.+Van+Der+Helmauthor=I.+Van+den+Steenauthor=L.+Vijgenauthor=M.+C.+Rouanauthor=G.+Fanningauthor=O.+Nyanguileauthor=K.+Van+Emelenauthor=K.+Simmenauthor=P.+Raboisson&title=Finger-loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+1%3A+Discovery+and+optimization+of+novel+1%2C6-+and+2%2C6-macrocyclic+indole+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DVan%2BDer%2BHelm%26aufirst%3DE.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger-loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%25201%253A%2520Discovery%2520and%2520optimization%2520of%2520novel%25201%252C6-%2520and%25202%252C6-macrocyclic%2520indole%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4431%26epage%3D4436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger-loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4437</span><span class="NLM_x">–</span> <span class="NLM_lpage">4443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4437-4443&author=S.+Vendevilleauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=M.+Canardauthor=S.+Lastauthor=I.+Van+den+Steenauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboisson&title=Finger-loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+II.+Optimization+of+tetracyclic+indole-based+macrocycle+leading+to+the+discovery+of+TMC647055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger-loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%2520II.%2520Optimization%2520of%2520tetracyclic%2520indole-based%2520macrocycle%2520leading%2520to%2520the%2520discovery%2520of%2520TMC647055%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4437%26epage%3D4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1377-1385&author=T.-I.+Linauthor=O.+Lenzauthor=G.+Fanningauthor=T.+Verbinnenauthor=F.+Delouvroyauthor=A.+Scholliersauthor=K.+Vermeirenauthor=A.+Rosenquistauthor=M.+Edlundauthor=B.+Samuelssonauthor=L.+Vrangauthor=H.+de+Kockauthor=P.+Wigerinckauthor=P.+Raboissonauthor=K.+Simmen&title=In+vitro+activity+and+preclinical+profile+of+TMC435350%2C+a+potent+hepatitis+C+virus+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520activity%2520and%2520preclinical%2520profile%2520of%2520TMC435350%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1377%26epage%3D1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=A.+Rosenquistauthor=M.+Nilssonauthor=L.+Salvador-Odenauthor=T.-I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+Wahlingauthor=K.+Wickstromauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure%E2%80%93activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3%2F4A+protease+leading+to+the+discovery+of+TMC435350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DWahling%26aufirst%3DH.%26aulast%3DWickstrom%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span> </span><span class="NLM_article-title">Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4637</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1002%2Fanie.201200110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4637-4640&author=M.+D.+Cummingsauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=K.+Amssomsauthor=S.+Lastauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboissonauthor=S.+Vendeville&title=Structure-based+macrocyclization+yields+hepatitis+C+virus+NS5B+inhibitors+with+improved+binding+affinities+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Macrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved Binding Affinities and Pharmacokinetic Properties</span></div><div class="casAuthors">Cummings, Maxwell D.; Lin, Tse-I.; Hu, Lili; Tahri, Abdellah; McGowan, David; Amssoms, Katie; Last, Stefaan; Devogelaere, Benoit; Rouan, Marie-Claude; Vijgen, Leen; Berke, Jan Martin; Dehertogh, Pascale; Fransen, Els; Cleiren, Erna; van der Helm, Liesbet; Fanning, Gregory; Van Emelen, Kristof; Nyanguile, Origene; Simmen, Kenny; Raboisson, Pierre; Vendeville, Sandrine</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4637-4640, S4637/1-S4637/20</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocyclization is one mol. design strategy that can be used to improve the drug-related characteristics of small mols. and peptides,'1"4' and thus may provide a route to a less restrictive "drug-likeness space".  Structure-based design is typically focused on the optimization of a chem. series to increase affinity toward a target protein: modification to gain addnl. binding contacts and rigidification to favor a bio-active conformation are two common strategies.  In addn. to affinity for the primary target, a 3D structure of a relevant protein-small mol. complex can be used to guide the optimization of other pharmaceutical properties.  Substituent positions that project away from the binding site may be chem. exploited to alter one or more PK- or ADME-related properties (e.g. "solubilizing groups") while having minimal effect on the therapeutically relevant binding interaction (PK = pharmacokinetics; ADME = absorption, distribution, metab., and excretion).  Pursuing a design strategy based on publicly available 3D structures, we combined rigidification and the introduction of a PK-enhancing group in a single modification by forming a macrocycle between two solvent-exposed substituent positions of a small-mol. inhibitor of an essential viral enzyme.  In the present work we have used structure-based design to guide macrocyclization, leading to the discovery of new inhibitors that maintain potency while showing substantially improved pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70QpVIVUDr7Vg90H21EOLACvtfcHk0lgsOZp13mcmpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGltLc%253D&md5=1dc1c86dcc8f22d406256e4a779e9e6e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200110%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DVendeville%26aufirst%3DS.%26atitle%3DStructure-based%2520macrocyclization%2520yields%2520hepatitis%2520C%2520virus%2520NS5B%2520inhibitors%2520with%2520improved%2520binding%2520affinities%2520and%2520pharmacokinetic%2520properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D4637%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">Apparent permeability was assessed in caco-2 cells and was found to be unpredictive for in vivo absorption. For example, <b>10a</b> was predicted to be poorly absorbed with a <i>P</i><sub>AB</sub> of 2.8 cm/s but showed a very good exposure in rats and dogs. We postulate that our acyl sulfamide derivatives are mostly present in a charged form (anion) at the pH of the caco-2 cells experiment (pH 7.4), thus underestimating their permeability in the stomach and intestines where the pH is lower. For <b>10a</b>, the measured p<i>K</i><sub>a</sub> of the acidic acyl sulfamide moiety was 5.7.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span> </span><span class="NLM_article-title">TMC647055, a potent non-nucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4676-4684&author=B.+Devogelaereauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=O.+Nyanguileauthor=A.+Tahriauthor=K.+Amssomsauthor=O.+Lenzauthor=M.+D.+Cummingsauthor=R.+F.+Claytonauthor=S.+Vendevilleauthor=P.+Raboissonauthor=K.+A.+Simmenauthor=G.+C.+Fanningauthor=T.-I.+Lin&title=TMC647055%2C+a+potent+non-nucleoside+hepatitis+C+virus+NS5B+polymerase+inhibitor+with+cross-genotypic+coverage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DClayton%26aufirst%3DR.%2BF.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DLin%26aufirst%3DT.-I.%26atitle%3DTMC647055%252C%2520a%2520potent%2520non-nucleoside%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520with%2520cross-genotypic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4676%26epage%3D4684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+Bosauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.-M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.-A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.-L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0lg9hXsrR4XZzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2–P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2%E2%80%93P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2%25E2%2580%2593P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Biswal, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yannopoulos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilimoria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. N.</span><span> </span><span class="NLM_article-title">Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">18202</span><span class="NLM_x">–</span> <span class="NLM_lpage">18210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=18202-18210&author=B.+K.+Biswalauthor=M.+M.+Cherneyauthor=M.+Wangauthor=L.+Chanauthor=C.+G.+Yannopoulosauthor=D.+Bilimoriaauthor=O.+Nicolasauthor=J.+Bedardauthor=M.+N.+James&title=Crystal+structures+of+the+RNA-dependent+RNA+polymerase+genotype+2a+of+hepatitis+C+virus+reveal+two+conformations+and+suggest+mechanisms+of+inhibition+by+non-nucleoside+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiswal%26aufirst%3DB.%2BK.%26aulast%3DCherney%26aufirst%3DM.%2BM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DYannopoulos%26aufirst%3DC.%2BG.%26aulast%3DBilimoria%26aufirst%3DD.%26aulast%3DNicolas%26aufirst%3DO.%26aulast%3DBedard%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DM.%2BN.%26atitle%3DCrystal%2520structures%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520genotype%25202a%2520of%2520hepatitis%2520C%2520virus%2520reveal%2520two%2520conformations%2520and%2520suggest%2520mechanisms%2520of%2520inhibition%2520by%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D18202%26epage%3D18210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thavonekham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Allosteric <i>N</i>-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase—Acylsulfonamides and acyl sulfamides as carboxylic acid replacements</span> <span class="citation_source-journal">Can. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=66-81&author=P.+L.+Beaulieuauthor=R.+Coulombeauthor=J.+Gillardauthor=C.+Brochuauthor=J.+Duanauthor=M.+Garneauauthor=E.+Jolicoeurauthor=P.+Kuhnauthor=M.-A.+Poupartauthor=J.+Rancourtauthor=T.+A.+Stammersauthor=B.+Thavonekhamauthor=G.+Kukolj&title=Allosteric+N-acetamide-indole-6-carboxylic+acid+thumb+pocket+1+inhibitors+of+hepatitis+C+virus+NS5B+polymerase%E2%80%94Acylsulfonamides+and+acyl+sulfamides+as+carboxylic+acid+replacements"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DStammers%26aufirst%3DT.%2BA.%26aulast%3DThavonekham%26aufirst%3DB.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DAllosteric%2520N-acetamide-indole-6-carboxylic%2520acid%2520thumb%2520pocket%25201%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%25E2%2580%2594Acylsulfonamides%2520and%2520acyl%2520sulfamides%2520as%2520carboxylic%2520acid%2520replacements%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D2013%26volume%3D91%26spage%3D66%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhP3rpRTy66MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">An optimized indole acetamide lead from the acyclic series (see ref  <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>) was found to have a half-life of 3 min in our in-house SPR experiment.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Pauwels, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostmans, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirynen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span> </span><span class="NLM_article-title">Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">6909</span><span class="NLM_x">–</span> <span class="NLM_lpage">6919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401396p&amp;key=10.1128%2FJVI.01543-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401396p&amp;key=17459932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401396p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVOisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=6909-6919&author=F.+Pauwelsauthor=W.+Mostmansauthor=L.+M.+Quirynenauthor=L.+van+der+Helmauthor=C.+W.+Bouttonauthor=A.+S.+Rueffauthor=E.+Cleirenauthor=P.+Raboissonauthor=D.+Surlerauxauthor=O.+Nyanguileauthor=K.+A.+Simmen&title=Binding-site+identification+and+genotypic+profiling+of+hepatitis+C+virus+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors</span></div><div class="casAuthors">Pauwels, Frederik; Mostmans, Wendy; Quirynen, Ludo M. M.; van der Helm, Liesbet; Boutton, Carlo W.; Rueff, Anne-Stephanie; Cleiren, Erna; Raboisson, Pierre; Surleraux, Dominique; Nyanguile, Origene; Simmen, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6909-6919</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The search for hepatitis C virus polymerase inhibitors has resulted in the identification of several nonnucleoside binding pockets.  The shape and nature of these binding sites differ across and even within diverse hepatitis C virus genotypes.  These differences confront antiviral drug discovery with the challenge of finding compds. that are capable of inhibition in variable binding pockets.  To address this, we have established a hepatitis C virus mutant and genotypic recombinant polymerase panel as a means of guiding medicinal chem. through the elucidation of the site of action of novel inhibitors and profiling against genotypes.  Using a genotype 1b backbone, we demonstrate that the recombinant P495L, M423T, M414T, and S282T mutant enzymes can be used to identify the binding site of an acyl pyrrolidine analog.  We assess the inhibitory activity of this analog and other nonnucleoside inhibitors with our panel of enzyme isolates generated from clin. sera representing genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpujEe1PIq2rLVg90H21EOLACvtfcHk0lgJGbNVhxY_-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVOisL8%253D&md5=cfc408253bdf44eff2d8f6dd3e47b2dc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FJVI.01543-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01543-06%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DQuirynen%26aufirst%3DL.%2BM.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%2BW.%26aulast%3DRueff%26aufirst%3DA.%2BS.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26atitle%3DBinding-site%2520identification%2520and%2520genotypic%2520profiling%2520of%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D6909%26epage%3D6919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Rydberg, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paonessa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carfi, A.</span><span> </span><span class="NLM_article-title">Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">390</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2009&pages=1048-1059&author=E.+H.+Rydbergauthor=A.+Cellucciauthor=L.+Bartholomewauthor=M.+Mattuauthor=G.+Barbatoauthor=S.+W.+Ludmererauthor=D.+J.+Grahamauthor=S.+Altamuraauthor=G.+Paonessaauthor=R.+De+Francescoauthor=G.+Migliaccioauthor=A.+Carfi&title=Structural+basis+for+resistance+of+the+genotype+2b+hepatitis+C+virus+NS5B+polymerase+to+site+A+non-nucleoside+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRydberg%26aufirst%3DE.%2BH.%26aulast%3DCellucci%26aufirst%3DA.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DMattu%26aufirst%3DM.%26aulast%3DBarbato%26aufirst%3DG.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DPaonessa%26aufirst%3DG.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DCarfi%26aufirst%3DA.%26atitle%3DStructural%2520basis%2520for%2520resistance%2520of%2520the%2520genotype%25202b%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520to%2520site%2520A%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D390%26spage%3D1048%26epage%3D1059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span> </span><span class="NLM_article-title">In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1878</span><span class="NLM_x">–</span> <span class="NLM_lpage">1887</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1878-1887&author=O.+Lenzauthor=T.+Verbinnenauthor=T.-I.+Linauthor=L.+Vijgenauthor=M.+D.+Cummingsauthor=J.+Lindbergauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=A.+Scholliersauthor=K.+Vermeirenauthor=T.+Ivensauthor=P.+Raboissonauthor=M.+Edlundauthor=S.+Stormauthor=L.+Vrangauthor=H.+de+Kockauthor=G.+C.+Fanningauthor=K.+A.+Simmen&title=In+vitro+resistance+profile+of+the+hepatitis+C+virus+NS3%2F4A+protease+inhibitor+TMC435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DIvens%26aufirst%3DT.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DS.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26atitle%3DIn%2520vitro%2520resistance%2520profile%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitor%2520TMC435%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D1878%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Bourgeois, S.; Reesink, H. W.; Leempoels, J.; Vijgen, L.; Rouan, M.-C.; Marien, K.; Remoortere, P. V.; Fanning, G.; Picchio, G.; Simmen, K.; Verloes, R.</span> Combination Therapy of TMC647055 with Simeprevir (TMC435) in Genotype 1 HCV Patients. EASL, The International Liver Conference, Amsterdam,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bourgeois%2C+S.%3B+Reesink%2C+H.+W.%3B+Leempoels%2C+J.%3B+Vijgen%2C+L.%3B+Rouan%2C+M.-C.%3B+Marien%2C+K.%3B+Remoortere%2C+P.+V.%3B+Fanning%2C+G.%3B+Picchio%2C+G.%3B+Simmen%2C+K.%3B+Verloes%2C+R.+Combination+Therapy+of+TMC647055+with+Simeprevir+%28TMC435%29+in+Genotype+1+HCV+Patients.+EASL%2C+The+International+Liver+Conference%2C+Amsterdam%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBourgeois%26aufirst%3DS.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRK','PDB','2BRK'); return false;">PDB: 2BRK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BRL','PDB','2BRL'); return false;">PDB: 2BRL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2DXS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2DXS','PDB','2DXS'); return false;">PDB: 2DXS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DRU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DRU','PDB','4DRU'); return false;">PDB: 4DRU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q0Z','PDB','3Q0Z'); return false;">PDB: 3Q0Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GMC','PDB','4GMC'); return false;">PDB: 4GMC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i28"><a href="/doi/suppl/10.1021/jm401396p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_10640"></div></div></div></div></div><hr /></hr><p class="last">Details of LCMS and chiral HPLC methods. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401396p/suppl_file/jm401396p_si_001.pdf">jm401396p_si_001.pdf (163.1 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401396p&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-5%3Barticle%3Aarticle%3A10.1021%2Fjm401396p%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401396p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a6df7dd7823e0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
